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ABSTRACT 
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis and is resistant to 
chemotherapy. Gemcitabine, a nucleoside analogue, is an important component of 
treatment for locally advanced and metastatic PDAC, but provides only modest 
survival benefit. The enzyme Ribonucleotide Reductase (RR) catalyses the conversion 
of ribonucleotides into deoxyribonucleotides, required for DNA synthesis and repair. 
Several studies have demonstrated that RR large subunit-1 (RRM1) is associated with 
gemcitabine resistance in PDAC. The RAS/RAF/MEK/ERK signalling pathways regulates 
cellular proliferation, differentiation and survival. Targeting downstream effectors of 
the RAS gene by direct inhibition of MEK (MAPKK) proteins is a rational therapeutic 
strategy, since aberrant activation of this pathway occurs frequently in PDAC.  
In this study, the ability of pimasertib (AS703026), a highly selective and allosteric 
MEK1/2 inhibitor, to enhance gemcitabine efficacy was tested and the molecular 
mechanism of their interaction was investigated. Synergistic antiproliferative effects 
and increased apoptosis were observed when pimasertib was combined sequentially 
with gemcitabine in human pancreatic cancer cells. Importantly, pimasertib reduced 
the expression of RRM1 protein and this was associated with sensitivity to 
gemcitabine. Pre-treatment with the proteasome inhibitor MG132 impaired RRM1 
downregulation induced by pimasertib, suggesting RRM1 is degraded through the 
ubiquitin-proteasome system. Immunoprecipitation experiments indicated enhanced 
MDM2-mediated polyubiquitination of RRM1 through lys48-mediated linkage 
following pimasertib treatment, an effect in part mediated by AKT. Finally, the 
combination treatment of pimasertib with gemcitabine caused significant tumor 
growth delay in an orthotopic pancreatic cancer model, with RRM1 downregulation in 
pimasertib-treated mice. 
These results indicate MEK as a potential target to sensitize gemcitabine therapy 
through modulation of RRM1 protein stability and underline the importance of drug 
scheduling in achieving efficacious antitumor activity. This study has provided 
mechanistic insights to the synergistic interaction between gemcitabine and 
pimasertib that could be further investigated in design of future clinical trials. 
  
 4 
ACKNOWLEDGEMENTS 
First I would like to thank my supervisors Professor Daniel Hochhauser and Professor 
John Hartley for giving me the opportunity to carry out a PhD under their guidance.  
Dear Daniel, thank you very much for your constant support, for keeping up with my 
mood swings for the entire four years. Thank you for reminding me always to be 
positive during the hard times, for teaching me how to be a tough and critical scientist 
and for just being a great PI! 
I would also like to thank Dr. Samantha Goodstal for supervising the project from 
overseas and the MERCK Serono team in Billerica (MA) for funding my PhD. 
I would like to thank Dr. Manuel Rodriguez Justo for performing 
immunohistochemistry quantification and for critical reading of the manuscript. 
An important thank you goes to Eleonora Li Causi, my collaborator at the Barts Cancer 
Institute (London, UK), who helped me with the animal work. 
Thank you to all the members of the DRUG/DNA interactions lab: Rouchen, Luke, 
Helen, Sylwia, Fei, Juanjo, Miguel and Kostas.  And to the former members, Raisa and 
Giammy for mentoring me from the beginning of this tough journey and for our 
amazing coffee breaks gossiping about the cancer institute life.  
A particular thank you to the amazing Trio: Hanna, Michael and Valenti, for keeping up 
with my pointless dramas about the paper revision, the thesis writing and for all the 
great Friday nights spent together at the Jeremy Bentham pub after work. 
Un grande grazie goes to my ex colleague and friend Valeria. I would not have made it 
without your support and friendship. I miss you a lot Vale! Thank you to Lucia, Anto 
and Sebastian for our fun spinning classes at Fitness First together and to Nieves for 
helping me with my PowerPoint presentations. 
To my PhD buddy Jocelyn and our nights out in Mayfair that helped us to distract from 
our lab life. Thank you to my London partners in crime: Letizia, Pascale, Maddalena 
and Matilde. Even though they had no idea what a MEK inhibitor is, they have always 
been interested in hearing about my experiments’ progress.  
Thank you to all my Italian friends for your long distance support. In particular, to my 
dear friend Michela and to all my Bolognese friends: Caterina, Agnese, Angela, 
 5 
Barbara, Simona and Cate. Grazie alla mia Fede, for our millions nights out together, 
for our trips and for our chats on the phone. You have truly always been there for me 
and always will.   
Thank you to Paul for introducing me to the PhD student’s world and taught me how 
to swim without sinking. You are a great example of how hard work and dedication 
can lead to great success. Thank you to LIGC! I am so glad to be part of this amazing 
gospel choir and to have found such great friends. 
Now, a very special OBRIGADO goes to Ema for supporting me throughout the final 
stage of my PhD…the writing! Thank you for being very patient with me, for always 
understanding me and for standing by my side. You are an amazing person and I am so 
glad to have you in my life. 
The biggest thank you goes to my big fat Italian family who has always believed in me. 
You are the most precious gift life could ever give me. 
To my mother, my biggest inspiration: no one could ever do a better job than you! To 
my great father who always allowed me to follow my dreams. All that I am I owe it to 
you two.  
To my aunt Stefania who followed me everywhere I went: Buffalo, Seattle or London. 
No matter what part of the world I was moving to she has always come along to make 
sure I was fine! There is no one quite as special as my older sister Vale who has taught 
me what the real values in life are.To my grandfather Mario who has watched over me 
during these four years and to zia Giovanna who transmitted me the passion for 
medical science.To my cousins Luca, Matteo, Fausto and Martina who represent the 
most fun part of my life. Marty: you are like sister to me and I am sure you will shine 
bright like a diamond one day!! To my amazing grandparents: Nonna Luciana (I love 
you so much) e Nonno Betto, for their unconditional love, tenderness, and words of 
wisdom.  
My curiosity for science began many years ago when as a little child I used to play in 
my auntie’s pharmacy store, wondering why and how these pills would work to cure 
human diseases. Therefore my last thank you goes to my auntie Dina, who walks 
beside us every day, to whom this thesis is dedicated 
Thank you all for having taken part of this amazing journey. 
 6 
 
 
 
 
 
 
 
“It’s the possibility of having a dream come true that makes life 
interesting” (Paulo Coelho) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7 
 
 
 
 
 
 
 
 
To my auntie Dina 
 
  
 8 
COMMUNICATIONS  
PRESENTATIONS 
 Poster Presentation at 10th NCRI cancer conference.  2-5th November 2014, 
Liverpool (UK). MEK inhibition enhances gemcitabine efficacy by increasing 
MDM2-mediated ubiquitination and degradation of RRM1. Vena F, Li Causi E, 
Hartley J.A, Hagemann T, Goodstal S, Hochhauser D. 
 
 Poster Presentation at EORTC-NCI-AACR 17th-21st November 2014 Barcelona. 
(Spain). MEK inhibition enhances gemcitabine efficacy by increasing MDM2-
mediated ubiquitination and degradation of RRM1. Vena F, Li Causi E, Hartley 
J.A, Hagemann T, Goodstal S, Hochhauser D. 
 
 Poster Presentation at UCL Cancer Institute/Colin Woolf Memorial Fund.  18th 
March 2015, London (UK). MEK inhibition enhances gemcitabine efficacy by 
increasing MDM2-mediated ubiquitination and degradation of RRM1. Vena F, 
Li Causi E, Hartley J.A, Hagemann T, Goodstal S, Hochhauser D. 
 
 Poster Presentation at AACR/Croucher Summer Course in Cancer Biology. 10th-
14th August 2015, Hong Kong (CH). The combination of MEK1/2 inhibitor 
pimasertib with gemcitabine induces schedule-dependent antitumor activity in 
pancreatic cancer models by reducing RRM1 protein. Vena F, Li Causi E, Justo-
Rodriguez M, Goodstal S, Hartley J.A, Hochhauser D. 
 
PUBLICATIONS 
 Vena F, Li Causi E, Rodriguez J.M, Goodstal S, Hagemann T, Hartley J.A, 
Hochhauser D. (2015). ”The MEK1/2 Inhibitor Pimasertib Enhances 
Gemcitabine Efficacy In Pancreatic Cancer Models By Altering Ribonucleotide 
Reductase Subunit-1 (RRM1)“. Clin Cancer Res. 
 
 9 
TABLE OF CONTENTS 
 
DECLARATION .......................................................................................................... 2 
ABSTRACT ................................................................................................................ 3 
ACKNOWLEDGEMENTS ............................................................................................ 4 
COMMUNICATIONS ................................................................................................. 8 
TABLE OF CONTENTS ................................................................................................ 9 
LIST OF FIGURES..................................................................................................... 14 
LIST OF TABLES ...................................................................................................... 18 
LIST OF ABBREVIATIONS ........................................................................................ 19 
INTRODUCTION ............................................................................................................ 26 
1.1 CANCER BIOLOGY ........................................................................................................ 27 
1.2 PANCREATIC CANCER .................................................................................................. 29 
1.2.1 Overview ............................................................................................................................ 29 
1.2.2 Epidemiology and risk factors ............................................................................................ 29 
1.2.3 Biology of pancreatic ductal adenocarcinoma (PDAC) ...................................................... 30 
1.2.4 Genetic alterations found in PDAC .................................................................................... 31 
1.2.4.1 Oncogenic K-RAS ......................................................................................................... 32 
1.2.4.1.1 KRAS is required for PanIN initiation and development into PDAC ................... 33 
1.2.4.1.2 Oncogenic K-RAS activity affects the tumor microenvironment ........................ 34 
1.2.4.2 CDKN2A gene inactivation .......................................................................................... 35 
1.2.4.3 TP53 mutation ............................................................................................................. 35 
1.2.4.4 SMAD4/DPC4 gene mutation ...................................................................................... 36 
1.2.4.5 Other genetic alterations found in PDAC .................................................................... 36 
1.2.4.5.1 The Wnt-β-catenin signalling pathway............................................................... 36 
1.2.4.5.2 Upregulation of the Epidermal Growth Factor Receptor (EGFR) ....................... 37 
1.2.4.5.3 BRCA mutation ................................................................................................... 38 
1.2.4.6 Telomere shortening ................................................................................................... 38 
1.2.5 Invasive and metastatic properties of PDAC cells .............................................................. 39 
1.3 Current therapies for Pancreatic Ductal Adenocarcinoma ......................................... 40 
1.3.1 Treatment options for localized disease ............................................................................ 40 
1.3.1.1 Adjuvant chemotherapy ............................................................................................. 41 
 10 
1.3.1.2 Chemoradiotherapy .................................................................................................... 42 
1.3.2 Treatment options for locally advanced and metastatic disease ...................................... 44 
1.3.2.1 Gemcitabine plus nab-paclitaxel ................................................................................. 45 
1.3.2.2 FOLFIRINOX ................................................................................................................. 46 
1.3.2.3 Gemcitabine plus erlotinib .......................................................................................... 47 
1.3.2.4 Gemcitabine plus capecitabine ................................................................................... 47 
1.3.3 Targeting the stromal compartment in PDAC .................................................................... 49 
1.4 Gemcitabine: a deoxycytidine analogue ..................................................................... 50 
1.4.1 Clinical pharmacology of gemcitabine ............................................................................... 50 
1.4.2 Gemcitabine metabolism and uptake ................................................................................ 50 
1.4.3 Mechanisms of action of gemcitabine ............................................................................... 51 
1.4.4 Molecular markers associated with gemcitabine response .............................................. 53 
1.4.4.1 Human Equilibrative Nucleoside Transporter (hENT1) ............................................... 53 
1.4.4.2 Deoxycytidine kinase (dCK) ......................................................................................... 54 
1.4.4.3 Cytidine Deaminase (CDA) .......................................................................................... 55 
1.4.4.4 Ribonucleotide Reductase (RR) ................................................................................... 55 
1.4.4.4.1 RRM1 overexpression is associated with poor response to gemcitabine in PDAC 
patients ............................................................................................................................. 58 
1.4.4.4.2 Ribonucleotide Reductase Inhibitors ................................................................. 59 
1.5 The RAS/RAF/MAPK signalling pathway ..................................................................... 60 
1.5.1 System biology of the RAS/RAF/MAPK pathway ............................................................... 60 
1.5.1.1 Epidermal growth factor receptor .............................................................................. 62 
1.5.1.2 RAS and RAF kinases ................................................................................................... 63 
1.5.1.3 Mitogen extracellular signal regulated kinase (MEK or MAPKK) protein.................... 64 
1.5.1.4 ERK kinases .................................................................................................................. 65 
1.5.2 MEK as a therapeutic target .............................................................................................. 66 
1.5.2.1 The development of MEK inhibitors ........................................................................... 66 
1.5.2.2 Pimasertib ................................................................................................................... 68 
1.5.2.3 Mechanisms of resistance to MEK inhibitors .............................................................. 70 
1.6 AIMS AND OBJECTIVES ................................................................................................ 72 
MATERIALS AND METHODS .......................................................................................... 73 
2.1 MATERIALS .................................................................................................................. 74 
2.1.1 Human and mouse pancreatic cancer cell lines and culture conditions ............................ 74 
2.1.2 Chemotherapies, MEK inhibitors and other reagents ....................................................... 74 
2.2 Methods ...................................................................................................................... 75 
2.2.1. Cell Line maintenance ....................................................................................................... 75 
2.2.1.1 Storage and retrieval from liquid nitrogen ................................................................. 75 
2.2.1.2 Cell count .................................................................................................................... 76 
 11 
2.2.2 Assessing growth inhibition ............................................................................................... 76 
2.2.2.1 Drug scheduling .......................................................................................................... 76 
2.2.2.2 MTT assay.................................................................................................................... 77 
2.2.2.3 Calcusyn Software analysis ......................................................................................... 78 
2.2.3 Caspase 3/7 assay .............................................................................................................. 78 
2.2.4 Western blotting analysis .................................................................................................. 79 
2.2.4.1 Protein extraction ....................................................................................................... 79 
2.2.4.2 Protein quantification ................................................................................................. 79 
2.2.4.3 Immunoblotting .......................................................................................................... 80 
2.2.4.4 Densitometry analysis ................................................................................................. 83 
2.2.5 Immunoprecipitation ......................................................................................................... 83 
2.2.6 Fluorescence-activated cell sorting (FACS) for cell cycle analysis ...................................... 83 
2.2.7 RNA isolation and real-time PCR ........................................................................................ 84 
2.2.8 Small interfering RNA (siRNA) transfection ....................................................................... 84 
2.2.9 Plasmid transfection .......................................................................................................... 85 
2.2.10 Treatment studies in murine models ..................................................................... 85 
2.2.10.1 Establishment of a syngeneic orthotopic mouse model of pancreatic cancer ......... 85 
2.2.10.2 Drugs treatment schedule in the orthotopic mouse model ..................................... 86 
2.2.10.3 Ultrasound analysis ................................................................................................... 87 
2.2.10.4 Immunohistochemistry (IHC) .................................................................................... 87 
2.2.10.5 IHC quantification ..................................................................................................... 88 
2.2.11 Statistical analysis .................................................................................................. 88 
THE CELLULAR EFFECTS OF PIMASERTIB IN COMBINATION WITH GEMCITABINE IN PDAC 89 
3.1 INTRODUCTION ........................................................................................................... 90 
3.1.1 Interaction of gemcitabine with targeted therapy ............................................................ 90 
3.1.2 Determining the effects of gemcitabine plus pimasertib combination in human pancreatic 
cancer cell lines ........................................................................................................................... 91 
3.1.3 Drugs administration schedule affects in vitro and in vivo response ................................ 91 
3.2 RESEARCH HYPOTHESIS AND AIMS ............................................................................. 93 
3.3 RESULTS ....................................................................................................................... 94 
3.3.1 Gemcitabine inhibits proliferation of human pancreatic cancer cell lines ........................ 94 
3.3.2 Pimasertib inhibits cell proliferation and activation of ERK signalling in human pancreatic 
cancer cell lines ........................................................................................................................... 96 
3.3.3 Cell cycle effects of pimasertib and gemcitabine .............................................................. 99 
3.3.4 Combination of pimasertib with gemcitabine according to a non-constant ratio design 100 
3.3.4.1 Simultaneous administration of pimasertib with gemcitabine induces antagonistic or 
additive antiproliferative effects........................................................................................... 101 
 12 
3.3.4.2 Sequential administration of pimasertib with gemcitabine induces synergistic 
antiproliferative effects ........................................................................................................ 104 
3.3.5 Pimasertib enhances gemcitabine-induced apoptosis in a sequence-dependent fashion
 .................................................................................................................................................. 108 
3.3.6 Effects of pimasertib on the modulation of genes involved in gemcitabine resistance .. 114 
3.3.7 Downregulation of RRM1 protein expression induced by MEK inhibition occurs through a 
posttranslational modification ................................................................................................. 119 
3.3.8 RRM1 basal protein expression predicts gemcitabine efficacy ....................................... 123 
3.3.9 Inhibition of RRM1 expression by siRNA sensitizes BxPC-3 and PANC-1 cells to 
gemcitabine .............................................................................................................................. 124 
3.4 DISCUSSION ............................................................................................................... 127 
3.4.1 Improving gemcitabine efficacy with MEK inhibitors ...................................................... 127 
3.4.2 RRM1 protein expression is modulated by MEK inhibition ............................................. 129 
3.5 CONCLUSIONS ........................................................................................................... 131 
PIMASERTIB INDUCES POLYUBIQUITINATION AND PROTEASOMAL DEGRADATION OF 
RRM1 ......................................................................................................................... 132 
4.1 INTRODUCTION ......................................................................................................... 133 
4.1.1 The Ubiquitin-Proteasome System (UBS): biology and mechanisms............................... 133 
4.1.2 AKT/PI3K signalling pathway ........................................................................................... 135 
4.1.3 PI3K/AKT signalling pathway is deregulated in human cancers ...................................... 135 
4.2 RESEARCH HYPOTHESIS AND AIMS ........................................................................... 138 
4.3 RESULTS ..................................................................................................................... 139 
4.3.1 Pimasertib-induced downregulation of RRM1 protein expression occurs through a post-
translational modification......................................................................................................... 139 
4.3.2 RRM1 is polyubiquitinated through lys48-mediated linkage .......................................... 141 
4.3.3 MDM2 inhibition impairs RRM1 degradation induced by pimasertib ............................. 142 
4.3.4 RRM1 interacts with MDM2 ............................................................................................ 146 
4.3.5 Pimasertib induces activation of P-AKT ........................................................................... 148 
4.3.6 AKT activation is required for pimasertib-mediated degradation of RRM1 .................... 148 
4.4 DISCUSSION ............................................................................................................... 151 
4.4.1 Ribonucleotide Reductase stability is modulated by the ubiquitin-proteasome system 151 
4.4.2 Pimasertib induces MDM2-mediated proteasomal degradation of RRM1 ..................... 152 
4.4.3 The PI3K/AKT pathway is involved in RRM1 degradation induced by pimasertib ........... 154 
4.5 CONCLUSIONS ........................................................................................................... 155 
EFFECTS OF PIMASERTIB IN COMBINATION WITH GEMCITABINE IN AN ORTHOTOPIC 
MODEL OF PANCREATIC TUMOR ................................................................................ 156 
5.1 INTRODUCTION ......................................................................................................... 157 
5.1.1 In vivo model systems to study human cancers .............................................................. 157 
 13 
5.1.1.1 Human tumour xenograft models ............................................................................ 157 
5.1.1.2 Genetically engineered mouse models of PDAC ....................................................... 158 
5.1.1.3 Syngeneic orthotopic mouse models ........................................................................ 160 
5.2 RESEARCH HYPOTHESIS AND AIMS ........................................................................... 161 
5.3 RESULTS ..................................................................................................................... 162 
5.3.1 Effects of pimasertib on TB32048 tumor cells ................................................................. 162 
5.3.2 Combination of pimasertib with gemcitabine induces tumor growth delay in TB32048 
mice .......................................................................................................................................... 166 
5.3.3 Pimasertib/gemcitabine combination inhibits proliferation and induces apoptosis in 
TB32048 mice ........................................................................................................................... 170 
5.3.4 Pimasertib inhibits P-ERK activation in vivo ..................................................................... 172 
5.3.5 Pimasertib reduces RRM1 protein levels in vivo .............................................................. 173 
5.3.6 Pimasertib increases P-AKT expression in vivo ................................................................ 174 
5.3.7 High dose of pimasertib induces tumor growth delay in TB32048 mice when combined 
with gemcitabine ...................................................................................................................... 175 
5.3.8 Metastatic spread is reduced in the combination cohort ............................................... 177 
5.4 DISCUSSION ............................................................................................................... 179 
5.4.1 In vivo model systems to study cancer therapeutics ....................................................... 179 
5.4.2 MEK inhibition plus gemcitabine combination induces antitumor activity in an orthotopic 
mouse model of pancreatic cancer .......................................................................................... 181 
5.4.3 Pimasertib modulates RRM1 expression in vivo .............................................................. 182 
5.5 CONCLUSIONS ........................................................................................................... 183 
CONCLUSIONS AND FUTURE WORK ............................................................................ 185 
6.1 FUTURE DIRECTIONS: ................................................................................................ 188 
6.1.1 What are the effects of simultaneous administrations of gemcitabine with pimasertib in 
vivo? .......................................................................................................................................... 188 
6.1.2 Does knockdown of MDM2 sensitize pancreatic tumour mouse models to gemcitabine 
treatment? ................................................................................................................................ 188 
6.1.3 Can pre-treatment with pimasertib sensitize pancreatic cancer models to PI3K inhibitors 
plus gemcitabine combination? ................................................................................................ 189 
6.1.4 Effect of RRM1 inhibition in a mouse model of pancreatic cancer ................................. 189 
6.1.5 Analysis of RRM1 expression on human samples of pancreatic cancer .......................... 190 
6.2 CONCLUSIONS ........................................................................................................... 190 
REFERENCES ............................................................................................................... 192 
PUBLICATIONS ........................................................................................................... 225 
 
  
 14 
LIST OF FIGURES 
Figure 1.1: Morphologic features and genetic alterations of pancreatic precursor 
lesions. .................................................................................................................... 32 
Figure 1.2: Molecular structure of Gemcitabine: 2-deoxy-2,2-difluorocytidine. .......... 42 
Figure 1.3: Treatment Options in PDAC. ........................................................................ 48 
Figure 1.4: Gemcitabine metabolism and mechanisms of action. ................................ 52 
Figure 1.5: Structure of Ribonucleotide Reductase (RR). .............................................. 56 
Figure 1.6: The MAPK signalling cascade. ...................................................................... 61 
Figure 1.7: The structure of MEK1/2 protein. ................................................................ 65 
Figure 2.1: Schematic representation of the syngeneic orthotopic mouse model of 
pancreatic cancer generated. ................................................................................ 86 
Figure 3.1: Effect of gemcitabine on the proliferation of human pancreatic cancer cell 
lines. ....................................................................................................................... 94 
Figure 3.2: Effects of gemcitabine on cell proliferation in BxPC-3 and PANC-1 cell lines.
 ................................................................................................................................ 96 
Figure 3.3: Dose-dependent inhibition of P-ERK signaling by pimasertib. .................... 97 
Figure 3.4: Time-dependent inhibition of P-ERK signalling by pimasertib. ................... 97 
Figure 3.5: Effects of pimasertib on cell proliferation in BxPC-3 and PANC-1 cell lines.
 ................................................................................................................................ 98 
Figure 3.6: Effect of pimasertib and gemcitabine on the cell cycle. .............................. 99 
Figure 3.7: Effects of simultaneous treatment of pimasertib plus gemcitabine on BxPC-
3 cells proliferation. ............................................................................................. 102 
Figure 3.8: Effects of simultaneous treatment of pimasertib plus gemcitabine on 
PANC-1 cells proliferation. ................................................................................... 103 
Figure 3.9: Effects of sequential treatment of pimasertib with gemcitabine on BxPC-3 
cells proliferation. ................................................................................................ 105 
 15 
Figure 3.10: Effects of sequential treatment of pimasertib with gemcitabine on PANC-1 
cells proliferation. ................................................................................................ 106 
Figure 3.11: Effects of short sequential administration of pimasertib with gemcitabine 
on BxPC-3 cells proliferation. ............................................................................... 107 
Figure 3.12: Simultaneous treatment of pimasertib with gemcitabine does not 
enhance apoptosis. .............................................................................................. 108 
Figure 3.12 continued: Simultaneous treatment of pimasertib with gemcitabine does 
not enhance apoptosis. ........................................................................................ 109 
Figure 3.13: Pre-treatment with pimasertib enhances gemcitabine-induced apoptosis.
 .............................................................................................................................. 110 
Figure 3.14: Sequential but not simultaneous combination of pimasertib with 100nM 
gemcitabine enhances gemcitabine-induced apoptosis...................................... 111 
Figure 3.14 continued: Sequential but not simultaneous combination of pimasertib 
with 100nM gemcitabine enhances gemcitabine-induced apoptosis. ................ 112 
Figure 3.15: Pimasertib plus gemcitabine combination enhances cleaved-Parp 
expression. ........................................................................................................... 113 
Figure 3.16: Effects of pimasertib on CDA protein levels. ........................................... 114 
Figure 3.17: Pimasertib reduces RRM1 protein levels. ................................................ 115 
Figure 3.18: Pimasertib reduces RRM1 protein levels. ................................................ 116 
Figure 3.19: Pimasertib reduces RRM1 protein levels in other human pancreatic cancer 
cell lines. ............................................................................................................... 117 
Figure 3.20: The MEK1/2 inhibitor AS703988 alters RRM1 protein expression. ......... 118 
Figure 3.21: EGFR inhibition does not affect RRM1 protein expression. .................... 119 
Figure 3.22: Knockdown of MEK1 and MEK2 by siRNA causes inhibition of RRM1 
protein. ................................................................................................................. 120 
Figure 3.23: Pimasertib effect on RRM2 mRNA levels in BxPC-3 and PANC-1 cells. ... 121 
Figure 3.24: RRM1 mRNA levels are not affected by pimasertib in BxPC-3 and PANC-1 
cells lines. ............................................................................................................. 122 
 16 
Figure 3.25: Pimasertib reduces RRM1 protein levels after a 4–hour treatment in BxPC-
3 and PANC-1 cell lines. ........................................................................................ 122 
Figure 3.26: RRM1 expression correlates with pancreatic cancer cell sensitivity to 
gemcitabine. ......................................................................................................... 123 
Figure 3.27: RRM1 downregulation sensitizes PANC-1 response to gemcitabine. ..... 125 
Figure 3.28: RRM1 downregulation sensitizes BxPC-3 response to gemcitabine. ...... 126 
Figure 4.1: The ubiquitin-proteasome pathway. ......................................................... 134 
Figure 4.2:  PI3K/PDK1/AKT signalling pathway. .......................................................... 136 
Figure 4.3: RRM1 protein levels are reduced by pimasertib through a post-
translational modification. ................................................................................... 140 
Figure 4.4: Pimasertib enhances polyubiquitination of RRM1. ................................... 141 
Figure 4.5: RNF2 E3 ligase activity on RRM1 protein stability. .................................... 142 
Figure 4.6: MDM2 modulates RRM1 degradation induced by pimasertib. ................. 143 
Figure 4.7: RRM1 protein levels are increased in truncated mutant MDM2 cells. ..... 144 
Figure 4.8: The MDM2 antagonist Nutlin-3 impairs RRM1 degradation. .................... 145 
Figure 4.9: Pimasertib enhances MDM2 interaction with RRM1. ............................... 146 
Figure 4.10: Pimasertib-induced downregulation of RRM1 is independent of P53 
activity. ................................................................................................................. 147 
Figure 4.11: Pimasertib induces rapid activation of P-AKT. ......................................... 148 
Figure 4.12: MDM2 interacts with P-AKT. ................................................................... 149 
Figure 4.13: PI3K/AKT signalling inhibition impairs the downregulation of RRM1. .... 150 
Figure 5.1: Schematic representation of the KC mouse model. .................................. 159 
Figure 5.2: Sequential combination of pimasertib followed by gemcitabine induces 
synergistic antiproliferative activity in KPC cells. ................................................. 162 
Figure 5.2 continued: Sequential combination of pimasertib followed by gemcitabine 
induces synergistic antiproliferative activity in KPC cells. ................................... 163 
Figure 5.3: Pimasertib reduces RRM1 protein levels in TB32048 cells. ....................... 164 
 17 
Figure 5.4: AKT inhibition impairs RRM1 downregulation induced by pimasertib in 
TB32048 cells........................................................................................................ 165 
Figure 5.5: The sequential combination of pimasertib with gemcitabine delays tumor 
growth in vivo. ...................................................................................................... 168 
Figure 5.6: Tumor volumes of TB32048 mice before and after drug treatment. ........ 169 
Figure 5.7:  TB32048 mice develop pancreatic tumor morphology. ........................... 170 
Figure 5.8:  Effects of pimasertib and gemcitabine on proliferation and apoptosis of 
TB32048 mice. ...................................................................................................... 171 
Figure 5.9: Pimasertib inhibits P-ERK protein expression in TB32048 mice. ............... 172 
Figure.5.10: Pimasertib destabilizes RRM1 protein inTB32048 mice. ......................... 173 
Figure 5.11: Pimasertib increases P-AKT expression in xenograft mice. ..................... 174 
Figure 5.12: Pimasertib (15mg/kg) in combination with gemcitabine delays tumor 
growth in vivo. ...................................................................................................... 175 
Figure 5.12 continued: Pimasertib (15mg/kg) in combination with gemcitabine delays 
tumor growth in vivo. ........................................................................................... 176 
Fig. 5.13: 15mg/kg pimasertib reduces P-ERK and RRM1 expression in TB32048 mice.
 .............................................................................................................................. 176 
Figure 5.15 Pimasertib 5mg/kg plus gemcitabine-treated mice do not reduce the 
incidence of metastases compared to other cohorts. ......................................... 177 
Figure 5.16: pimasertib 15mg/kg plus gemcitabine-treated mice develop less 
metastases compared to vehicle-treated mice. .................................................. 178 
Figure 5.17: Establishment of pancreatic ductal organoids. ....................................... 180 
Figure 5.18: Graphical abstract of the mechanism of action of pimasertib with 
gemcitabine. ......................................................................................................... 184 
 
  
 18 
LIST OF TABLES 
Table 1.1:  Clinical trials results in metastatic PDAC patients. ....................................... 45 
Table 1.2:  List of genes associated with gemcitabine resistance. ................................ 53 
Table 2.1: Primary and secondary antibodies used for western blotting analysis. ....... 82 
Table 3.1: Characteristics of human pancreatic cancer cell lines. ................................. 95 
Table 3.2: IC50 values of BxPC-3, MIAPaCa-2 and PANC-1 cell lines. .......................... 123 
Table 5.1: Schematic schedule of treatments. ............................................................. 167 
 
  
 19 
LIST OF ABBREVIATIONS 
ADAM              Metallopeptidase domain 17 
ADM                Acinar-to-Ductal Metaplasia 
APC             Adenomatous Polyposis Coli 
Ara-C               Cytosine Arabinoside  
ATCC                American Tissue Culture Collection 
ATP             Adenosine Triphosphate 
ATM             Ataxia Telangiectasia Mutated 
ATR             Ataxia Telangiectasia Rad3-related 
BRAF             V-Raf Murine Sarcoma Viral Oncogene Homolog B 
BRCA1             Breast Cancer 1, early onset 
BRCA2             Breast Cancer 2, early onset 
BSA              Bovine Serum Albumin 
CAF                  Cancer-associated fibroblasts 
CC3                  Cleaved Caspase 3 
CDA                 Cytidine deaminase 
CDKN2A          Cyclin-Dependent Kinase Inhibitor 2A 
c-Jun             Jun aminoterminal kinase (or JNK) 
CRT                 Chemoradiotherapy 
CT            Cycle Threshold 
CI            Combination Index 
CRC            Colorectal Cancer 
DACH            1,2-Diaminocycloexhane 
DBSs            DNA Double Strand Breaks 
dC                   Deoxycytidine 
 20 
dCTD               Deoxycytidylate deaminase 
dCTP                Deoxycytidine triphosphate 
dCK                  Deoxycytidine kinase  
dFdC                Defluorodeoxycytidine 
DMEM             Dulbecco’s Modified Eagle’s Medium 
DMSO              Dimethyslulphoxide  
dNTP                Deoxynucleotide triphosphate 
dTMP               Deoxythymidine monophosphate 
DUBs             DeUbiquitinating enzymes 
dUTP               Deoxyuridine monophosphate 
ECM                Extracellular Matrix 
EDTA            Ethylenediaminetetraacetic Acid 
EGF            HER1 or ErbB1, Epidermal Growth Factor 
EGFR            Epidermal Growth Factor Receptor 
EGTA             Ethylene Glycol Tetra-acetic Acid 
EMT            Epithelial-Mesenchynal Transition 
ER            Endoplasmic Reticulum 
ErbB2             HER2 or ErbB2/neu, Epidermal Growth Factor Receptor 2 
ErbB3            HER3, Epidermal Growth Factor Receptor 3 
ErbB4            HER4, Epidermal Growth Factor Receptor 4 
ERCC1             Excision Repair Cross-Complementation Group 1 
ERK1/2            Extracellular Signal-Regulated Kinases 
ESC                  Embryonic Stem Cells 
FA                    Fraction Affected 
FACS              Fluorescence-Activated Cell Sorting 
FAMM             Familial atypical multiple mole melanoma 
 21 
FDA                 Food and Drug administration 
FGF             Fibroblast Growth Factor 
FGFR             Fibroblast Growth Factor Receptor 
FdUTP              Fluorodeoxyuridine triphosphate 
FOLFIRI            Folinic acid, Fluorouracil and Irinotecan 
FOLFIRINOX      Folinic acid, Fluorouracil, Irinotecan and Oxaliplatin 
FOLFOX            Folinic acid, Fluorouracil and Oxaliplatin 
5-FU    5-Fluorouracil 
FUTP                 Fluorouridine triphosphate 
Fzd                  Frizzled Receptors 
GAB2   GRB2 Activating Protein 2 
GAPs   GTPase Activating Proteins 
GAS   Gamma interferon activation site 
GDP   Guanosine DiPhosphate 
GemCap          Gemcitabine plus Capecitabine 
GEMM             Genetically Engineered Mouse Model 
GM-CSF            Granulocyte-macrophage colony-stimulating factor 
GTP                 Guanosine Triphosphate 
GPCRs   G-Protein Coupled Receptors 
GPX2   Glutathione peroxidase 2 gastrointestinal 
Grb2   Growth Factor Receptor Bound Protein 2 
GSH   Glutathione  
GSK3   Glycogen Synthase Kinase 3 
GTP   Guanosine TriPhosphate 
GSTZ1   Glutathione Transferase Zeta 1 
GO    Glucose Oxidase 
 22 
HB-EGF Heparin-Binding EGF 
hCNT              Concentrative Nucleoside transporters 
HCl            Hydrochloric acid 
hENT               Equilibrative Nucleoside transporters 
HH                  HedgeHog 
H2O2                Hydrogen Peroxide 
HR                   Hazard Ratio 
HRAS            Harvey RAS 
HRP            Horseradish Peroxidase 
IGF1R            Insulin-like Growth Factor 1 Receptor 
IHC                 Immunohistochemistry 
IP3             Inositol 1,3,5 triphosphate 
IPM                Intracellular mucinous neoplasms 
JAK            Janus Kinase 
JNK            c-Jun-N-terminal Kinase 
KD            Kinase Domain 
KPC                KrasLSL.G12D/+; p53R172H/+; PdxCretg/+ 
K-RAS            Kirsten Rat Sarcoma Viral Oncogene Homologue 
mAbs            Monoclonal Antibodies 
MAPK            Mitogen Activated Protein Kinase 
MDM2            Mouse Double Minute 2 Homologue 
mDNA            Mitochondrial DNA 
MEK 1/2         Mitogen-Activating Protein Kinase Kinase 1/2 
MEK 4/6         Mitogen-Activating Protein Kinase Kinase 4/6 
MET            Met Proto-Oncogene 
MMP             Matrix MetalloPeptidase 
 23 
MPACT            Metastatic Pancreatic Adenocarcinoma Clinical Trial 
mTOR             Mammalian target of rapamycin 
MTT             Methylthiazolyldiphenyl-tetrazolium bromide 
NAC   N-Acetyl-L-Cysteine  
NaCl  Sodium Chloride 
NADPH Nicotinamide Adenine Dinucleotide Phosphate 
NAOH  Sodium Hydroxide 
NER  Nucleotide Excision Repair 
NF  Nuclear Factor  
NHEJ  Non-Homologous End Joining  
Nrf2  Nuclear Factor Erythroid 2-like 
NRAS   Neuroblastoma RAS Viral (V-Ras) 
NSCLC  Non-Small Cell Lung Cancer 
OD  Optical Density 
OS  Overall Survival 
OH-  Hydroxyl Radical 
p16                    Cyclin-Dependent Kinase Inhibitor 2A 
p21  Cyclin-Dependent Kinase Inhibitor 1A 
p27  Cyclin-Dependent Kinase Inhibitor 1B 
p38  Mitogen Activated protien kinase p38 
p53                    Tumor suppressor  
p53-R2              p53 inducible Ribonucleotide Reductase subunit-2 
PBS   Phosphate buffered saline  
PCR  Polymerase Chain Reaction 
PDAC                 Pancreatic Ductal Adenocarcinoma 
PDGF  Platelet-Derived Growth Factor 
 24 
PDGFR  Platelet Derived Growth Factor Receptor 
PDK1  Phosphoinositide-Dependent Kinase 1 
PDX                  Patient-derived Xenograft  
PFA  Paraformaldehyde 
PFS   Progression Free Survival 
PI3K  Phosphatidylinositol 3-kinase 
PIK3CA  Phosphatidylinositol 3-kinase 
PIK3CB  PI3-Kinase P110 Subunit Beta 
PIP2  PhosphatidylInositol 4,5-bisPhosphate 
PIP3  PhosphatidylInositol 3,4,5 triPhosphate 
PIP4K2A Phosphatidylinositol-4-Phosphate 5-Kinase Type II Alpha 
PKC  Protein Kinase C 
PCR                  Polymerase Chain Reaction 
PTEN  Phosphate and tensin homologue phosphatase 
PTB  Phospho-Tyrosine Binding 
PTPN12 Protein-Tyrosine Phosphatase G1  
Rb  Retinoblastoma 
RIPA  Radioimmunoprecipitation Assay Buffer 
ROS  Reactive Oxygen Species 
RPS6              Ribosomal S6 protein  
RR                    Ribonucleotide Reductase 
RRM1               Ribonucleotide Reductase Subunit-1 
RRM2               Ribonucleotide Reductase Subunit-2 
RSK   p90 Ribosomal S6 Kinase 
RT-PCR  Real Time PCR 
RTKs    Receptor Tyrosine Kinases 
 25 
SDS  Sodium Dodecyl Sulfate 
SH2  Src-Homology 2 domain  
SH3  Src-Homology 3 domain 
shRNA              Short-hairpin RNA 
siRNA              Small-interfering RNA 
SMAD4              Mothers against decapentaplegic homolog 4 
SMO                  Smoothened gene 
SOS               Son of Sevenless 
SPARC                Secreted protein acidic and rich in cysteine 
Src   V-Src Avian Sarcoma Viral Oncogene Homolog 
TE   Tris-EDTA 
TBS   Tris-Buffered Saline 
TGF-   Transforming Growth Factor- 
TGF-β   Transforming Growth Factor-β 
TKIs   Tyrosine Kinase Inhibitors 
Top1   Topoisomerase I 
TP53   Tumour suppressor P53 
TK                     Tyrosine kinase 
TKIs    Tyrosine kinase inhibitors 
TKR                   Tyrosine kinase receptors 
TS   Thymidylate synthase 
Ub   Ubiquitin 
UV   Ultra-Violet irradiation 
VEGF              Vascular Endothelial Growth Factor  
      
 26 
 
 
 
 
CHAPTER 1  
INTRODUCTION 
 
 
 
 
 
 
 
  
 27 
1.1 CANCER BIOLOGY 
Intense research conducted over the past two decades on cancer cell biology has 
supported the conclusion that cancer is a complex disease characterised by the 
sequential acquisition of genomic alterations and importantly, that every human 
tumor is unique in its genomic mutations (Vogelstein et al. 2013). Tumorigenesis 
arises from an acquired abnormal and uncontrolled cell proliferation (Croce 2008). 
Mutations that enable cells to become tumorigenic and ultimately develop cancer 
affect two classes of genes: oncogenes (with gain of function mutations) and tumor 
suppressor genes (with recessive loss of function of mutations). Oncogenes are 
involved in cell proliferation; on the other hand, tumor suppressor genes inhibit cell 
division (Vogelstein and Kinzler 2004). The acquisition of mutations within these genes 
drives the transition of normal human cells into malignant cells (Vogelstein and Kinzler 
2004). Cells acquire six fundamental physiologic hallmarks capabilities that enable 
tumor development and growth:  
First, they acquire the capability to sustain chronic proliferation. This is achieved for 
example by not depending solely on mitogenic growth signals but by generating their 
own growth signals or by becoming insensitive to anti-growth signals (Hunter 1997). 
Additionally, cancer cells can increase the levels of receptor proteins that stimulate 
proliferative signalling or activate their downstream components (Hanahan and 
Weinberg 2011). Excessive amounts of oncogenic signaling (such as K-RAS) can induce 
cells into a viable but non-proliferative state (senescence) (Collado and Serrano 2010). 
Finally, defects in negative feedback mechanisms that control pathways that modulate 
proliferative signals thus ensuring homeostasis result in sustained cellular 
proliferation. An example is represented by loss of function mutation of PTEN 
phosphatase, which leads to amplification of PI3K signaling (Yuan and Cantley 2008). 
Programmed cell death (apoptosis) is composed of upstream regulators activated in 
response to physiological stresses, which in turn activate downstream components 
responsible for the destruction of the cell (Adams and Cory 2007). Cancer cells acquire 
the ability to escape programmed cell death pathways, for example through the loss 
of the P53 tumor suppressor gene or by increasing antiapoptotic protein expression 
such as Bcl-2 and Bcl-XL (Hanahan and Weinberg 2011). 
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The third biological hallmark acquired by cancer cells is the ability to escape growth 
suppressor’s activity controlling cell proliferation such as the Rb (retinoblastoma-
associated) and TP53 proteins. These proteins decide whether a cell should 
proliferate, undergo senescence (irreversible growth arrest) or trigger apoptosis 
(Hanahan and Weinberg 2011). 
The growth of new blood vasculature, known as angiogenesis, sustains cells 
proliferation by supplying them with the appropriate nutrients and oxygen (Hayflick 
1997). The process of angiogenesis is tightly regulated in normal cells but it is almost 
always switched on in tumor cells. The ability to induce and sustain angiogenesis can 
be caused by increased expression of angiogenic inducers (such as VEGF) and 
downregulation of angiogenic inhibitors. Additionally, oncogenes such as myc or Ras 
and immune inflammatory cells can turn on angiogenesis from early stages of tumor 
development (Hanahan and Folkman 1996). 
Another important hallmark of cancer cells is the ability of unlimited replicative 
potential (Hanahan and Weinberg 2011). In normal cells telomeres, regions of 
repetitive DNA, protect the chromosomes end from degradation or fusion. Without 
these structures, chromosome ends get damaged, causing a DNA damage response 
that leads to senescence or apoptosis. During DNA replication, telomeres shorten and 
ultimately cells stop dividing. Telomere lengths are maintained by telomerase 
enzymes, whose expression is increased in tumor cells, enabling them to replicate 
indefinitely (Kim et al. 1994). 
Finally, cancer cells are able to invade and metastasise. This process begins with 
malignant tumor cells escaping the primary tumor site, intravasating into blood 
vessels and invading adjacent tissues where micrometastases are formed. Ultimately 
these metastases generate macroscopic tumors and metastasize into distant organs 
(Fidler 2003). Loss of E-cadherin, a gene responsible for the formation of adherens 
junctions between adjacent epithelial cells, is frequent in tumors that originate from 
epithelial tissues and is associated with enhanced invasion and metastasis (Cavallaro 
and Christofori 2004). 
Taken together, this multiplicity of changes is responsible for tumor development and 
for driving the malignant progression of the disease (Vogelstein and Kinzler 2004).  
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This thesis will focus on a specific type of gastrointestinal malignancy: pancreatic 
cancer. 
 
1.2 PANCREATIC CANCER 
1.2.1 Overview 
Pancreatic cancer, with an overall 5-year survival rate of less than 5% and a median 
survival of less than 6 months is the 5th leading cause of cancer-related death 
worldwide (Vogelzang et al. 2012). Early detection is impaired by absence of 
symptoms, the inaccessible position, which make diagnosis difficult and the lack of 
specific diagnostic markers (Bardeesy and DePinho 2002) (Costello et al. 2012). In 
addition, the rapid acquisition of resistance to chemotherapy and the ability to 
metastasize rapidly contribute to its aggressiveness and mortality rate (Collisson et al. 
2012). Only 15-20% of patients are candidates for surgical resection, which represents 
the only chance for a complete cure (Ottenhof et al. 2011). However, even in this 
small subset, there is a 5-year survival rate of 20%. The remaining 75-80% of cases are 
diagnosed with locally advanced or metastatic disease, in which systemic 
chemotherapy provides only small and temporary benefit and the overall survival is 
less than 1 year (Von Hoff et al. 2013).  
 
1.2.2 Epidemiology and risk factors  
Pancreatic cancer risk increases with advanced age, with less than 10% of patients 
diagnosed being under the age of 50 years (Deutsch et al. 1999). Tobacco smoking can 
also increase the risk of pancreatic cancer by 70-100% (Iodice et al. 2008). 
Furthermore, heavy alcohol consumption and body mass index (BMI) > 35 are 
environmental risk factors that contribute to the development of this disease. Benign 
diseases such as type-two diabetes increase the risk of pancreatic cancer by 20 fold 
(Everhart and Wright 1995) (Raimondi et al. 2009).  
Lastly, the inheritance of specific genetic mutations that cause familial syndromes can 
be related to increased pancreatic cancer risk (Zhen et al. 2015). For example, 
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individuals with FAMMM (familial atypical multiple mole melanoma) syndrome, 
characterised by germline mutations in the CDKN2A (p16) gene, have a 13-fold 
increased risk of developing pancreatic cancer (Bartsch et al. 2002) (Lynch et al. 2002). 
Individuals carrying germline BRCA2 gene mutations have also a higher risk of 
pancreatic cancer (Ozcelik et al. 1997) and almost 17% of familial pancreatic cancers 
carry a mutation within the BRCA2 gene (Murphy et al. 2002). Finally, germline 
mutations in the MLH1 gene, involved in DNA mismatch repair are linked to familial 
PDAC (Yeo et al. 2002).  
Chronic pancreatitis, an inflammatory disease of the pancreas, leads to the 
transformation of acinar cells into duct-like cells, a process called acinar-to-ductal 
metaplasia (ADM) (Reichert and Rustgi 2011). ADM can generate pancreatic lesions 
and develop into malignant PDAC (Reichert and Rustgi 2011). Hereditary pancreatitis, 
characterised by germline mutations of catyonic trypsinogen gene PRSS1, is associated 
with increased risk of developing pancreatic cancer (Witt et al. 2000).  
Cystic fibrosis is caused by mutation in the cystic fibrosis transmembrane regulatory 
gene (CFTR), which impairs cyclic AMP mediated chloride function, thus causing duct 
obstruction due to mucous secretion. This hereditary syndrome can also augment the 
risk of pancreatic cancer (Maisonneuve et al. 2007). 
 
1.2.3 Biology of pancreatic ductal adenocarcinoma (PDAC) 
Pancreatic cancer can be classified into two major categories according to the type of 
cells it originates from: exocrine and endocrine tumours. Exocrine pancreatic tumours 
are further divided into adenocarcinomas and a variety of other pancreatic 
neoplasms. Pancreatic ductal adenocarcinoma (PDAC), a cancer of the exocrine 
pancreas, is the most frequent type of pancreatic cancer (Warshaw and Fernandez-del 
Castillo 1992). PDAC is characterised by cuboidal or columnar cells that undergo acinar 
to ductal metaplasia (ADM). These ductal cells are surrounded by fibroblasts, immune 
cells, pancreatic stellate cells and excessive production of extracellular matrix (ECM)-
rich connective tissue: this phenomenon is referred to as desmoplasia and is a 
common feature in PDAC tumors (Jaster 2004). The desmoplastic reaction reduces 
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tumor tissue elasticity and increases tumor interstitial fluid pressure that represents a 
barrier for many chemotherapeutic agents (Lohr et al. 1994) (Heldin et al. 2004).  
PDAC originates from precursor lesions identified as intraductal papillary mucinous 
neoplasm (IPMN), mucinous cystic neoplasm (MCN) or pancreatic intraepithelial 
neoplasia (PanIN), the latter being the most frequent pre-lesions to occur and the best 
characterised (Hruban et al. 2004) (Figure 1.1). PanINs are classified into different 
grades based on their morphological characteristics and severity of the lesions: PanIN 
1A (flat duct lesions), PanIN 1B (papillary duct lesions), PanIN 2 (papillary duct lesions 
with dysplasia) and PanIN 3 (also known as carcinoma-in-situ), which present all the 
cancer characteristics. PanIN lesions are part of the tumor progression path that 
ultimately generates invasive carcinoma (Hruban et al. 2001) (Ottenhof et al. 2011) 
(Fig 1.1). PanIN lesions are characterised by hypovascularity, immune cell infiltration 
and feature specific genetic alterations that increase in frequency and variety with the 
progression of PanIN stages. These biological alterations are required for PanIN 
lesions to progress into invasive carcinoma and are also implicated in the rapid 
metastatic spread that characterises this malignant disease (Hezel et al. 2006).  
 
1.2.4 Genetic alterations found in PDAC 
PDAC is characterised by a series of alterations in multiple genes (Samuel and Hudson 
2012). Although less than 10% of PDACs are hereditary and germline mutations of 
BRCA2, INK4A have been related with familial PDAC (Schenk et al. 2001, Jaffee et al. 
2002), the acquisition of a high diversity of somatic mutations is believed to be the 
main driver of neoplastic progression (Samuel and Hudson 2012).  
A clinical study performing global genomic analyses on PDAC samples identified about 
63 genetic alterations affecting almost 12 different signalling pathways, including K-
RAS, TGF-β signalling, the HedgeHog and the Wnt pathway (Jones et al. 2008). The 
four hallmark genetic alterations that characterize PDAC are represented by mutation 
of K-RAS, TP53, SMAD4 and CDKN2A genes (Bardeesy and DePinho 2002). 
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Figure 1.1: Morphologic features and genetic alterations of pancreatic precursor lesions.  
Human pancreatic precursor lesions: IPMN, MCN and PanINs. PanINs are graded from I to III and 
ultimately generate invasive PDAC. Genetic alterations occurring in PanINs are listed (Hezel et al. 2006). 
 
1.2.4.1 Oncogenic K-RAS  
RAS proteins are monomeric G proteins and belong to the family of small GTPases (or 
GTP binding proteins) that control several signalling pathways within the cell 
(Rajalingam et al. 2007). The MAPK (mitogen activated protein kinase) pathway is one 
of the many signalling cascades regulated by RAS and promotes cellular proliferation, 
differentiation and survival (Malumbres and Barbacid 2003). K-RAS mutations are 
present in almost 90% of PDACs (Morris et al. 2010); however, mutant K-RAS may also 
be found in chronic pancreatitis or healthy pancreas (Luttges et al. 1999). RAS proteins 
are bound to GDP or GTP and they function as molecular switches (Pylayeva-Gupta et 
al. 2011). A point mutation at codon G12 of the K-RAS oncogene is the most frequent 
to occur (Smit et al. 1988). This mutation affects the GTP-ase activity, by reducing GTP 
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hydrolysis, which leads to constitutive activation of K-RAS and increased stimulation of 
multiple effector pathways, such as RAF/MEK/ERK and PI3K/mTOR. The persistent 
activation of these pathways leads to uncontrolled cellular proliferation and 
transformation (Pylayeva-Gupta et al. 2011). The first studies that investigated the 
role of the K-RAS gene in cancer showed that mutation of K-RAS induced the 
formation of tumors in vivo; therefore K-RAS has been classified as oncogene 
(Fernandez-Medarde and Santos 2011). 
 
1.2.4.1.1 KRAS is required for PanIN initiation and development into PDAC 
K-RAS mutation is the earliest and most frequent genetic alteration to occur in PanIN 
lesions (Kanda et al. 2012). Several studies on genetically engineered mouse models 
(GEMMs) have demonstrated the fundamental role that oncogenic K-RAS plays in the 
pathogenesis of PDAC (Morris et al. 2010). Mouse models characterised by 
constitutively activated oncogenic K-RAS developed PanIN lesions similar to the ones 
observed in the human disease. As the mice aged, these lesions acquired a dense 
stroma, inflammatory cells and progressed into invasive adenocarcinoma (Aguirre et 
al. 2003) (Hingorani et al. 2003). A pivotal study on inducible K-RASG12D mice, in which 
K-RAS is expressed in pancreatic epithelium in a reversible manner, observed that 
activation of oncogenic K-RAS followed by induction of acute pancreatitis generated 
acinar-to-ductal metaplasia (ADM) and infiltration of immune cells that progressed to 
PanIN formation, as opposed to K-RAS wild type mice in which the damage repaired 
rapidly and the pancreas resumed its normal histological features (Guerra et al. 2007) 
(Collins et al. 2012). Furthermore, these inducible K-RASG12D-driven PDAC models 
showed complete regression of PanINs and downregulation of PanIN markers in 
epithelial cells upon K-RASG12D inactivation indicating that K-RAS activity is required for 
PanIN progression (Collins et al. 2012). 
Although, there is clear evidence showing that K-RAS is essential in the initiation and 
development of early PanINs, expression of mutant K-RAS alone is not sufficient to 
cause cellular transformation. For example, an in vivo study showed that mice 
expressing K-RAS mutations in the whole organ developed tumors from only a small 
percentage of cells (Guerra et al. 2007). Furthermore, induction of oncogenic K-RAS in 
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mice during early organogenesis led to the development of a tumor-free pancreas 
with PanIN lesions occurring only after few weeks and progression to PDAC at 1 year 
(Hingorani et al. 2003). Other genetic alterations have been shown to accelerate or 
sustain the appropriate levels of oncogenic K-RAS activity required to fully drive the 
neoplastic process (di Magliano and Logsdon 2013). The introduction of a mutant p53 
allele on the p53 gene in inducible K-RAS mice accelerated PDAC development 
induced by K-RAS mutations (Collins et al. 2012) and increased metastasis compared 
to identical mice carrying a null P53 allele (Morton et al. 2010). Furthermore, initiation 
of PanIN lesions and progression into fully invasive adenocarcinoma in KRAS-driven 
mice has been shown to be accelerated by introducing mutations within the SMAD4 
and CDKN2A genes (Morris et al. 2010). Finally, EGFR activation has been shown to 
increase the activity of oncogenic K-RAS to initiate pancreatic tumorigenesis (Ardito et 
al. 2012). 
 
1.2.4.1.2 Oncogenic K-RAS activity affects the tumor microenvironment 
The pancreatic tumor microenvironment is characterised by a dense desmoplastic 
stroma surrounded by inflammatory cells (Hezel et al. 2006). Chronic pancreatitis has 
been recognised as a risk factor in developing PDAC (Malka et al. 2002). Induction of 
oncogenic K-RAS in the acinar compartment during embryonic development 
generated PanIN lesions, which ultimately developed into invasive PDAC, a phenotype 
not observed if K-RAS was induced during adulthood (Guerra et al. 2007). However, 
treatment with careulin, which induced pancreatitis, was sufficient to cause 
transformation of acinar cells into ductal cells and for PDAC development in inducible 
K-RAS adult mice (Guerra et al. 2007). These observations suggested that 
inflammatory responses cooperate with K-RAS in promoting PDAC development. 
The findings discussed above indicate the crucial role of sustained oncogenic K-RAS 
activity for pancreatic cancer formation and development and highlight the 
importance of other genetic alterations or inflammatory stimuli in driving K-RAS 
induced carcinogenesis. 
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1.2.4.2 CDKN2A gene inactivation 
Inactivation of the CDKN2A (cyclin dependent kinase inhibitor 2A) tumour suppressor 
gene is found in almost 90% of sporadic pancreatic adenocarcinomas and usually 
occurs in high-grade PanIN lesions. The CDKN2A gene encodes for the P16/INK4A and 
P14ARF proteins. Alterations within these genes cause uncontrolled G1/S phase 
transition, since the inhibition of retinoblastoma (Rb-1) protein phosphorylation by 
p16 is lost and thus the cell cycle is no longer regulated (Wilentz et al. 1998). Mutation 
of CDKN2A cooperates with activated KRAS to promote tumor progression (Bardeesy 
et al. 2006). 
 
1.2.4.3 TP53 mutation  
The most common genetic mutation observed in human cancer occurs in the P53 gene 
and is associated with poor patient prognosis (Bieging et al. 2014). Upon DNA damage 
or other oncogenic stresses, P53 is activated and triggers transient cell cycle arrest, 
senescence or apoptosis depending on the stimulus and cellular context (Bieging et al. 
2014). 
P53 mutation is usually caused by missense alteration of the DNA binding-domain 
(Rozenblum et al. 1997) (Freed-Pastor et al. 2012), resulting in loss of wild-type P53 
function (Bieging et al. 2014). Between 50% and 75% of PDAC patients carry a 
mutation of the P53 tumor suppressor gene, which usually occurs in advanced PanIN3 
lesions (Li et al. 2004). The introduction of an inactivating mutation in the P53 gene 
accelerated PDAC development in inducible K-RAS mouse models compared to 
identical mice harbouring a P53null allele, suggesting that this contributes to 
pancreatic tumor progression (Guerra et al. 2007).  
An in vivo study has shown that TP53 mutations prevent growth arrest, senescence 
and promote metastasis in mutant K-RAS mice of pancreatic cancer (Morton et al. 
2010). Furthermore, a microarray analysis on human PDAC tissues revealed a direct 
correlation between mutant P53 accumulation and lymph node metastasis, 
confirming the prometastatic functions of P53 mutation (Morton et al. 2010).  
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Finally a recent study generated a pancreatic cancer mouse model by injecting into 
nude mice KPC cells (generated by the KPC mouse model, characterised by oncogenic 
K-RAS and mutant TP53R172H) whose mutant TP53 R172H had been knocked down with 
short hairpin RNA (shRNA). The incidence of metastasis was significantly lower in mice 
in which mutant TP53 was depleted compared to mice transfected with control 
shRNA, indicating that P53 mutation is required to sustain metastatic spread in this 
murine model (Weissmueller et al. 2014).  
 
1.2.4.4 SMAD4/DPC4 gene mutation 
SMAD4 (mother against decapentaplegic, drosophila, homolog of 4)/DPC4 (deleted in 
pancreatic carcinoma 4) is a tumour suppressor gene that mediates the TGF-β 
(transforming growth factor beta) signalling network, which induces growth inhibition 
(Massague et al. 2000). Loss of SMAD4/DPC4 is frequent in PanINs, thus inducing 
disruption of TGF-β signalling, which leads to uncontrolled cell proliferation 
(Massague et al. 2000). A recent study observed that TGF-β1 contributed to the 
induction of a desmoplastic reaction in PDAC models, a common pathological 
characteristic in pancreatic tumors, causing impaired drug delivery into the tumor site 
(Lohr et al. 2001). 
 
1.2.4.5 Other genetic alterations found in PDAC  
1.2.4.5.1 The Wnt-β-catenin signalling pathway 
The Wnt signalling cascade consists of a family of glycoproteins that bind to receptors 
of the Frizzled (Fzd) family (Anastas and Moon 2013). The canonical Wnt-β-catenin 
signalling pathway regulates proliferation and differentiation during embryonic 
development. Ligands binding to this pathway trigger a signalling cascade that 
prevents the degradation of β-catenin (Morris et al. 2010). Activation of this pathway 
and accumulation of β-catenin is frequently found in PanIN lesions of PDAC mice. To 
establish whether the Wnt pathway is required in pancreatic cancer development, the 
effects of inhibitors of the Wnt pathway receptor Fzd were examined in mouse 
models and a delay in PanIN formation and progression was observed (Zhang et al. 
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2013). Other preclinical results demonstrated that both pharmacological and 
biological (by using specific siRNA) inhibition of the Wnt pathway significantly blocked 
proliferation and enhanced apoptosis in PDAC cell lines (Pasca di Magliano et al. 
2007). These results indicate that the development of PDAC also depends on the 
acquisition of genetic alterations within embryonic pathways and provide a strong 
rationale for developing therapeutic strategies targeting the Wnt signalling cascade 
for PDAC treatment. 
 
1.2.4.5.2 Upregulation of the Epidermal Growth Factor Receptor (EGFR)  
Upregulation of receptor tyrosine kinases, in particular of epidermal growth factor 
receptor (EGFR) and its ligands, has been found in low-grade PanINs (Tobita et al. 
2003) (Morgan et al. 2008). Concomitant activation of oncogenic K-RAS and EGFR 
signalling accelerates the progression of a different type of pancreatic lesions (IPMN) 
into invasive neoplasia (Siveke et al. 2007). Preclinical studies have indicated that 
inhibition of EGFR signalling impairs PDAC development and progression in KRAS-
driven pancreatic cancer mouse models (Navas et al. 2012).  
As previously mentioned, PDAC is characterised by the formation of metaplastic-duct 
like cells from the corresponding acinar cells (ADM), a process triggered by chronic 
pancreatic inflammation (Guerra et al. 2007). A study on oncogenic KrasG12D mice 
observed upregulation of the EGFR pathway in acinar cells, which strikingly increased 
upon induction of pancreatic damage caused by cerulein treatment. EGFR activation 
was detected upon duct cells formation in primary acinar cells explants isolated from 
the same mice suggesting that EGFR is required in the acinar to ductal transformation 
both in vitro and in vivo (Ardito et al. 2012). To confirm this hypothesis, the 
investigators showed that ADM transformation occurred in acinar cells explants 
derived from KrasG12D mice after 3 days in culture but was not observed in KrasG12D 
and EgfrKO mice. K-RAS-driven pancreatic tumorigenesis was suppressed by 
pharmacological inhibition of EGFR and by depletion of ADAM17, a metalloproteinase 
involved in EGFR activation (Ardito et al. 2012).  
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1.2.4.5.3 BRCA mutation 
The BRCA1 and BRCA2 tumour suppressor genes play a fundamental role in regulating 
gene transcription, maintaining chromosomal stability and in the repair of DNA double 
strand breaks (Roy et al. 2012). BRCA mutation induces alterations in the homologous 
recombination-based DNA repair pathway, thus leading to genomic instability 
(Venkitaraman 2002). BRCA2 gene mutations occur at a late stage in pancreatic 
tumorigenesis (Murphy et al. 2002) (van der Heijden et al. 2004). Tumors harbouring 
mutant BRCA genes have been associated with increased sensitivity to platinum-based 
chemotherapeutic agents and poly (ADP-ribose) polymerase (PARP) inhibitors. In 
normal cells, DNA damage is repaired by homologous recombination. However, in 
BRCA deficient tumors, this process is impaired and double strand breaks cannot be 
efficiently repaired (Lord and Ashworth 2012). PDAC patients with BRCA mutation 
who received platinum-based therapies demonstrated a better OS than patients who 
were treated with non-platinum agents (22 months versus 9 months) (Golan et al. 
2014). Therefore, BRCA could be an important prognostic factor for PDAC and there is 
now increasing interest in exploring whether platinum-based regimens would provide 
benefit to PDAC patients carrying BRCA2 mutations. 
 
1.2.4.6 Telomere shortening  
Telomeres are a region of repetitive nucleotide sequences at the end of a 
chromosome that protects these ends from sticking to other chromosome ends. Short 
telomeres induce chromosomal rearrangements through anaphase bridging and 
breakage-fusion cycles, which generate chromosomal instability (Artandi et al. 2000). 
Previous evidence classified telomere shortening as a neoplastic event that commonly 
occurs in pancreatic cancer. Specifically, quantitative fluorescence in situ hybridization 
(FISH) biopsies on non-cancerous or cancerous pancreatic tissues showed alteration of 
telomeres function in low-grade to high-grade of pre-cancerous PanIN lesions, a 
phenomenon that leads to chromosomal abnormalities and as a consequence to the 
development of invasive PDAC (Matsuda et al. 2015). 
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1.2.5 Invasive and metastatic properties of PDAC cells  
Metastasis is a multistep process in which cancerous cells detach from the primary 
tumor, invade the surrounding stroma, intravasate into the circulatory systems (blood 
and lymph) and finally disseminate into distant organs (Valastyan and Weinberg 2011) 
(Valastyan and Weinberg 2011). Almost 90% of cancer-related deaths are caused by 
metastasis and not by the primary tumor (Mehlen and Puisieux 2006).  
Previous evidence has indicated that metastatic spread occurs at late stage in the 
clonal evolution of pancreatic cancer and that primary tumors have to proliferate for 
almost ten years before they acquire the genetic and epigenetic alterations required 
to produce a metastatic phenotype (Campbell et al. 2010). However, a study that 
analysed data from a large number of PDAC patients’ biopsies adopted a 
mathematical model to investigate tumor progression and efficacy of 
chemotherapeutic treatments (Haeno et al. 2012). In this study, the investigators 
predicted that cancer cells acquire the ability to metastasize during early PanIN stages 
and observed that chemotherapy was more effective at prolonging survival after 
tumor resection compared to surgery alone since micrometastases can occur during 
early tumorigenesis and surgery would only block local tumor progression. These 
results suggest that systemic chemotherapy should be adopted quickly after tumor 
diagnosis, even before surgery, to increase the chance of survival (Haeno et al. 2012).  
The transition from an epithelial to a mesenchymal phenotype is known as EMT (or 
epithelial to mesenchymal transition). In this process cells lose their epithelial 
characteristics and acquire a fusiform morphology, are more motile and express 
mesenchymal markers (Lee et al. 2006). The EMT process occurs in early premalignant 
lesions, can be induced by chronic inflammation diseases and has been shown to 
contribute to pancreatic cancer cell dissemination and metastasis (Polyak and 
Weinberg 2009).  
Different molecular pathways contribute to metastasis formation in PDAC. Cellular 
migration and tumor metastasis driven by oncogenic K-RAS has shown to be enhanced 
when K-RAS mutant mice expressed conditional knockout of the p16 (INK4A) gene 
(Qiu et al. 2011). Additionally, loss of SMAD4 (Mazur and Siveke 2012) and increased 
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production of fibroblastic cells contributes to metastasis dissemination (Xu et al. 
2010).  
As previously mentioned, a study on pancreatic cancer mouse models revealed that 
mutant P53 accelerated cell invasion and was required to sustain metastatic spread. 
Interestingly, in these mouse models, which harboured oncogenic K-RAS gene, mutant 
p53 enhanced metastasis formation by increasing platelet-derived growth factor 
receptor β (PDGFRβ) expression, an effect that was reversed by genetic knockdown or 
pharmacological inhibition of PDGFRβ (Weissmueller et al. 2014). The results from this 
study indicate that anti-PDGFRB therapies represent a potential therapeutic strategy 
to reduce the metastatic potential of pancreatic cancer in patients harbouring P53 
mutation (Weissmueller et al. 2014). 
 
1.3 Current therapies for Pancreatic Ductal Adenocarcinoma 
1.3.1 Treatment options for localized disease 
Surgical resection is the first treatment choice when pancreatic tumor is still localized 
and represents the only chance for a complete cure or long-term survival. However, 
almost 70% of the patients that had a successful surgical resection do not survive due 
to local recurrence of the disease (Gillen et al. 2010) or due to the development of 
metastasis (Werner et al. 2013).  
The common surgical procedure performed when the tumor is localized to the head of 
the pancreas is a pancreatic duodenectomy, or Whipple's procedure (after Allen 
Oldfather Whipple, the initiator of the procedure) and consists of removal of the 
gallbladder, common bile duct, part of the duodenum, and the head of the pancreas 
(Michalski et al. 2007).  
Among PDAC patients that have had surgical resection, less than 20% live more than 5 
years (Hidalgo et al. 2015). For this reason adjuvant treatments have become an 
important post-operative choice, with the ultimate goal to improve long-term survival 
(Hidalgo 2010). Several clinical studies have demonstrated that higher median overall 
survival was achieved in patients treated with adjuvant chemotherapy after surgical 
resection of the tumor (Neoptolemos et al. 2004) (Oettle and Neuhaus 2007). 
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Gemcitabine and 5-fluorouracil chemotherapies represent the standard adjuvant 
regimens used in resected PDAC patients and they will be discussed in detail in the 
next sections. 
 
1.3.1.1 Adjuvant chemotherapy  
5-fluorouracil (5-FU) is a uracil analogue where the hydrogen atom at position 5C is 
replaced with a fluorine atom (Longley et al. 2003). 5-FU exerts its cytotoxicity by 
being incorporated into RNA during its synthesis or by inhibiting the Thymidylate 
Synthase (TS) enzyme. The TS enzyme catalyses the reduction of deoxyuridine 
monophosphate (dUMP) to deoxithymidine monophosphate (dTMP), thus providing 
the necessary dTMPs pools for DNA synthesis and repair (Longley et al. 2003).  
Intracellular 5-FU is converted into three active metabolites: fluorodeoxyuridine 
monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine 
triphosphate (FUTP). The FUTP is incorporated into cellular RNA causing alterations of 
RNA processing with severe effects on cellular metabolism and survival. FdUMP and 
FdUTP, in contrast, are the metabolites that mainly cause DNA disruption and TS 
inhibition.  
Gemcitabine, is an analogue of deoxycytidine (Fig. 1.2), in which two hydrogens on the 
2 carbons of deoxycytidine (dC) are substituted with two fluorine’s (dFdC) (Gesto et al. 
2012) and belongs to the class of antimetabolite agents. Gemcitabine represents a 
standard treatment for PDAC although it provides benefit to only 25% of patients 
(Burris et al. 1997). The use of gemcitabine as post-operative therapy was supported 
by the results obtained from a phase III trial in which adjuvant gemcitabine therapy 
delayed disease recurrence and produced manageable toxicities in patients with 
resected PDAC tumors. (Oettle et al. 2007). 
The first data exploring the effects of adjuvant chemotherapy came from a large 
multicentre trial known as the ESPAC-1 (The European Study Group for Pancreatic 
Cancer) (Neoptolemos et al. 2001) (Neoptolemos et al. 2004). In this clinical study, a 
total of 289 patients with surgically resected PDAC were assigned to receive 
chemotherapy, chemoradiotherapy, or no treatment. This study showed a 5-year 
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survival rate of 21% among patients treated with 5-FU compared to an 8% survival 
rate among patients who did not receive chemotherapy. The median overall survival 
in patients treated with chemotherapy was 15.9 months compared to the median 
overall survival of 17.9 months for patients who received chemoradiotherapy (hazard 
ratio for death of 1.28; 95% CI, 0.99 to 1.66; P=0.5).  Overall, this study concluded that 
adjuvant chemoradiotherapy does not improve survival of resected patients possibly 
because it delays the administration of chemotherapy, which, in order to be 
beneficial, should be given immediately after resection (Neoptolemos et al. 2004). The 
results from the ESPAC trial strongly support the use of adjuvant treatments in 
resected PDAC patients. 
 
 
 
 
Figure 1.2: Molecular structure of Gemcitabine: 2-deoxy-2,2-difluorocytidine. 
Gemcitabine is a cytidine analogue, in which two hydrogen atoms on the 2 carbons of deoxycytidine 
(dC) are replaced with two fluorine atomos (dFdC). 
 
1.3.1.2 Chemoradiotherapy  
Chemoradiotherapy (CRT) is an adjuvant treatment option for some resected PDAC 
patients and for locally advanced PDAC patients in the USA but is less frequently 
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adopted in the UK. The results of a study conducted at the John Hopkins hospital 
demonstrated that adjuvant CRT improved median overall survival in patients with 
resected pancreatic adenocarcinoma compared to patients that did not receive CRT 
after surgery (21.2 months vs 14.4 months; P<0.01) (Herman et al. 2008), as opposed 
to the results observed in the ESPAC trial, supporting the use of CRT after surgical 
resection in PDAC patients. An important difference with trials consisted on the 
absence of maintenance chemotherapy in the CRT cohort, which could explain the 
different outcome of the two results. 
Gemcitabine, capecitabine or 5FU are the most common chemotherapies used in 
combination with radiotherapy (Hidalgo et al. 2015). In vitro evidence has 
demonstrated that gemcitabine sensitizes tumor cells to radiation treatment in a 
schedule dependent fashion (Ostruszka and Shewach 2000). A recent preclinical study 
has shown that gemcitabine radiosensitizing effects can be restored in gemcitabine 
resistant cell lines by upregulation of deoxycytidine kinase (dCK), the enzyme 
responsible for converting gemcitabine into its active form (Kerr et al. 2014).  
A Phase I trial proved that radiation plus twice-weekly administrations of gemcitabine 
(40mg/m2) was well tolerated and induced antitumor activity in locally advanced 
PDAC patients, (Blackstock et al. 1999) a result that led to a Phase II trial which further 
investigated the efficacy of this treatment regimen. However, no significant survival 
benefit was observed (Blackstock et al. 2003). The same investigators conducted a 
Phase II study to investigate the effects of radiation plus gemcitabine treatment 
followed by gemcitabine in patients with resected pancreatic tumor. The combination 
regimen resulted in a median overall survival of 18.3 months (95% CI=13.7-25.9) 
(Blackstock et al. 2006). 
In agreement with previous findings, randomised trials that compared gemcitabine 
CRT with 5FU CRT indicated a higher survival benefit in gemcitabine treated patients 
accompanied by significant haematological toxicity (Zhu et al. 2011). On the other 
hand, in a recent Phase II trial (SCALOP trial), a survival advantage and less toxic 
profile were observed with capecitabine-based chemo-radiotherapy compared to 
gemcitabine-based CRT after a course of induction chemotherapy (Mukherjee et al. 
2013). 
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1.3.2 Treatment options for locally advanced and metastatic disease 
PDAC patients with locally advanced or metastatic disease are treated with 
chemotherapy to prolong survival and improve quality of life. 5-FU represented the 
only chemotherapeutic option in the advanced settings until 1997 (Kleeff et al. 2007), 
when a randomized trial conducted by Burris and colleagues showed a better median 
OS with gemcitabine treatment compared to 5-FU (5.65 months vs. 4.41 months; 
Long-Rank Test P=0.0025) (Burris et al. 1997). Although the increase in survival was 
modest, improved quality of life as shown by increased weight gain, reduced pain and 
a lower toxicity profile was observed in gemcitabine-treated patients; for these 
reasons, gemcitabine was approved by the Food and Drug Administration (FDA) and 
became the standard therapy for advanced PDAC treatment (Burris et al. 1997).  
Combination therapies in advanced PDAC patients have been an intense subject of 
investigation (Shi et al. 2012). Several preclinical and clinical studies have investigated 
whether the addition of targeted therapy to standard chemotherapy would enhance 
its effectiveness and increase survival. Targeted therapies affect molecular targets 
involved in cancer cell growth, progression and dissemination and they represent a 
new treatment choice for many types of human cancers (Huang et al. 2014). Some 
examples include small molecule inhibitors targeting signal transduction pathways, 
monoclonal antibodies or angiogenesis inhibitors (Huang et al. 2014). The main 
limitation of using targeted therapy is the development of drug resistance, which 
occurs through feedback loop activation of other signalling pathways (Lito et al. 2013). 
For this reason, targeted therapies are often used in combination with other 
chemotherapeutic agents. 
Up to now, only three clinical studies that involved gemcitabine-based combinations 
(with chemotherapeutic or targeted agents) or a novel chemotherapy combination 
have reported significant survival benefit in PDAC (Garrido-Laguna and Hidalgo 2015) 
The results from these studies are summarized in Table 1.1 and will be discussed in 
the next paragraphs. 
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Table 1.1:  Clinical trials results in metastatic PDAC patients. 
The table illustrates Median Overall Survival (OS), Progression Free Surival (PFS) and 1-year survival rate 
of patients receiving gemcitabine plus nab-paclitaxel treatment or gemcitabine alone; FOLFIRINOX 
treatment or gemcitabine alone and gemcitabine plus erlotinib or gemcitabine alone. Table adapted 
from (Thota et al. 2014). 
 
 
1.3.2.1 Gemcitabine plus nab-paclitaxel  
Paclitaxel is an anticancer agent that acts by stabilizing microtubules and preventing 
their depolymerisation (Pazdur et al. 1993). Since paclitaxel is a hydrophobic 
molecule, several formulations have been developed to increase solubility and 
cremaphore-paclitaxel (Cre-paclitaxel) was the first formulation to be developed. 
However, this oil solvent induced hypersensitivity reaction and altered paclitaxel 
pharmacology (Ma and Hidalgo 2013). A later formulation consisting of a solvent-free 
albumin bound nanoparticle form of paclitaxel (nab-paclitaxel) was developed to limit 
toxicities of solvent-based formulations (Hoy 2014). Nab-paclitaxel had more 
favourable pharmacologic properties plus reduced risk of paclitaxel-induced 
neutropenia, which allowed the use of higher doses compared with the cre-paclitaxel 
formulation. 
A Phase III trial (MPACT) was conducted after the promising results obtained from a 
Phase-I/II study of gemcitabine in combination with nab-paclitaxel (Von Hoff et al. 
2011). The MPACT study involved 861 patients and resulted in a significant 
improvement in median OS of 8.5 months versus 6.7 months (hazard ratio for death 
0.72; 95% CI, 0.62 to 0.83; P<0.001). A better median PFS of 5.5 months versus 3.7 
months (hazard ratio for disease progression or death was 0.69; 95% CI, 0.58 to 0.82; 
P<0.001) and manageable toxicities were also observed in patients treated with 
gemcitabine plus nab-paclitaxel combination compared to gemcitabine alone (Von 
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Hoff et al. 2013). These results led to the FDA approval of abraxane® (nab-paclitaxel) 
for patients with locally advanced and metastatic PDAC. 
The molecular mechanisms behind the synergy between gemcitabine and nab-
paclitaxel have been investigated. A pre-clinical study demonstrated synergistic 
antitumor activity between nab-paclitaxel and gemcitabine in the KPC mouse model. 
This synergistic interaction was associated with paclitaxel-induced downregulation of 
CDA (cytidine deaminase) protein levels, the enzyme responsible for deactivating 
gemcitabine, through reactive oxygen species-mediated degradation. Furthermore, an 
increase in tumor vascularity and a decrease in desmoplastic stroma were induced by 
nab-paclitaxel treatment, an effect that facilitated gemcitabine accumulation into the 
tumor (Frese et al. 2012). These results provided novel mechanistic insights into the 
antitumor activity of nab-paclitaxel.  
 
1.3.2.2 FOLFIRINOX  
FOLFIRINOX consists of a combination of three chemotherapeutic agents: 5FU, 
irinotecan and oxaliplatin plus leucovorin (a folic acid). This chemotherapy regimen 
has been included as one of the first-line treatment options for metastatic PDAC 
patients with good performance status since the results of the PRODIGE/ACCORD 11 
study: In this Phase III trial, patients treated with FOLFIRINOX showed improved 
median OS of 11.1 months versus 6.8 months (hazard ratio for death 0.57; 95% CI, 
0.45 to 0.73; P<0.001), compared to patients receiving gemcitabine alone. 
Importantly, the 1-year survival was 48.4% with FOLFIRINOX regimen compared to the 
20.6% of gemcitabine-treated patients. Patients exposed to this chemotherapy 
regimen experienced severe toxicities such as neutropenia, neurological and 
haematological disorders; however, toxicity did not impact the overall quality of life 
(Conroy et al. 2011). The significance of this study is that chemotherapy prolongs 
survival in pancreatic cancer.  
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1.3.2.3 Gemcitabine plus erlotinib 
EGFR activation is required for PDAC initiation and progression (Tobita et al. 2003) 
(Navas et al. 2012). Thus, EGFR represents a rational therapeutic target that could 
enhance gemcitabine response in PDAC patients. Erlotinib, a tyrosine kinase inhibitor 
of EGFR induced synergistic antitumor activity in combination with gemcitabine in 
pancreatic cancer mouse models by antagonizing gemcitabine-induced activation of 
the MAPK signalling pathway (Miyabayashi et al. 2013).  
A Phase III clinical study, which involved a large number of patients with locally 
advanced or metastatic PDAC, demonstrated that the addition of erlotinib to 
gemcitabine produced a median OS of 6.24 months versus 5.91 months in patients 
treated with gemcitabine alone (hazard ratio for death, 0.82; 95% CI, 0.69 to 0.99; 
P=0.038). A significantly longer progression free survival was also observed with the 
combination compared to gemcitabine alone, with a hazard ratio of 0.77; 95% CI, 0.64 
to 0.92; P=0.04 (Moore et al. 2007). Although the survival benefit was modest, it was 
clinically significant and led to the FDA approval of this combination regimen for non-
resectable PDAC. Other EGFR-targeted therapies have been tested, such as the 
monoclonal antibody inhibitor of EGFR cetuximab, but so far, the erlotinib plus 
gemcitabine regimen is the only molecular targeted agent that has demonstrated 
increased survival benefit compared to gemcitabine alone (Werner et al. 2013) (Philip 
et al. 2010). 
 
1.3.2.4 Gemcitabine plus capecitabine 
Capecitabine is a fluoropyrimidine that is converted into 5FU inside the cell through 
the sequential action of enzymes present at higher levels in tumor tissues rather than 
normal tissues (Schuller et al. 2000). Capecitabine has been approved by the FDA as 
first line single agent for the treatment of metastatic colorectal and breast cancer 
(Courtin et al. 2013). The gemcitabine plus capecitabine (GemCap) regimen became a 
treatment option for metastatic PDAC patients with a good performance status, after 
the results of a meta-analysis, conducted by pooling the results of different trials, 
showed improved survival benefit and manageable toxicities with the GemCap 
combination compared to gemcitabine alone (Cunningham et al. 2009). 
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Figure 1.3: Treatment Options in PDAC. 
PDAC patients with local disease are candidates for surgical resection, which usually follows adjuvant 
therapy. Locally advanced and metastatic disease treatment options are: gemcitabine, gemcitabine plus 
erlotinib, FOLFIRINOX regimen, gemcitabine plus Nab-paclitaxel and gemcitabine plus capecitabine.  
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1.3.3 Targeting the stromal compartment in PDAC  
PDAC is characterised by a dense desmoplastic stroma made of activated cancer-
associated fibroblasts (CAFs), inflammatory cells, endothelial cells coated with 
extracellular matrix (ECM) and poor vascular perfusion (Hidalgo 2010). The stroma 
contributes to resistance to chemotherapeutic agents because it compromises drug 
delivery into the tumor site (Neesse et al. 2011).  
This stromal reaction occurring in PDAC is in part mediated by constitutive activation 
of the Hedgehog (HH) signalling pathway, which frequently occurs through mutation 
of the SMO gene (smoothened gene), an HH activating protein. Although SMO 
mutations have not been observed in pancreatic cancer, transgenic mouse models of 
pancreatic adenocarcinoma treated with SMO inhibitors showed decreased 
accumulation of fibroblasts and increased density of vasculature. This effect was 
accompanied by enhanced intracellular gemcitabine delivery and increased survival 
(Olive et al. 2009).  
The tumor stroma produces high expression of glycoprotein SPARC (secreted protein 
acidic and rich in cysteine), which has albumin-binding properties. Since the nab-
paclitaxel formulation is based on albumin protein, it was suggested that tumor-
SPARC could facilitate drug penetrance into the tumor through its uptake mediated by 
SPARC proteins (Infante et al. 2007). Results from Phase-I and -II trials obtained from 
combining nab-paclitaxel plus gemcitabine suggested that SPARC expression was not 
correlated with patient response to gemcitabine alone or gemcitabine plus nab-
paclitaxel treatment (Hidalgo et al. 2015). Mouse models of pancreatic 
adenocarcinoma were used to further investigate the function of SPARC in the nab-
paclitaxel response. In these models, nab-paclitaxel accumulation in the tumor was 
not dependent on stromal-derived SPARC expression and a similar effect on tumor 
growth inhibition was observed between SPARC-null mice (in which SPARC was 
deleted) and SPARC-wild type mice (Neesse et al. 2014) (Hidalgo et al. 2015). These 
findings indicate that SPARC should not be used in clinical decision making as a 
predictive biomarker of nab-paclitaxel/gemcitabine response. 
The extracellular matrix is enriched with glycosaminoglycans including hyaluronic acid, 
which has been found to be in excess in almost 87% of human pancreatic cancers 
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(Jacobetz et al. 2013) (Provenzano et al. 2012) Hyaluran degradation occurs via the 
action of hyaluronidase enzymes and its accumulation has been shown to be 
responsible for the poor drug perfusion into the tumor (Jacobetz et al. 2013). The 
combination of gemcitabine with hyaluronidase enzymatic agents has been evaluated 
to overcome this stromal barrier and has proved to be effective in KPC mouse models. 
In particular, mice showed increased survival and enhanced accumulation of 
gemcitabine into the tumor site due to a reduction of interstitial fluid pressure and a 
change in the stromal architecture of the tumor (Provenzano et al. 2012). 
 
1.4 Gemcitabine: a deoxycytidine analogue 
1.4.1 Clinical pharmacology of gemcitabine 
Gemcitabine is administered intravenously, at a dose of 1,000-1,250 mg/m2 once 
weekly on a 21-day cycle or day 1,8,15 on a 28-day cycle (Veltkamp et al. 2008). The 
standard infusion schedule is 1,000mg/m2 for 30 minutes, which saturates plasma 
levels of dCK and induces less toxicity compared with higher infusions of gemcitabine 
(van Moorsel et al. 1997). Gemcitabine is rapidly deactivated through its deamination 
by cytidine deaminase (CDA) enzyme; in fact, its elimination half-life is between 10 
and 30 minutes (Grunewald et al. 1990) (Veltkamp et al. 2008). 
 
1.4.2 Gemcitabine metabolism and uptake 
Gemcitabine (2',2'-Difluorodeoxycytidine) is a deoxycytidine analogue, whose 
structure is analogue of cytosine arabinoside (Ara-C), except for the two fluorine 
atoms on the 2 position of the sugar ring (Ewald et al. 2008). Being highly hydrophilic, 
gemcitabine requires intracellular uptake, in order to cross the lipophilic membrane, 
by specific enzymes called equilibrative (ENTs) and concentrative (CNTs) nucleoside 
transporters. There are two human equilibrative type (hENT1, hENT2) and three 
human concentrative type (hCNT1, hCNT2, hCNT3) transporters (Gesto et al. 2012).  
Previous evidence has demonstrated that gemcitabine uptake across the cell 
membrane is mainly mediated by hENT1 transporter (Ritzel et al. 2001).  
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Gemcitabine is a pro-drug, which needs to be transformed into its active drug 
metabolite by intracellular phosphorylation (Mini et al. 2006). Deoxycytidine kinase 
(dCK) converts gemcitabine into its corresponding dFd-5’-monophosphate (dFdCMP) 
form, the rate-limiting step for the production of the active metabolite. Previous 
studies have shown that dCK has higher affinity for gemcitabine than for Ara-C 
(Heinemann et al. 1998). dFdCMP is then phosphorylated again into its diphosphate 
and triphosphate metabolites (dFdCDP and dFDCTP) by pyrimidine monophosphate 
kinase and other as yet unknown enzymes (Heinemann et al. 1998) (Ohhashi et al. 
2008). Gemcitabine triphosphate exerts its cytotoxic effect by inhibiting DNA 
duplication and ultimately gets inactivated by cytidine deaminase (CDA) into its 
deaminated metabolite 2’, 2’-difluoro-2’-deoxyuridine (dFdU) (Heinemann et al. 1992) 
(Fig. 1.4). 
 
1.4.3 Mechanisms of action of gemcitabine 
Gemcitabine’s main mechanism of action is inhibition of DNA synthesis: dFdCTP 
competes with dCTP (deoxycytidine triphosphate) for incorporation into DNA. After 
dFdCTP incorporation, the addition of only one more deoxynucleotide by DNA 
polymerase induces the termination of chain elongation (Huang et al. 1991). 
Furthermore, the incorporation of an extra single nucleotide prevents dFdCTP from 
being detected by DNA repair enzymes, thereby replication fork stalling and 
subsequent double strand breaks occur (Plunkett et al. 1995). dFdCTP can also be 
incorporated into the RNA strand, inhibiting RNA synthesis in specific cancer cell lines. 
Another important mechanism of action of the dFdCDP metabolite is inhibition of 
Ribonucleotide Reductase by covalent binding to RRM1 subunit (Heinemann et al. 
1990). Ribonucleotide Reductase (RR) catalyses the production of 
deoxyribonucleotides (dNTP) required for the synthesis of new DNA, therefore its 
inhibition results in a decrease of dNTP pools that can be incorporated into the DNA 
strand (Mini et al. 2006).  
Additional mechanisms of action of gemcitabine include induction of apoptosis 
through activation of caspase signalling or p38 signalling (Pourquier et al. 2002, 
Chandler et al. 2004) and enhancement of topoisomerase 1 (top1) cleavage 
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complexes. In vitro findings observed an increase in the frequency of collisions 
between top1 cleavage complexes and replication/transcription forks upon 
gemcitabine treatment, which caused DNA-strand breaks (Pourquier, Gioffre et al. 
2002). Furthermore, topoisomerase 1 deficient cells developed resistance to 
gemcitabine, confirming top1 poisoning as an important mechanism of gemcitabine 
cytotoxicity (Pourquier et al. 2002). 
 
 
 
 
Figure 1.4: Gemcitabine metabolism and mechanisms of action. 
Gemcitabine (dFdC) uptake inside the cells occurs through nucleoside transporters. Gemcitabine (dFdC) 
is phosphorylated into dFdCMP by DCK enzyme. Two additionaly phosphorylation steps occur to 
convert dFdCMP into dFdCTP molecule. The active form of gemcitabine (dFdCTP) binds and thus inhibits 
DNA synthesis. In addition, dFdCDP inhibits Ribonucleotide Reductase enzyme activity.  Deactivation of 
gemcitabine (dFdC) into dFdU is mediated by CDA enzyme (Ueno et al. 2007). 
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1.4.4 Molecular markers associated with gemcitabine response 
The main cause of gemcitabine-limited response in PDAC patients is resistance, which 
can be acquired by pancreatic cancer cells through various mechanisms after drug 
exposure or can be intrinsic. Acquisition of resistance to gemcitabine is a common 
event in PDAC patients (Kim et al. 2008). The most extensively studied molecular 
targets associated with gemcitabine response are shown in Table 1.2. 
 
 
Table 1.2:  List of genes associated with gemcitabine resistance. 
 
 
1.4.4.1 Human Equilibrative Nucleoside Transporter (hENT1) 
Human Equilibrative Nucleoside Transporter-1 (hENT1) mediates the active transport 
of gemcitabine and other pyrimidine nucleosides across the cell membrane, and if 
expressed at high levels, the amount of gemcitabine uptake inside the cell increases 
and so does its cytotoxic activity (Yao et al. 2011). A number of studies have suggested 
that hENT1 expression could be a useful marker in predicting PDAC patient response 
to gemcitabine therapy after surgical resection. For example, a randomized trial 
involving resected pancreatic cancer patients receiving adjuvant gemcitabine 
associated high hENT1 expression with increased survival (Farrell et al. 2009). A similar 
result was observed after a microarray analysis was performed on tissues from 
pancreatic cancer patients taking part of the ESPAC (European Study Group for 
Pancreatic Cancer) 3 trial, who received either 5-FU with folinic acid or gemcitabine. 
The results from this trial showed no significant difference in overall survival (OS) 
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between gemcitabine and 5-FU/folinic acid-treated patients. However, among 
patients treated with gemcitabine, an overall survival (OS) of 26.2 months was 
observed in patients with high expression of hENT1 compared to 17.1 months in 
patients with low expression of hENT1 (Greenhalf et al. 2014). Although these results 
were promising, another Phase-II trial showed no correlation between hENT1 
expression and gemcitabine efficacy in metastatic PDAC patients (Poplin et al. 2013). 
However, the different findings observed among these studies could be associated 
with the fact that different antibodies were used to quantify hENT-1 expression 
(Svrcek et al. 2015). Contradictory results have also been found in vitro. In fact, 
overexpression of hENT1 was associated with increased gemcitabine sensitivity of a 
panel of different pancreatic cancer cells (Mori et al. 2007), whereas another study 
observed no correlation between the IC50 of gemcitabine and hENT1 expression of 
different pancreatic cancer cell lines (Nakano et al. 2007). These data indicate that 
there is not yet convincing evidence of the role of hENT1 as a prognostic biomarker of 
gemcitabine response in PDAC. Additional studies should be conducted before using 
hENT1 as a predictor of gemcitabine efficacy.  
 
1.4.4.2 Deoxycytidine kinase (dCK) 
Gemcitabine phosphorylation by deoxycytidine kinase (dCK), is the necessary step for 
further phosphorylation to active metabolites and to exert its cytotoxic activity 
(Heinemann et al. 1988). Overexpression of dCK has been associated with gemcitabine 
sensitivity in various cancer xenograft models (Kroep et al. 2002).  
Immunohistochemical labeling of dCK on 44 tissues from pancreatic cancer patients 
showed a significant correlation between low/high dCK staining and OS or PFS 
following gemcitabine treatment. Interestingly, low levels of dCK immunolabeling 
were detected in older patients, which could in part explain the reason of lower 
survival rate at advanced age. The findings from this study indicate that 
immunohistochemical analysis of dCK before start of adjuvant therapy could help 
predict which patients are ideal candidates for gemcitabine treatment (Sebastiani et 
al. 2006). 
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 A recent study in bladder cancer models showed that gemcitabine resistant cell lines 
had significantly low levels of dCK mRNA and protein expression. Additionally, 
downregulation of dCK expression with specific siRNA resulted in increased 
gemcitabine resistance in bladder cancer cell lines. In agreement, re-expression of dCK 
in these cell lines restored gemcitabine radiosensitivity (Kerr et al. 2014). Altogether 
these results support that dCK is an important predictive marker of gemcitabine 
efficacy. 
 
1.4.4.3 Cytidine Deaminase (CDA)  
Gemcitabine is mainly inactivated to dFdU (difluorodeoxyuridine) by the catabolic 
enzyme cytidine deaminase (CDA) (Wong et al. 2009). CDA expression has been 
associated with gemcitabine resistance. Patients with low levels CDA in the plasma, 
receiving gemcitabine-based combinations exhibited a higher toxicity profile compare 
to patients with high plasma CDA levels (Ciccolini et al. 2010).  
Modulation of CDA expression has also been showed to alter gemcitabine cytotoxicity. 
This was observed in a pre-clinical study on KPC mouse models, which showed that 
addition of nab-paclitaxel to gemcitabine produced significant antitumor activity, an 
effect associated with reduction of CDA protein levels, which was caused by paclitaxel-
induced production of reactive oxygen species (ROS) (Frese et al. 2012). 
 
1.4.4.4 Ribonucleotide Reductase (RR) 
Ribonucleotide Reductase (RR) controls the rate-limiting step of DNA replication, since 
uniquely this enzyme catalyses the conversion of ribonucleotide diphosphates into 
deoxyribonucleotide diphosphates required for new DNA synthesis and repair (Aye et 
al. 2015). In particular, the hydroxyl at the 2’ carbon of a ribonucleoside diphosphate 
(NDP) is reduced to a hydrogen to generate the corresponding deoxy (d)NDP. dNDPs 
are phosphorylated by nucleoside diphosphate kinase to produce dNTPs (Kunz and 
Kohalmi 1991). Mammalian RRs consist of two homodimers, each of them composed 
of two subunits: a large subunit RRM1 (90kda) and a small subunit RRM2 (45kda) (Fig. 
1.5). When the large subunit associates with the small subunit an active 
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heterotetrameric enzyme is formed (Nordlund and Reichard 2006). RRM1 can also 
bind to a subunit analogue of RRM2, which is dependent of p53 activity (p53R2) 
(Tanaka et al. 2000) (Fig. 1.5). Upon DNA damage, p53R2 expression is induced and 
forms a complex with RRM1 to provide dNTPs for DNA repair. Additionally, p53R2 is 
involved in the synthesis of mitochondrial DNA (Tanaka et al. 2000). However, only 
wild type p53 cells exhibit activated p53R2; mutant P53 cells rely on RRM2 activity 
(Zhou et al. 2003). 
 
 
 
Figure 1.5: Structure of Ribonucleotide Reductase (RR).  
The two subunits (RRM1 + RRM2 or RRM1 + p53R2) associate to form the active holoenzyme. RRM1 
contains the catalytic site, RRM2 a tyrosil free radical next to a binuclear iron centre. RR catalyses the 
production of dNTP pools from the corresponding dNDP that are required for new DNA synthesis and 
repair. (Aye et al. 2015). 
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The RR enzyme ensures a proper balance of the four DNA nucleotides in order to 
maintain genomic integrity. Failure of this can lead to DNA strand breaks, enhanced 
mutagenesis or may induce cell death (Nordlund and Reichard 2006). RR activity is 
tightly regulated. The RRM1 subunit contains a catalytic site and two allosteric 
regulatory sites: the first allosteric site controls substrate specificity (S), the other 
regulates on/off enzyme activity (A). In particular, ATP binding stimulates RR activity, 
whereas dATP interaction induces feedback inhibition. Substrate specificity is 
regulated by the nucleotide effectors (ATP, dCTP, dATP, dTTP and dGTP) interaction 
with the allosteric site S (Nordlund and Reichard 2006). The catalytic domain is active 
only when RRM2 associates with RRM1. RRM2 subunit contains a tyrosyl free radical 
next to a binuclear iron centre necessary for the reduction of NDP to dNDP to occur 
(Reichard 1993) (Fairman et al. 2011) (Figure 1.5). The diferrous ions react with 
molecular oxygen to generate the protein radical (Aye et al. 2015). 
The RR enzyme is also regulated by the cell cycle. Its activity reaches maximum levels 
during S-phase in order to produce the amount of dNTP pools required in proliferating 
cells for new DNA synthesis (Chabes and Thelander 2000). The levels of RRM1 protein 
are in excess and constant throughout the cell cycle because of its long half-life (20h) 
(D'Angiolella et al. 2012). In contrast, RRM2 protein levels, whose half-life is about 6h, 
are low in G1 and reach maximum peaks in S phase, as with the mRNA levels (Chabes 
and Thelander 2000). Cells in G0/G1 phase produce dNTP for DNA repair and for 
mitochondrial DNA (mtDNA) replication through the activity of the p53R2 subunit, 
which is constantly expressed at low levels in all phases of the cell cycle and its 
transcriptional expression is induced upon DNA damage in a P53-dependent way 
(Tanaka et al. 2000).  
CHO cells transfected with cDNA encoding for a mutation in RRM1 activation site, 
which is resistant to dATP inhibition resulted in a 15-20 fold increase in the 
spontaneous rate of mutations, indicating the importance of RR activity (Caras and 
Martin 1988). 
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1.4.4.4.1 RRM1 overexpression is associated with poor response to gemcitabine in 
PDAC patients 
The large regulatory subunit of Ribonucleotide Reductase (RRM1) is mainly expressed 
in the cytoplasm and predominantly expressed in cancerous tissues compared to 
adjacent normal tissues (Wang et al. 2013). From preclinical and clinical studies 
conflicting results have emerged regarding the biological role of RRM1 in cancer. 
Several lines of evidence suggest that RRM1 acts as a tumor suppressor gene. For 
example, RRM1 overexpression suppressed tumorigenicity and reduced metastatic 
burden in a mouse model of lung cancer (Fan et al. 1997, Gautam et al. 2003). 
Furthermore, high tumor-associated expression of RRM1 was associated with longer 
survival and later disease recurrence in NSCLC cancer patients who underwent surgery 
but did not receive any adjuvant chemotherapy (Bepler et al. 2004). Similar results 
were obtained from a study conducted on NSCLC patients who had undergone 
surgery. High RRM1 and ERCC1 (Excision repair cross-complementary gene 1) co-
expression was associated with better disease-free survival (DFS) and OS (Zheng et al. 
2007). 
On the other hand, several findings have demonstrated that RRM1 is associated with 
gemcitabine resistance (Davidson et al. 2004) (Lee et al. 2010). One of the reasons for 
RRM1 overexpression being correlated with increased gemcitabine resistance is due 
to the expansion of dNTP pools that compete with dFDCTP for being incorporated into 
the DNA strand (Davidson et al. 2004). Additionally, dNTPs inhibit the activity of dCK 
enzyme, thereby preventing gemcitabine intracellular phosphorylation (Bouffard et al. 
1993). 
RRM1 overexpression in tumor patients has been associated with poor response to 
gemcitabine treatment. For example, a result from a clinical study showed that 
pancreatic cancer resected patients with high RRM1 expression had a better OS and 
DFS than those having low levels of RRM1 expression. However, among patients who 
received gemcitabine treatment after tumor recurrence, only those with low RRM1 
expression benefited from gemcitabine therapy (Akita et al. 2009).  
An oligonucleotide microarray analysis was conducted in gemcitabine resistant cells 
and parental cells to investigate any significant alterations in gene expression. A 
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significant upregulation of RRM1 mRNA and protein expression in the resistant cell 
lines was observed. Importantly, sensitivity to gemcitabine in these cell lines was 
restored upon RRM1 knock down with specific siRNA (Nakahira et al. 2007). Similar 
results obtained from RRM1 overexpressing mouse tumor cells, confirmed the ability 
of RRM1 downregulation (by siRNA) to potentiate chemosensitivity to gemcitabine 
(Wonganan et al. 2012). Additionally, efficient RRM1 downregulation obtained from 
systemic administration of RRM1 siRNA complexed with polyethilenimine was 
achieved in tumors of mice injected with the same RRM1 overexpressing tumor cell 
line. Importantly, knock down of RRM1 enhanced the antitumor activity of 
gemcitabine against RRM1 overexpressing tumor-bearing mice further indicating that 
RRM1 should be evaluated as a target to overcome gemcitabine resistance 
(Wonganan et al. 2012).  
Finally, a clinical study on RRM1 expression was conducted on locally advanced NSCLC 
patients before they received gemcitabine treatment. A negative correlation between 
RRM1 gene expression and patient response to gemcitabine was observed, suggesting 
that RRM1 should be used as a predictive biomarker of gemcitabine therapy in 
patients with NSCLC (Bepler et al. 2006). 
These present findings confirm RRM1 as a prognostic biomarker and modulator of 
gemcitabine response and suggest RRM1 expression should be evaluated in the design 
of tailored clinical trials to select patients who might benefit from gemcitabine 
treatment.  
 
1.4.4.4.2 Ribonucleotide Reductase Inhibitors  
RR enzyme has been long evaluated as a therapeutic target in cancer. Inhibitors of RR 
activity are classified into two main categories: Nucleoside analogues, such as 
gemcitabine, which bind to RRM1 and form a substrate radical that leads to enzyme 
inactivation (Chapman and Kinsella 2011). The other class of inhibitors is represented 
by redox active metal chelators, such as hydroxyurea, which target the di-iron centre 
of RRM2 subunit (Chapman and Kinsella 2011). Additionally, small interfering RNA 
(siRNA) strategies that target RR activity have been shown to be effective as a 
mechanism of chemosensitisation (Wonganan et al. 2012). 
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1.5 The RAS/RAF/MAPK signalling pathway  
1.5.1 System biology of the RAS/RAF/MAPK pathway 
Mitogen-activated protein kinases (MAPKs) are a family of protein kinases that 
phosphorylate specific tyrosine, serine or threonine on target proteins and regulate 
different and sometimes opposing cellular processes: proliferation, differentiation, 
invasion, apoptosis and gene expression (Johnson and Lapadat 2002). Mammalian 
cells have four well-characterised MAPK signalling cascades: 1) extracellular signal-
regulated kinases (ERK1 and ERK2), 2) c-Jun amino-terminal kinases (JNKs) 1, 2, and 3, 
3) p38 isoforms α, β, γ, and δ, 4) ERK5 groups. The JNK pathway regulates gene 
transcription, activation of p38 pathway is mediated by inflammatory cytokines or 
stress stimuli and the ERK pathway regulates cell proliferation among other functions 
(Johnson and Lapadat 2002). 
The RAS-RAF-MEK-extracellular signal-regulated kinase (ERK) (Fig. 1.6) is responsible 
for the regulation of cell proliferation, differentiation and survival. It is one of the 
most studied signalling pathways because is often deregulated in human cancers such 
as PDAC (Xu et al. 2013). This pathway can be activated by different mitogenic stimuli 
such as growth factors (EGF and TGF-α) (Neuzillet et al. 2012). The binding of a ligand 
to the receptor leads to its dimerisation followed by autophosphorylation of tyrosine 
kinase residues. Next, activated receptor tyrosine kinase (RTK) binds adaptor proteins 
such as the Src homology 2 domain in Grb2 adaptor protein (growth factor-receptor-
bound protein 2). The Src domain anchors the GTP exchange factor SOS (Son of 
sevenless). Grb2-SOS complex physically interacts with RAT sarcoma protein (RAS) 
molecules, favouring the formation of a RAS-GTP activated state (Downward 2003). 
Activated GTP-RAS recruits and activates RAF protein, which in turn phosphorylates 
MEK1/2, ultimately leading to the phosphorylation of the extracellular signal-
regulated kinases (ERK1 and ERK2) (Roberts and Der 2007). ERK1/2 proteins can 
translocate to the nucleus, where they phosphorylate and regulate various 
transcription factors leading to changes in gene expression involved in the regulation 
of cell proliferation and survival (Mendoza et al. 2011).The degree of activity of the 
RAS-ERK signalling pathway depends on the strength and duration of the stimuli and 
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on other factors such as MAPK phosphatases and scaffold proteins (Neuzillet et al. 
2013). 
 
 
Figure 1.6: The MAPK signalling cascade.  
Ligand binding to TRK receptors induces a conformational change that leads to GTP-RAS activation. RAS 
interacts with and activates RAF, which in turn activates MEK1/2. MEK phosphorylates and activate 
downstream ERK. Activated ERK enters into the nucleus and induces gene transcription involved in 
cellular proliferation, migration, and differentiation.  
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1.5.1.1 Epidermal growth factor receptor  
EGFR is a 170kda transmembrane glycoprotein member of the receptor tyrosine 
kinase (RTK) superfamily, which consists of four members: EGFR or ErbB1 (HER1), 
ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4) (Yarden 2001). RTKs are characterised 
by an extracellular ligand-binding region, a single membrane spanning region and a 
regulatory intracellular region containing the kinase domain (KD). The intracellular 
region contains the juxtamembrane domain, the N and C lobes that incorporate the 
Adenosine Triphosphate (ATP) binding site and the carboxyl tail. Furthermore, EGFR, 
ErbB2 and ErbB4 but not ErbB3 possess an active tyrosine kinase domain in the C-
terminal region (Yarden 2001). There are four extracellular domains (I-IV). Domains I 
and III are responsible for ligand binding, domains II and IV are essential for receptor 
dimerisation. Monomeric EGFR is in an auto inhibitory tethered conformation in which 
the dimerization arm is not exposed (domain II). Upon ligand binding to domain I and 
III, the receptor changes conformation which allows its dimerization and activation. 
Both the juxtamembrane and the c-terminal domain play a role in the auto-inhibition 
mechanism as they physically block the ATP binding pocket. (Lemmon 2009).  
EGFR can be activated by various ligands including Epidermal Growth Factor (EGF), 
Transforming Growth Factor-α (TGF-α) and amphiregulin (Normanno et al. 2006). 
EGFR can form homodimers followed by ligand binding and transmit signal 
autonomously or form heterodimers. EGFR dimerisation occurs via an asymmetric 
mechanism of interaction between the C-lobe of one monomer and the N-lobe of 
another monomer. The activated kinase can then phosphorylate tyrosine residues on 
the receiver monomer which switch their position and activate each other (Jura et al. 
2009). The phosphorylation of the intracellular tyrosine residues leads to recruitment 
of Src-Homology (SH2) and Phospho-tyrosine Binding (PTB) domains leading to the 
activation of downstream signalling pathways (Burgess et al. 2003).  
EGFR was the first tyrosine kinase receptor to be associated with human cancers 
(Hynes and Lane 2005). Aberrant activation of EGFR in cancer leads to a range of 
cellular responses including cell hyper-proliferation, motility and EMT transition and it 
can occur through both ligand-dependent and independent mechanisms. The first 
consists of autocrine production of ligands in EGFR overexpressing tumors. The second 
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includes receptor overexpression via gene amplification, acquisition of somatic 
mutations and escape from endocytotic degradation (Gschwind et al. 2001). 
 
1.5.1.2 RAS and RAF kinases 
RAS, one of the first oncogenes to be discovered, mediates transmission of signals 
from the cell surface into the nucleus through interaction with many downstream 
signaling pathways (Goodsell 1999). The family of RAS proteins include Harvey-RAS 
(HRAS), Kirsten-RAS (KRAS), and N-RAS (Goodsell 1999). RAS proteins do not possess 
transmembrane domains but are attached to the inner side of the plasma membrane 
through farnesyl groups. RAS are small GTP binding proteins that function as binary 
molecular switches. In its inactive state RAS is bound to a guanosine di phosphate 
(GDP). Guanine nucleotide exchange factors (SoS) regulate the GDP/GTP switch that 
promotes formation of active RAS-GTP (Roberts and Der 2007). RAS binding to 
GTPase-activating proteins mediates GTP hydrolysis to guanosine diphosphate (GDP), 
a mechanism that allows RAS to return into its neutral state (Goodsell 1999).  
After RAS activation the effector loop domain of RAS physically interacts with several 
downstream targets including RAF. RAF proteins are a family of serine/threonine 
kinases and consist of A-RAF, B-RAF and C-RAF (Lavoie and Therrien 2015). RAF is 
recruited to the plasma membrane by GTP-RAS through interaction with the RAS 
binding domain (RBD). RAS binding to RAF leads to RAF dimerization and its catalytic 
activation (Lavoie and Therrien 2015). RAF phosphorylates downstream MEK1 and 
MEK2 on two distinct serine residues in their activation loop. MEK activation is usually 
induced by B-RAF and to less extent by C-RAF or A-RAF (Anderson et al. 1990).  
K-RAS mutations represent the most frequent and earliest oncogenic event to occur in 
PDAC. Activating mutations within the K-RAS gene makes RAS insensitive to GAP 
protein, which remains constantly in its switched on state. They are generally point-
activating mutations, most of which occur at codon 12, by substitution of glycine with 
aspartic acid, valine or arginine (Thomas et al. 2007).  
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B-RAF is frequently mutated in melanoma, which results in the hyperactivity of the 
MAPK pathway; however B-RAF mutation is a rare event in PDAC (Ishimura et al. 
2003).  
 
1.5.1.3 Mitogen extracellular signal regulated kinase (MEK or MAPKK) 
protein 
MEK or MAPKKs are a family of proteins that belong to the RAS/RAF/MEK/ERK 
signalling cascade. MEK proteins are dual-specificity kinases with a molecular weight 
between 44-46 kDA. Seven MEK proteins have been identified and are involved in four 
different MAPK signalling pathways but only MEK1 and MEK2 (Fig. 1.6) belong to the 
RAS-RAF-ERK signalling pathway (Dhanasekaran and Premkumar Reddy 1998). MEK1 
and MEK2 share an 80% amino acid identity and are expressed ubiquitously in all 
mammalians cells. MEK1 is encoded by the gene located on chromosome 15q22.31, 
MEK2 is encoded by the gene located on chromosome 19p13.3 (Chang and Karin 
2001). The structure of MEK protein consists of an amino- terminal domain, a kinase 
domain, and a carboxyl-terminal domain. The kinase domain represents the catalytic 
domain, is made of 290 residues and contains the ATP binding site.  The carboxyl-
terminal sequence contains the domain for versatile docking (DVD), which is made of 
about 20 aminoacids and represents the binding site of upstream components of the 
RAS pathway. The N-terminal domain consists of about 70 aminoacids and contains a 
docking site for interaction with ERK, an inhibitory/allosteric segment and a nuclear 
export sequence (Roskoski 2012) (Akinleye et al. 2013). The structural difference 
between MEK1 and MEK2 is represented by the presence of a phosphorylation site 
(T292) in the proline-rich region in the C-terminus of MEK1 required for the negative 
regulation of MEK by ERK1/2(Catalanotti et al. 2009) . Activation of MEK1 and MEK2 
by upstream serine kinase RAF occurs through phosphorylation of two serine residues 
at positions 218 and 222 in the catalytic domain. MEK phosphorylates the 
serine/threonine and tyrosine residues in the activation loop of the downstream ERK 
substrate (Ohren et al. 2004). The high specificity of MEK is due to the fact ERK 
represents the only known physiological target and this selectivity renders MEK 
proteins an attractive target for therapy (Neuzillet et al. 2012). 
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Figure 1.7: The structure of MEK1/2 protein.  
MEK proteins possess an N-terminal sequence, a C-terminal sequence and a kinase domain, which 
contains the catalytic site. Adapted from (Akinleye et al. 2013). 
 
 
1.5.1.4 ERK kinases 
Extracellular signal-regulated kinases ERK1 (44 kDA) and ERK2 (42 kDA) are 
serine/threonine kinases that show a 70% amino acid similarity. ERK represents the 
only substrate of MEK and is activated by dual phosphorylation on their tyrosine and 
threonine residues (Downward 2003). Unlike MEK or RAF protein, ERK has a variety of 
cytosolic or nuclear substrates. Once activated, ERK dissociates from MEK, and 
translocate into the cytoplasm or nucleus, where it phosphorylates a large number of 
proteins such as transcription factors, cytoskeletal proteins and kinases. Elk1, p53 and 
c-fos are some of the nuclear transcription factors that regulate cell proliferation, 
survival, as well as angiogenesis and migration, which are activated by ERK (Yoon and 
Seger 2006). ERK activation promotes cell cycle progression by activating cyclin D1, c-
Myc and retinoblastoma protein (Rb).  Furthermore, ERK signalling inhibits the 
activation of pro-apoptotic proteins (Bim and Bad) and stimulates anti-apoptotic 
members (Bcl-2, Blc-x) (Neuzillet et al. 2014). ERK controls many signalling pathways 
and gene regulatory circuits. Thus, ERK signalling affects a wide variety of cellular 
events that include proliferation, differentiation, invasion and survival (Yoon and 
Seger 2006). 
ERKs are inactivated through the removal of phosphatases from the threonine and 
tyrosine residues generally mediated by MAPK phosphatases (Sun et al. 1993). 
Additionally, ERK participates in feedback loop mechanisms that inhibit its activity, 
such as inhibition of upstream RAF or MEK (Slack-Davis et al. 2003). 
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1.5.2 MEK as a therapeutic target  
The RAS/RAF/MEK/ERK signalling pathway is frequently dysregulated in human 
cancers (Chang and Karin 2001). K-RAS mutation, occurring in 90% of all human 
PDACs, has a predominant role in the initiation, progression and maintenance of PDAC 
(di Magliano and Logsdon 2013). Unfortunately the RAS oncogene has so far proved to 
be undruggable (Berndt et al. 2011). For this reason drug development has shifted its 
focus towards distinct downstream effectors components of oncogenic K-RAS 
signalling, such as RAF or MEK (McCubrey et al. 2010). 
 
1.5.2.1 The development of MEK inhibitors 
MAPKK or MEK belongs to a family of enzymes upstream MAPK or ERK protein. 
Several MEK inhibitors have been developed as potential therapeutic candidates in 
human cancer treatments, some of which are under current investigation in preclinical 
and clinical studies (McCubrey et al. 2010) (Zhao and Adjei 2014), while others have 
already been proved to give survival benefits in the clinical setting (Flaherty et al. 
2012).  
The exquisite characteristic of MEK inhibitors is represented by the fact the most of 
them do not compete with the ATP binding site, but bind to an allosteric pocket 
adjacent to it; this prevents any undesired side effects caused by inhibition of other 
protein kinases (Ohren et al. 2004). Additionally, MEK inhibitors are highly selective 
since the only target of MEK is represented by ERK (Akinleye et al. 2013) (Zhao and 
Adjei 2014). The binding of a MEK inhibitor to a unique allosteric site induces a 
conformational change within the activation loop and a deformation of the catalytic 
site that prevents MEK from interacting with ERK (Sebolt-Leopold and Herrera 2004).  
U0126 and PD98059 were the first MEK inhibitors to be developed but because of the 
poor pharmacological characteristics they did not reach clinical development 
(McCubrey et al. 2010) (Montagut and Settleman 2009). CI-1040 was the first MEK1/2 
inhibitor to be tested in clinical trials after preclinical studies showed its ability to 
significantly reduce tumor growth in colon cancer and melanoma xenograft models 
(Sebolt-Leopold et al. 1999) (Collisson et al. 2003). A Phase I study indicated that CI-
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1040 was well tolerated by patients and induced antitumoral activity in humans 
(Lorusso et al. 2005); However, a phase-II study testing CI-1040 on colorectal cancer 
(CRC), NSCLC, pancreatic and breast cancer patients showed insufficient antitumor 
activity to advance further development (Rinehart et al. 2004).  
A second-generation of inhibitors (such as PD0325901) characterised by better 
bioavailability and higher potency compared to CI-1040, was later developed (Barrett 
et al. 2008). Unfortunately, a phase-II study conducted in NSCLC patients who had 
already received systemic therapy showed no objective responses after treatment 
with PD0325901 (Haura et al. 2010). 
Selumetinib (AZD6244) is a potent MEK1/2 inhibitor that has been tested in several 
Phase-II trials in different human cancers. For example, selumetinib was given in 
combination with capecitabine in PDAC patients who did not benefit from 
gemcitabine therapy. However, no significant improvement in OS was detected 
(Bodoky et al. 2012). Furthermore, a Phase-II study tested the selumetinib plus 
dacarbazine combination in BRAF-mutant melanoma patients, but no significant 
overall survival benefit was observed in these patients compared to patients treated 
with dacarbazine monotherapy (13.9 months in the selumetinib plus dacarbazine 
group versus 10.5 months in dacarbazine group; HR 0.93, 80% CI, 0.67-1.28, one-sided 
P<0.39) (Robert et al. 2013). Several other Phase-I, -II and -III trials involving 
selumetinib are currently underway. 
Trametenib is a potent, selective and ATP non-competitive inhibitor of MEK1 and 
MEK2 activity, which prevents RAF-induced phosphorylation of MEK1, therefore 
prolonging its effect on ERK1/2 inhibition (Gilmartin et al. 2011). Trametenib has been 
recently approved for the treatment of unresectable or metastastic B-RAF mutant 
melanoma after a successful trial showed significant survival benefit for patients 
treated with single-agent trametenib (Flaherty et al. 2012). Its efficacy has also been 
evaluated in combination with gemcitabine in metastatic PDAC patients but has 
shown no improvement in OS and PFS compared to gemcitabine monotherapy 
(Infante et al. 2014). 
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1.5.2.2 Pimasertib 
Pimasertib, also known as MSC1936369B or AS703026, is a potent, highly selective 
and orally available small molecule inhibitor of MEK1 and MEK2 protein and belongs 
to the second-generation class of ATP non-competitive MEK inhibitors. Pimasertib 
binds to an allosteric site adjacent to the ATP binding site, blocking MEK into an 
inactive conformation, which prevents it from interacting with and activating 
downstream ERK (Yoon et al. 2011).  
Previous preclinical studies involving pimasertib on PDAC models have not been 
reported. Nevertheless, the in vitro and in vivo antitumor activity of pimasertib has 
been evaluated in other human cancers with aberrantly activated MAPK pathway. The 
antitumor activity of pimasertib has been evaluated in a preclinical study of multiple 
myeloma (MM), a disease often characterised by deregulated MAPK signalling 
pathway (Kim et al. 2010). In this study, pimasertib treatment significantly inhibited 
growth and induced apoptosis of MM cell lines, patients-derived MM cells and in MM 
xenograft models; an effect that was not correlated with the B-RAF or K-RAS 
mutational status of the cells. Immunoblotting analysis showed a significant decrease 
of P-ERK and increase of P-AKT protein levels up to 72 hours treatment with 
pimasertib. This was accompanied by a decrease in MAF oncogene expression and a 
reduction in osteoclastogenesis, suggesting that MEK activity modulates the bone 
marrow (BM) microenvironment. Moreover, pimasertib enhanced the cytotoxic effect 
of conventional anti-MM chemotherapies, suggesting that the MEK inhibitors activity 
should be tested in clinical trials for MM patients alone or in combination with 
chemotherapy (Kim et al. 2010). 
Colorectal cancer (CRC) is frequently characterised by abnormal expression of EGFR. 
Monoclonal antibodies targeting EGFR (cetuximab, panitumumab) represent 
treatment options currently in use for metastatic CRC. However, EGFR inhibition 
benefits only K-RAS wild-type (WT) CRC patients (Di Fiore et al. 2007). The activity of 
pimasertib on both WT and mutant K-RAS CRC cell lines was examined. As opposed to 
cetuximab, which induced antiproliferative effects and inhibited EGFR signalling 
exclusively in WT cells, pimasertib effectively abrogated P-ERK activation and inhibited 
proliferation in all cell lines tested regardless their K-RAS mutational status (Yoon et al. 
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2011). Furthermore, pimasertib induced antitumor activity in mutant K-RAS xenograft 
models of CRC along with a marked decrease of P-ERK expression, in contrast to 
cetuximab. However, no synergistic effects were observed when pimasertib was 
combined with cetuximab both in vitro and in vivo (Yoon et al. 2011). 
Another study examined the combination effects between pimasertib and PI3K/mTOR 
inhibitor in human colon and lung cancer cell lines. Synergistic antiproliferative and 
apoptotic effects along with sustained blockade of MAPK and PI3K signalling pathways 
were observed in the combination regimen compared to single agents (Martinelli et 
al. 2013). Response to pimasertib was not associated with the mutational status of 
RAF, RAS or PI3KCA genes. Furthermore, the combination of a dual PI3K/mTOR 
inhibitor (BEZ235) with pimasertib significantly delayed tumor growth in lung 
carcinoma and CRC xenografts, suggesting that dual inhibition of these pathways 
could potentiate the efficacy of MEK inhibitors alone (Martinelli et al. 2013). 
Finally, pimasertib by inducing a G1 arrest of the cell cycle, enhanced apoptosis 
caused by BH3 mimetics in AML cell lines and xenograft models suggesting that this 
combination should be evaluated for future clinical trials of AML patients (Airiau et al. 
2015). 
Phase-I and II trials testing pimasertib have been conducted and have shown clinical 
activity both alone and in combination with targeted therapies or chemotherapies.  
(Delord, J. et al. 2010). A clinical trial of pimasertib in combination with FOLFIRI (5-FU, 
irinotecan, leucovorin) was assessed in mutant KRAS colorectal cancer patients. The 
maximum tolerated dose (MTD) of pimasertib (45mg per day) was well tolerated by 
patients. However, the study was unable to progress to Phase-II because of the 
toxicity induced by dose escalation of pimasertib from 45 to 60mg combined to 
FOLFIRI (Macarulla et al. 2015).  
  
 70 
A Phase-I/II trial involving gemcitabine in combination with pimasertib in metastatic 
pancreatic adenocarcinoma patients was assessed. Firstly, a Phase-I dose escalation 
safety run established the maximum tolerated dose of pimasertib (Cutsem EV et al. 
2015). The patients participating in this trial were divided in two arms:  
 Arm (A): Patients receiving pimasertib 60mg with gemcitabine 1000mg/m2 
simultaneously. 
 Arm (B): Patients receiving placebo with weekly gemcitabine 1000mg/m2.  
The primary endpoint of the study was progression free survival (PFS). This trial, which 
has been recently concluded, showed a median PFS of 3.7 months for arm (A) versus 
2.8 months for arm (B) (hazard ratio of 0.883, 95% CI: 0.549–1.42; p=0.608). The OS of 
arm A and B was 7.3 months versus 8.3 months respectively. Unfortunately the results 
did not show a clinically significant improvement in PFS and OS, with higher adverse 
events observed more frequently in patients treated with the combination of 
pimasertib with gemcitabine (Cutsem EV et al. 2015). This trial was conducted in 
parallel with our in vitro and in vivo work on pancreatic cancer models, which 
demonstrated the importance of administering a sequential combination of 
pimasertib followed by gemcitabine in order to achieve significant antitumor activity 
(Chapter 3 and Chapter 5 will explain these findings in detail).  
 
1.5.2.3 Mechanisms of resistance to MEK inhibitors 
Despite promising results in preclinical models with MEK inhibitors, several factors 
cause their limited clinical activity and contribute to the resistance to MEK inhibitors 
(Zhao and Adjei 2014) . 
First, inhibition of ERK blocks negative feedback loops that regulate RAS or RAF 
signalling, thus enabling stronger reactivation of MEK or other downstream 
antiapoptotic pathways (Sale and Cook 2014) (Brummer et al. 2003). In agreement 
with this hypothesis, mutant B-RAF tumors are particularly sensitive to MEK inhibition, 
since this negative feedback mechanism between ERK and RAF proteins is weak or in 
some cases non-functional (Friday et al. 2008). Another mechanism of intrinsic 
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resistance to MEK inhibitors is the EGFR dependent reactivation of parallel signalling 
pathways such as PI3K/AKT that has been observed in PDAC (Mirzoeva et al. 2013). 
Second, oncogenic K-RAS activates multiple effector pathways, thus activation of 
alternative signalling cascades could rescue cancer cells from the anti-proliferative 
effects induced by MEK inhibition (Turke et al. 2012) (Steelman et al. 2008).  
Third, there are no biomarkers that could predict patients’ response to MEK inhibitors 
and enable patient stratification for personalised treatment (Zhao and Adjei 2014).  
Fourth, MEK inhibitors usually exert a cytostatic response, which limits their efficacy 
and this is one of the reasons why MEK inhibitors are often administered in 
combination with other cytotoxic agents (McCubrey et al. 2010). 
Fifth, the tumor microenvironment has shown to play an important role in the 
development of resistance to MEK inhibitors.  In particular, a recent study reported 
that MEK inhibitor treatment increased the number of macrophages within the tumor 
of B-RAF mutant melanoma models, accompanied by a significant increase of TNFα 
expression (Smith et al. 2014). The increase in macrophages observed was correlated 
with inhibition of MEK inhibitor-induced apoptosis through TNFα-dependent 
mechanism. Therefore these results suggest that targeting components of the tumor 
microenvironment could represent a possible therapeutic strategy to enhance MEK 
inhibitors sensitivity (Smith et al. 2014). 
Novel MEK inhibitor-based combination therapies should be explored to overcome 
the development of acquired resistance.  
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1.6 AIMS AND OBJECTIVES  
The aim of this thesis is to investigate the biological effects of a novel allosteric 
MEK1/2 inhibitor (pimasertib) and its ability to enhance gemcitabine cytotoxicity in 
pancreatic cancer models. Although some gemcitabine-based combinations and novel 
chemotherapy regimens have shown increased survival benefit compared to 
gemcitabine monotherapy in PDAC, the survival benefit conferred by these novel 
treatment options is still limited and there is an urgent need to investigate new 
therapeutic strategies. The use of MEK inhibitors is a clear rational strategy to 
sensitise tumours characterised by aberrant activation of RAS effector pathways.  
The following objectives will be addressed: 
 
1. Chapter Three: aims to investigate the effects of gemcitabine in combination 
with the MEK1/2 inhibitor pimasertib on human pancreatic cancer cells 
proliferation, apoptosis and on the regulation of signalling pathways. 
 
2. Chapter Four: examines the effects of pimasertib on the modulation of genes 
involved in gemcitabine metabolism and mechanism of action and the 
molecular mechanisms by which pimasertib sensitize human pancreatic cancer 
cells to gemcitabine treatment. 
 
3. Chapter Five: investigates the effects of pimasertib plus gemcitabine 
combination in a syngeneic orthotopic model of pancreatic cancer.  
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 MATERIALS 
2.1.1 Human and mouse pancreatic cancer cell lines and culture 
conditions 
Human pancreatic cancer cell lines MIAPaCa-2, PANC-1, BxPC-3 and SUIT-2 were 
purchased from ATCC (American type culture collection), USA.  
PANC-1 and MIAPaCa-2 cells were grown in DMEM supplemented with 10% fetal 
bovine serum, 1% of 200Mm L-Glutamine, 1% of 10,000 units Penicillin-10mg/ml 
Streptomycin (Sigma-Aldrich, UK). BxPC-3 and SUIT-2 cells were cultured in RPMI-1640 
with 10% fetal bovine serum, 1% of 200mM L-Glutamine, 1% of 10,000 units Penicillin-
10mg/ml Streptomycin (Sigma-Aldrich, UK). All cell lines were regularly tested for 
mycoplasma contamination. 
TB32048, a pancreatic cancer cell line syngeneic for C57BL/6 mice was derived from 
the KPC genetic pancreatic cancer mouse model (LSL-KRASG12D/+ 
LSLTrp53R172H/+Pdx1-Cre) and was kindly provided by Dr. David Tuveson (Cold 
Spring Harbor, USA). TB32048 cells were grown in DMEM supplemented with 10% 
fetal bovine serum, 1% of 200Mm L-Glutamine, 1% of 10,000 units Penicillin-10mg/ml 
Streptomycin (Sigma-Aldrich, UK). 
 
2.1.2 Chemotherapies, MEK inhibitors and other reagents 
The MEK1/2 inhibitors AS703026 (pimasertib) and AS703988 were provided by EMD 
Serono (Billerica, MA, USA). Gemcitabine was provided as a 38mg/ml solution from 
the pharmacy department of McMillan Cancer Centre (London, UK). 
Pimasertib was dissolved in dymethyl sulfoxide (DMSO) to produce a 10mM stock 
solution and stored at -20°. Gemcitabine was kept at room temperature and used 
within one month from the opening date.  
Gefitinib (Iressa, ZD 1839) was obtained from the London Oncology Clinic (LOC, 
London), dissolved in DMSO to produce a 10mM stock solution and stored at -20°. The 
PI3K inhibitor, GDC0942 was purchased from Stratech Scientific Ltd, dissolved in 
DMSO to make a 10mM stock solution and stored at -20. 
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MG132, a specific proteasome inhibitor, was purchased from Sigma Aldrich and 
prepared as a 1mM stock in DMSO, and stored at -20°C until use.  
 
2.2 Methods 
2.2.1. Cell Line maintenance 
Cells were cultured in 10 or 15cm2 tissue culture dishes (Thermo scientific) at 37°C in a 
humidified atmosphere of 5% CO2 and procedures were carried out in sterile 
conditions in Class II biological safety cabinets. Cells were routinely passaged by 
removing the medium and by gently washing once with sterile PBS. Following PBS 
removal, cells were detached by incubation with 2-5mL of Trypsin-EDTA (volume of 
trypsin was adjusted to the dimension of the cell culture dish) for 3-5min at 37°C. 
After detachment, complete medium was added to the cells in order to stop the 
action of the trypsin (volume of medium was equal to the amount of trypsin used). 
Cells were then collected and centrifuged at 1000rpm for 5min. The resulting cell 
pellets were resuspended in fresh medium before reseeding into new culture dishes 
at a ratio of 1/3 to 1/5 according to the cell line. Cells were passaged for a maximum 
of two months before being discarded and fresh cultures set-up.   
 
2.2.1.1 Storage and retrieval from liquid nitrogen 
Cells were frozen in liquid nitrogen for long-term storage. Cells were plated in 10cm 
tissue cultured dishes (Corning) and while exponentially growing, were trypsinised and 
collected by centrifugation as described in the previous section. The cell pellets were 
then resuspended in 1mL of freezing media [(media supplemented with 20% FBS and 
10% dimethylsulphoxide (DMSO) (Sigma-Aldrich)] per culture dish, aliquoted in 
cryotubes (Thermo scientific) and stored at -80°C for 24-72h prior long-term storage in 
liquid nitrogen tanks. In order to resuscitate cells from frozen stocks, cryotubes were 
rapidly warmed-up in a 37°C water bath, after which cells were supplemented with 
5mL of fresh medium and centrifuged for 5min at 1000rpm to remove the residual 
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DMSO. The resulting pellet was then gently suspended in 10mL of fresh media and 
cells were seeded in a 10cm tissue culture dishes and incubated at 37°C. 
 
2.2.1.2 Cell count 
Cells were counted, once resuspended in 10ml of complete growth medium, using a 
hemocytometer. A hemocytometer has two chambers and each chamber has a 
microscopic grid etched on the glass surface (4 squares each containing 16 smaller 
squares all connected by a 25 square grid). The chambers are overlaid with a glass 
coverslip that rests on pillars exactly 0.1mm above the chamber floor. 15µl of this 
dilution was loaded into one chamber. The number of cells present in the original 
solution was determined by counting the number of cells within the 4 large squares. 
The obtained numbered was then divided by 4 (number of squares) and then 
multiplied by 2 (dilution 1:2). The total number of cells obtained was multiplied by 
1X104, giving the number of cells per ml of suspension. 
 
2.2.2 Assessing growth inhibition 
2.2.2.1 Drug scheduling 
Cells were diluted 2.5 X 10^4/ml (BxPC-3, MIAPaCa-2 and SUIT-2) or 2.0 X 10^4/ml 
(PANC-1) and plated in 96 well plates. The following day cells were continuously 
exposed to increasing concentrations of each drug alone for 96h to determine the 
cells sensitivity to each drug, their IC50s and to select cell lines with most sensitivity 
and resistance to gemcitabine. IC50s are defined as the concentrations of drug that 
result in 50% cell survival compared with untreated cells. Drug combination 
experiments were carried out by using a fixed dose of pimasertib and increasing doses 
of gemcitabine. Different drug combination schedules were assessed:  
 Gemcitabine and pimasertib were given simultaneously and continuously for 
48h. 
 Pimasertib was given 4h before gemcitabine for a total of 48h treatment. 
 Pimasertib was given 4h before gemcitabine for a total of 24h treatment. 
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2.2.2.2 MTT assay  
A common methodology used to analyse cell viability is the clonogenic assay, which 
measures the ability of a single cell to proliferate indefinitely, thus to produce a large 
colony. The clonogenic assay is routinely used to look at the survival effects after 
exposure to radiation.  
Because of the long duration of the experiment, a preferable method used to study 
chemosensitivity of tumor cells and to perform novel drugs screening is the low-cost 
MTT (methylthiazolyldiphenyl-tetrazolium bromide) assay, which measures cell 
viability in an accurate and less time-consuming way. The MTT assay is based on the 
capacity of viable cells with active mitochondria to reduce the yellow soluble 
tetrazolium salt (MTT) to form a blue formazan precipitate, a reaction catalysed by 
dehydrogenase enzymes. It is semi-automated since it can be performed in a 96-well 
plate and the production of formazan (blue precipitate) can be analysed by a 
spectrophotometer. 
The ability of gemcitabine, pimasertib or their combination to inhibit cell proliferation 
was measured using this assay. Experiments were conducted in flat-bottom 96-well 
plates (Corning). 200L of 2.0-2.5x104 cells/mL were plated in each well and left to 
adhere overnight in full serum medium. Cells were exposed to increasing 
concentrations of gemcitabine, pimasertib or their combination according to the 
schedules previously described. Drug dilutions were prepared in complete culture 
media and 200L of drug-containing media was added to each well. For every 
concentration used, four technical repeats were performed and untreated control 
samples were incubated with complete media supplemented with vehicle DMSO for 
DMSO-diluted drugs. Following 96h or 48h drug exposure, 20L of a MTT (5mg/mL)-
PBS solution were added to each well and plates were left in the incubator for a 
further 4h. At the end of the incubation, the cell culture media was removed by gentle 
aspiration and the formazan crystals were resuspended in 200L of DMSO. The 
quantity of formazan, which is directly proportional to the number of viable cells, is 
measured by recording changes in absorbance at 540nm on a Varioskan Flash 
Multimode Reader (Thermo Scientific). Percentage proliferation was calculated by 
averaging the absorbance values obtained from each of the technical repeats and by 
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normalising the values of drug treated samples to the absorbance values obtained 
from the untreated control samples (% proliferation= OD of treated/OD of untreated 
*100).  
 
2.2.2.3 Calcusyn Software analysis 
The fraction affected (Fa) obtained from the single drug treatments or from the 
combination assays were used for the calculation of the combination indices (CI), 
which describe drug interactions. The Calcusyn Software (Biosoft), based upon the 
Chou– Talalay method was used for determining CI values, according to a non-fixed 
ratio design (Bijnsdorp et al. 2011). The Chou- Talalay plot indicates the CI on the y-
axis as a function of effect level (Fa) on the X-axis. 
CI values were obtained from three independent experiments for each set of 
combinations, each performed in triplicate, using results obtained from each drug 
alone and in combination within the same experiment. CI < 1 indicates synergism, 1 < 
CI > 1 suggests an additive effect, and CI > 1 corresponds to antagonism.  
 
2.2.3 Caspase 3/7 assay 
The Caspase-Glo® 3/7 Assay (Promega) is a luminescent assay that measures caspase-
3 and -7 activities. The assay provides a luminogenic caspase-3/7 substrate, which, 
following cleavage generates a ‘glow-type’ signal produced by a luciferase.  2.0-
2.5x104 cells were plated in opaque 96 well plates and left to adhere overnight. The 
following day, drug treatments were performed. 24h or 48h later, the addition of the 
Caspase-Glo® 3/7 reagent in an ‘add-mix-measure’ format resulted in cell lysis, 
followed by caspase cleavage of the substrate and generation of a ‘glow-type’ 
luminescent signal detected with the Varioskan Flash Multimode Reader (Thermo 
Scientific). The luminescent signal detected was directly proportional to the enzymatic 
activity of caspase 3/7 enzymes indicating apoptosis. Luminescent values in treated 
samples were normalized to untreated controls and fold increase compared to the 
controls (assigned a value of 1) was calculated. 
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2.2.4 Western blotting analysis 
2.2.4.1 Protein extraction 
Cells were washed twice with ice-cold PBS buffer. Sigma Lysis buffer containing fresh 
1.5X protease inhibitor and 1.5X phosphatase inhibitor (Roche, UK), was added to the 
cells (kept on ice) for few minutes. Next, cells were scraped using cell scrapers (VWR, 
UK), collected into eppendorf tubes and left on ice for 15 minutes at 4°C. Samples 
were then pelleted by centrifugation for 15 minutes at 4°C (13,000rpm). The total cell 
lysate (supernatant) was placed in a fresh eppendorf tube and stored at -80°C. 
 
2.2.4.2 Protein quantification 
Proteins were quantified using the colorimetric RC-DC protein assay from Bio-Rad 
Laboratories. Protein quantification is based on the use of three reagents: A, S, and B. 
A 1:8 dilution of each protein sample was prepared in order to quantify each sample 
in triplicate (35L).  A mix of reagent A and S was also prepared (20l of reagent S 
with 1ml of reagent A) and 25L of this mix was added in each well of a flat-bottom 96 
well plate.  A Bovine Serum Albumin (Sigma-Aldrich) standard curve was used to 
calculate the protein concentration of the samples under investigation. 10l of each of 
the BSA standards (100g/mL, 200g/mL, 400g/mL, 600g/mL, 800g/mL, 
1000g/mL) or unknown sample replicates were pipetted per well. 200L of reagent B 
was then added to each well and the content of the plate was mixed on a shaking 
platform for 15min at RT. Absorbance (OD) was measured at 750nm with the 
Varioskan Flash Multimode Reader (Thermo Scientific). The average absorbance 
measurement of the blank sample was subtracted from the all the measurements of 
both standard and unknown samples. A standard curve was then prepared by plotting 
the average absorbance value of each BSA standard vs. its concentration (g/mL). The 
standard curve generated can be used to calculate the protein concentration of each 
unknown sample. 
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2.2.4.3 Immunoblotting 
25-40g of protein from samples prepared as in section 2.2.4.1 were centrifuged for 
10 seconds, heat-denatured for 5min at 95°C in sample buffer containing 100 mM 
Tris-Cl (pH 6.8), 4% SDS, 10% 2-mercaptoethanol, 20% glycerol, and 0.02% 
bromophenol blue (Life Technologies) and loaded on a 7% Tris-acetate, or 4-12% Bis-
Tris NuPAGE gel (Novex, Pre-cast gels, Life Technologies). 10x Running NuPAGE [60.5g 
Tris-Base (Sigma-Aldrich), 89.5g Tricine (Sigma-Aldrich) and 10g of SDS (Sigma-
Aldrich)] or 20x MOPS [52.3g MOPS (Sigma-Aldrich), 30.3g Tris-Base (Sigma-Aldrich), 
5g SDS (Sigma-Aldrich) and 1.5g EDTA (Sigma-Aldrich)] running buffers were diluted to 
1x with distilled water and were used for protein electrophoresis on Tris-acetate or 
Bis-Tris gels at 175 Volts. The protein marker ‘AmershamTM RainbowTM Marker’ (GE 
Healthcare) was used as a molecular weight protein standard. Proteins were 
subsequently transferred to polyvinylidene difluoride membranes (Immobilon®-P 
transfer membrane; Millipore), which had been previously activated by immersion in 
Methanol (VWR) for 1 min. The transfer buffer was prepared with a 1:10 dilution of a 
10x Tris-Glycine buffer [30.3g Tris-Base (Sigma-Aldrich) and 144.1g Glycine (Sigma-
Aldrich)] in distilled water and 20% Methanol. Proteins were transferred at 35V for 2.5 
hours at RT using the XCell II Blot module (Life Technologies) and membranes were 
subsequently blocked for 1h at room temperature in blocking buffer containing 5% 
BSA (Sigma-Aldrich) in 1x TBS, 0.1% Tween-20 (Sigma-Aldrich). All primary antibodies 
were incubated overnight at 4°C and are listed in Table 2.1. The antibody dilutions 
were kept at 4°C and supplemented with 0.02% Sodium Azide (Severn Biotech) for at 
least one month.  Anti-rabbit or mouse IgG, HRP-linked Antibodies (Cell Signaling 
Technologies) were used to detect the primary antibodies binding (dilutions ranging 
from 1:1000 to 1:5000 depending on the primary antibody used). Membranes were 
washed three times in 1xTBS-0.1% Tween-20 buffer for 5min following incubation 
with primary and secondary antibodies. The antibody binding to the protein of 
interest was detected by enhanced chemiluminescence (ECL system, Amersham) on 
autoradiography film (Kodak X-Omat). Reprobing of membranes with different 
antibodies specific for proteins with similar molecular weight (e.g. phosphorylated and 
total proteins) was performed by stripping the original bound antibody from the 
membrane with 15 min incubation with the RestoreTM PLUS western blot stripping 
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buffer (Thermo Scientific). Alternatively, protein lysates were re-analysed by western 
blotting in the exact same conditions. 
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Antibodies  Dilutions Dilution buffer Supplier 
Anti-EGFR 1/1000  TTBS 5% BSA Cell signalling,UK 
Anti-P-EGFR Y845  1/1000  TTBS 5% BSA Cell signalling,UK 
Anti-RRM1 1/1000 TTBS 5% BSA Cell signalling,UK 
Anti-ERK 1/1000 TTBS 5% BSA Cell signalling,UK 
Anti-P/ERK 1/1000 TTBS 5% BSA Cell signalling,UK 
Anti-P/MEK1/2 1/1000 TTBS 5% BSA Cell signalling,UK 
Anti-MEK1 1/1000 TTBS 5% BSA Cell signalling,UK 
Anti-MEK2 1/1000 TTBS 5% BSA Cell signalling,UK 
Anti-CDA 1/500  TTBS 5% BSA Abcam  
Anti-RRM2 1/1000 TTBS 5% BSA Santacruz Biotech 
Anti-Calnexin 1/1000 TTBS 5% BSA Cell signalling,UK 
Anti-K48 1/1000 TTBS 5% BSA Cell signalling,UK 
Anti-C-Parp TTBS 1/1000 BSA TTBS 5% BSA Cell signalling,UK 
Anti-rabbit-HRP-
secondary 
TTBS 1/1000 BSA TTBS 5% BSA Cell signalling,UK 
Anti-mouse-HRP-
secondary 
TTBS 1/2000 BSA TTBS 5% BSA DAKO scientific 
Anti-MDM2 TTBS 1/1000 BSA TTBS 5% BSA Santa Cruz Biotech. 
Anti-p/MDM2 TTBS 1/1000 BSA TTBS 5% BSA Cell signalling,UK 
Anti-p53 TTBS 1/500 BSA TTBS 5% BSA Santa Cruz Biotech. 
Anti-β-actin TTBS 1/3000 BSA TTBS 5% BSA Cell signalling,UK 
 
Table 2.1: Primary and secondary antibodies used for western blotting analysis. 
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2.2.4.4 Densitometry analysis 
The ImageJ Software was used to compare the intensity of bands obtained from 
immunoblotting analysis. Blots were scanned, bands of interest were selected and 
intensity (pixel density) was measured. The band intensity obtained with the antibody 
of interest was normalized to the intensity of the respective loading control.  
 
2.2.5 Immunoprecipitation 
To investigate protein-protein interaction and RRM1 polyubiquitination, cells were 
plated at 2-5 × 105/mL in 15cm dishes and allowed to proliferate overnight before 
treatment. Cells were then pre-treated for 1 hour with the proteasome inhibitor 
MG132 followed by 4h treatment with pimasertib. Approximately 107 cells/dish were 
lysed in 500μL of CelLytic M Cell lysis reagent (Sigma) supplemented with protease 
and phosphatase inhibitor (Roche) according to manufacturer's protocol. 550-750 µg 
of protein sample was incubated with 1 μg of anti-RRM1 (Abcam) or anti-MDM2 
antibody (Santa Cruz Biotechnology) coupled to protein A beads and left rotating at 
4°C overnight. IPs were eluted by boiling in SDS-PAGE loading buffer for 5 min at 95° 
and analysed by immunoblotting for RRM1, K-48, P-MDM2 and MDM2. 
 
2.2.6 Fluorescence-activated cell sorting (FACS) for cell cycle analysis 
Cell cycle alterations were studied by flow cytometry analysis (FACS). BxPC-3 cells 
were plated at a density of 1 × 106 cells in 6 well plates. Twentyfour hour later cells 
were incubated with the indicated drugs for 48 hours. Cells were washed and 
harvested by trypsinization and centrifugation (3500 rpm, 5 min). The pelleted cells 
were washed twice with PBS (0.01 m, pH 7.4) and fixed in cold 70% (v/v) ethanol and 
incubated at -20° overnight. The DNA of the fixed cells was stained with propidium 
iodide (PI) solution which consists of 50 μg/mL propidium iodide, 0.1 mg/mL RNase A, 
0.05% Triton X-100, and PBS (all Sigma-Aldrich) and incubated for 1h at room 
temperature in the dark before analysis. The cell cycle status of the cells was analysed 
with FACScan flow cytometer (Becton Dickinson, CA, USA) using Cell Quest™ software 
(Becton Dickinson, CA, USA). 
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2.2.7 RNA isolation and real-time PCR  
1X10^5 BxPC-3 and PANC-1 cells were plated in a six-well plate. The next day cells 
were treated with pimasertib or gemcitabine for 24h. Cells were trypsined and 
collected by centrifugation. Cell pellets were processed with the RNeasy kit (Qiagen) 
for RNA extraction according to the manufacturer’s protocol and concentration was 
determined using the NanoDrop 2000 Spectrophotometer. 1μg of extracted RNA was 
transcribed reversely into c-DNA by using Omniscript RT kit (Qiagen) and then used for 
real Time PCR (RT-PCR). TaqMan dye was used as a detector and the applied 
biosystem 7500 RT-PCR machine was employed for PCR amplification. PCRs were done 
in a 20μL reaction volume containing 10μL of 2× buffer/enzyme mix, 1μL of 20× assay 
mix, 1μL of 20× GAPDH (Hs02758991_g1) endogenous control assay mix and 1μL input 
cDNA. The following protocol was used: initial incubation at 95°C for 10 minutes 
followed by 45 cycles at 95°C (15 seconds) and 60°C (1 minute).  Cycle Threshold (CT) 
values, used to calculate the changes in gene expression, and were generated by the 
Applied Biosystems SDS software. Gene expression analysis (CT method and 
statistical analysis) was performed with the SABiosciences online tool 
(http://www.sabiosciences.com/pcr/arrayanalysis.php). Each sample was assayed in 
triplicates. RRM1 (01040698_m1) and RRM2 (00357247_g1), Assays-on-demand were 
obtained from Applied Biosystems.  
 
2.2.8 Small interfering RNA (siRNA) transfection 
MEK1, MEK2, MDM2, p53 and RRM1 smart-pool siRNA and non-targeting control 
(scrambled) smart-pool siRNAs were purchased from Thermo Scientific. The siRNA 
pools (20nmol) were resuspended in 1mL RNAse-free water according to 
manufacturer’s instruction in order to obtain a stock of 20M. Working stocks of 2M 
were obtained by performing a 1:10 dilution of the siRNA aliquots (20M) in 1x siRNA 
buffer (Thermo Scientific). Transfection protocols (siRNA concentration, cell density, 
transfection time, transfection reagent quantity) were optimised for the different cell 
lines and siRNAs used. Briefly, cells were plated at a concentration of 105/ml into 6-
well cultured plates and allowed to attach overnight. The following day, both siRNA 
and DharmaFECT-1 transfection reagent (Thermo Scientific) were diluted in serum-
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free Opti-MEM media (Life Technologies) according to the manufacturer’s instructions 
(usually siRNA final concentration range was between 50-100nM) and incubated for 
5min at RT. siRNA-Opti-MEM dilution was then mixed with the Dharmafect-Opti-MEM 
solution by pipetting carefully up and down and the mixture was left at room 
temperature for 20min. Following incubation, 400L of the siRNA-Dharmafect 
solution were added per/well in a total volume of 2mL of antibiotic-free complete 
medium. The next day transfection medium was replaced with complete medium and 
cells were then left at 37C for an additional 24 or 48h. Protein knockdown was 
confirmed by immunoblotting analysis. 
 
2.2.9 Plasmid transfection 
The plasmid pCMV-myc3-HDM2 was a gift from Yue Xiong (Addgene plasmid # 20935) 
(Zhang et al. 2003) and the plasmid pCMV-myc3-Mdm2 p60 was a gift from Tyler Jacks 
& Trudy Oliver (Addgene plasmid # 52059) (Oliver et al. 2011). 
1x105 MIAPaCa-2 cells were seeded in six well plates with antibiotics-free media. After 
24 hours cells were transiently transfected with pCMV-myc3-HDM2 or pCMV-myc3-
Mdm2 p60 (2μG-10μG) using the GeneJuice transfection reagent, according to the 
manufacturer’s protocol (Novagen EMD Bioscience). 48h post transfection, 600g/mL 
neomycin (G418) (Sigma-Aldrich) was added to the medium. Transfected cells were 
incubated for 72 hours keeping selective pressure in the medium before pimasertib 
treatment. 
 
2.2.10 Treatment studies in murine models 
2.2.10.1 Establishment of a syngeneic orthotopic mouse model of 
pancreatic cancer 
The murine pancreatic adenocarcinoma cell line TB32048 was used to establish a 
syngeneic orthotopic mouse model of pancreatic cancer. TB32048 cells were derived 
from the genetically engineered mouse model KPC (LSL-KRASG12D/+ 
LSLTrp53R172H/+Pdx1-Cre). 
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Subconfluent cultures of TB32048 cells were harvested with 0.25% trypsin, re-
suspended and washed with PBS. 1 X 10^5 cells were resuspended in ice-cold PBS and 
ice-cold Matrigel at 1:1 ratio. The mixture was mixed and the suspension was injected. 
Six- to eight-week-old C57BL/6 black female mice were used in all in vivo experiments 
according to the Animal Research Ethics and United Kingdom Coordination Committee 
on Cancer Research Guidelines and Home Office Regulations (Project license 
PPL70/7411). All animals were housed under specific pathogen-free conditions and all 
procedures involving animals were conducted according to the requirements of the 
United Kingdom Home Office Animals (Scientific Procedures) Acts, 1986. After 
acclimatization for 1 week, mice were anesthetized and laparotomy was performed. 
Part of the pancreas was well exposed. 1×10^
5 
TB32048 tumor cells in 30 μL of PBS: 
Matrigel (1:1) were orthotopically injected into the pancreas using an inoculator with 
a 30-gauge needle.  
 
 
Figure 2.1: Schematic representation of the syngeneic orthotopic mouse model of pancreatic cancer 
generated. 
An orthotopic model of pancreatic tumor was established by implanting TB32048 cells (derived from 
the KPC mouse model of PDAC) into the pancreas of immunocompetent mice. 
 
2.2.10.2 Drugs treatment schedule in the orthotopic mouse model 
After tumors were established, drug treatment was assessed. Gemcitabine was 
administered intraperitoneally and pimasertib was suspended in 0.5% carboxyl 
methylcellulose and 0.25% Tween 20 and injected by oral gavage. Mice were treated 
with gemcitabine 80mg/kg (twice/week), single agent pimasertib at 5mg/kg or 
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15mg/kg (daily) or sequential combination of pimasertib followed by gemcitabine for 
a total of 2 5-day treatment cycles. The control mice were treated with 0.5% carboxyl 
methylcellulose and 0.25% Tween 20 by oral gavage. In the combination cohort, 
gemcitabine treatment was initiated 4 hours after pimasertib administration. After 
two treatments cycles of 5 days each all mice were sacrificed. Tumors were excised, 
weighed and fixed in paraformaldehyde for IHC analysis. 
 
2.2.10.3 Ultrasound analysis 
Ultrasound imaging was peformed to measure tumor volumes at the beginning and at 
the end of each drug treatment using the VEVO2100 high frequency imaging system. 
Mice were anesthetized using 1.5 liters/min oxygen/isofluorane mixture and then 
gently taped to the imaging stage. The vital signs were monitored on the VEVO2100 
(VisualSonics Inc, Ontario, Canada). Ultrasound images were captured using the 
abdominal package in B-mode, and three images per pancreas (10 fields/analysis) 
were captured via 3D-Mode combined with B-Mode for volume analysis following 
manufacturer's instructions (VisualSonics).  
 
2.2.10.4 Immunohistochemistry (IHC) 
Immunohistochemistry was performed to determine specific protein expression in 
TB32048 tumors. Samples were fixed in paraformaldehyde.4mm paraffin sections 
underwent automated dewaxing (Leica Bond Dewax AR9222) and endogenous 
peroxidase was blocked using 3-4% (v/v) hydrogen peroxide (part of Leica Bond Refine 
Polymer Kit, DS9800). Automated antigen retrieval was then performed on the 
sections. For Ki67, Cleaved Caspase-3 (CC3) and RRM1, Leica Bond ER2 (EDTA-based, 
pH9, AR9640) was applied to the slides and they were heated to 100 degrees Celsius 
(30 minutes for Ki67, p-AKT and CC3 and 10 minutes for RRM1). No antigen retrieval 
was used for P-ERK. The antibody was used on the slides obtained from mice 
pancreatic tumors at a dilution of 1/100 (Ki67), 1/1000 (CC3), 1/200 (RRM1 and P-
ERK), with 15 minutes incubation or 1/200 (p-AKT), with 30 minutes incubation. Signal 
visualisation was performed using Bond Polymer (Anti-rabbit Poly-HRP-IgG) for 8 min. 
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DAB was applied for 10 minutes and then Bond DAB Enhancer (Copper Sulfate-based, 
AR9432) was applied for 5 min. Cell nuclei were counterstained with haematoxylin. 
The Leica Bond Polymer Detection Kit (DS9800) was used for peroxidase blocking, 
visualization and counterstaining. Bond Wash (AR9590) was used for all washing steps 
between reagent steps.  
 
2.2.10.5 IHC quantification 
Immunostaining for RRM1, p-AKT and p-ERK was assessed in at least five fields at 400× 
magnification. Immunoreactivity was evaluated semi-quantitatively based on staining 
intensity and proportion. The proportion of staining was scored from 0 to 3 as 
follows:  3: >50% of positive cells; 2: 10-49%; 1: <10% of positive cells. Intensity of 
staining was scored from 0 to 3 (0, absent; 1, weak; 2, moderate; 3, intense). The 
immunoreactive score (IRS) for each sample was determined by multiplying the 
intensity and the proportion of stained cells.  
For ki67 staining the number of positive cells were counted and compared to the total 
number of nuclei in a field. Values were expressed in percentage. (Nuclear staining in 
> 40% was considered positive, < 40% was considered negative). For CC3 staining the 
number of positive cells were counted and compared to the total number of nuclei in 
a field. Values were expressed in percentage. (Nuclear staining in < 1% was considered 
negative, between 1-5% was considered positive). 
Analysis was undertaken blindly without knowledge of treatment variables. 10 images 
per slides were analysed. 
 
2.2.11 Statistical analysis 
The One-way ANOVA or Two-way ANOVA with Bonferroni post-tests were used to 
calculate statistical significance for the in vitro experiments. *P <0.05, as calculated by 
GraphPad Prism (version 6.0; GraphPad Software Inc.), was considered statistically 
significant. Differences in final tumor weights were confirmed using a Student’s t-test 
and considered statistically significant when P < 0.05. 
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CHAPTER 3  
THE CELLULAR EFFECTS OF 
PIMASERTIB IN COMBINATION WITH 
GEMCITABINE IN PDAC 
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3.1 INTRODUCTION 
3.1.1 Interaction of gemcitabine with targeted therapy 
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease for which current 
therapies are often ineffective (Hidalgo 2010). Gemcitabine, a nucleoside analogue, 
has represented a standard treatment for PDAC since 1997 (Burris et al. 1997). 
However, both intrinsic and acquired gemcitabine resistance is a crucial factor, which 
limits patients’ response to treatment (Nakano et al. 2007).  
The identification of small molecule inhibitors that could modulate the expression of 
molecular markers known to impair gemcitabine efficacy represents a key strategy to 
improve pancreatic cancer patient’s response to gemcitabine. 
A large number of gemcitabine-based combinations have been evaluated in clinical 
trials but show limited efficacy. An exception is the combination of gemcitabine plus 
nab-paclitaxel, which has yielded a small but significant improvement in survival along 
with manageable toxicities. Thus, this regimen represents one of the standard 
treatments for locally advanced and metastatic PDAC (Conroy et al. 2011, Von Hoff et 
al. 2011). Identifying new therapeutic strategies that significantly improve PDAC 
patients’ response to gemcitabine and other chemotherapies are urgently needed.  
The RAS/RAF/MEK/ERK signalling pathway regulates fundamental cellular processes 
such as survival, proliferation, differentiation and invasion (Normanno et al. 2006). 
The K-RAS oncogene is mutated in almost all PDACs and sustained activation is 
required for pancreatic tumorigenesis and development (di Magliano and Logsdon 
2013). Targeting downstream RAS effectors in cancers characterised by a deregulated 
MAPK pathway by using inhibitors of MEK protein have proved to be successful in the 
clinic (Flaherty et al. 2012) and several preclinical studies have demonstrated their 
efficacy in PDAC model systems (Alagesan et al. 2015). In particular, previous findings 
have shown improved antitumor activity when gemcitabine was combined with MEK 
inhibitors in biliary cancer, underling the importance of this drug combination (Xu et 
al. 2013).  
Pimasertib, a potent, highly selective MEK1/2 inhibitor, binds to an adjacent allosteric 
site, which locks MEK into a catalytically inactive conformation, thereby preventing 
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any side effects associated with inhibition of other protein kinases (Yoon et al. 2011). 
Combinations of chemotherapy or targeted therapy with pimasertib caused 
synergistic antitumor activity in different human cancer where they have been tested 
(Kim et al. 2010). (Yoon et al. 2011) (Martinelli et al. 2013) (Airiau et al. 2015).  
 
3.1.2 Determining the effects of gemcitabine plus pimasertib 
combination in human pancreatic cancer cell lines 
This chapter aims at investigating the combination effects of pimasertib with 
gemcitabine. The combination index (CI) theorem derived by Chou-Talay, provides the 
means for quantifying synergism, additivity or antagonism with a computerised 
simulation (Chou 2010). CI values describing drug interactions are calculated using the 
Calcusyn Software. CI values greater than 1 indicate antagonism; values less than 1 
indicate synergism. A dose-effect curve of each drug alone has to be determined since 
each drug has different potency and produces a dose-response curve of different 
shape (Chou 2010). A non-constant ratio treatment was used to determine the effects 
of increasing concentrations of gemcitabine with a fixed concentration of pimasertib 
(≈ IC35) in BxPC-3 and PANC-1 cell lines. CI values from each experiment were derived 
to accurately quantify the effects of these drugs in combination and characterize their 
interaction. 
 
3.1.3 Drugs administration schedule affects in vitro and in vivo response  
One of the main challenges in combination therapy is to find the optimal design 
schedule. Different factors can change the outcome of a patient’s response: (a) drugs 
dosage, (b) the order of drugs administration, (c) the timing between two different 
administrations and (d) the duration of each drug exposure (Fitzgerald et al. 2006). 
This concept was well demonstrated by a preclinical study on triple negative breast 
cancer (TNBC) models, in which the combination effects of an EGFR inhibitor 
(erlotinib) with doxorubicin was investigated (Lee et al. 2012). Sequential treatment 
with erlotinib followed by doxorubicin sensitized TNBC cells and xenograft models to 
DNA damage and enhanced doxorubicin-induced apoptosis, an effect that was 
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abolished when the sequence was reversed or when the two agents were given 
simultaneously. Importantly, the synergistic effects obtained by erlotinib plus 
doxorubicin combination were caused by re-activation of pro-apoptotic pathways 
induced by sustained EGFR inhibition and whose activity had been abolished by 
deregulated EGFR signalling (Lee et al. 2012).  
Preclinical studies are crucial to investigate the best drug combination schedules, 
particularly when combined with inhibitors of oncogenic signalling pathways, for the 
design of new clinical trials. In this present study, the efficacious drug combination 
design between the MEK inhibitor pimasertib and gemcitabine chemotherapy will be 
discussed. 
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3.2 RESEARCH HYPOTHESIS AND AIMS 
Hypothesis: MEK inhibitors have been shown to be effective in tumors characterised 
by genetic alterations within the RAS/MEK/ERK signalling cascade by blocking the 
transmission of proliferative signals induced by this pathway. Gemcitabine represents 
a standard treatment for locally advanced and metastatic PDAC patients, however, 
providing small survival benefit. Gemcitabine-based combinations treatments in PDAC 
patients have proved promising and some have resulted in FDA approval (nab-
paclitaxel plus gemcitabine, erlotinib plus gemcitabine).  
This chapter investigates the interaction between pimasertib and gemcitabine in 
human pancreatic cancer cell lines, aiming to: 
 Investigate the effects of pimasertib on the inhibition of human pancreatic 
cancer cell proliferation and ERK signalling. 
 Understand how the combination of pimasertib with gemcitabine affects 
proliferation and apoptosis. 
 Investigate the effects of pimasertib and gemcitabine in modulating the 
expression of genes associated with gemcitabine resistance. 
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3.3 RESULTS 
3.3.1 Gemcitabine inhibits proliferation of human pancreatic cancer cell 
lines 
The chemosensitivity of a panel of human pancreatic cancer cell lines (PANC-1, BxPC-
3, SUIT-2 and MIAPaCa-2) to gemcitabine was evaluated. Cells were treated with 
increasing concentrations of gemcitabine (0.01µM to 100µM) continuously for 96 
hours after which cell proliferation was measured by MTT assay. The concentrations 
needed to inhibit cell growth by 50% were calculated (IC50). SUIT-2 and BxPC-3 were 
the most sensitive cell lines, exhibiting an IC50 of 14.15nM and 40.97nM respectively, 
whereas PANC-1 was the most resistant, with an IC50 of 10.9µM (Table 3.1). MIAPaCa-
2 cell line exhibited an IC50 of 69.4nM (Table 3.1). Gemcitabine induced a dose-
dependent effect on cell growth inhibition until 100nM dose. As the concentrations of 
gemcitabine increased (1µM, 10 µM and 100µM) all cell lines reached a plateau of 
proliferation (Figure 3.1).   
                                  
 
 
Figure 3.1: Effect of gemcitabine on the proliferation of human pancreatic cancer cell lines.  
PANC-1, BxPC-3, MIAPaCa-2 and SUIT-2 cells were treated for 96 hours with increasing concentrations 
of gemcitabine (0.1μM to 100μM). Inhibition of cell growth was measured using MTT assay. 
Absorbance values obtained from treated samples were normalized to untreated controls and 
presented as % proliferation. Each experiment was performed in triplicate and results are presented as 
mean, error bars ± SD.  
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BxPC-3 and PANC-1 cell lines were selected to perform drug combination studies and 
for the mechanistic studies of this project. BxPC-3 cells are wild type for K-RAS and 
PANC-1 cells harbour an activating point mutation within the K-RAS gene at codon 12 
(Loukopoulos et al. 2004). Both BxPC-3 and PANC-1 cells carry an inactivating 
mutation within the p53 tumor suppressor gene (Moore et al. 2001). Table 3.1 
outlines the main biological characteristics of the cell lines used in this study in terms 
of their K-RAS and P53 mutations and their gemcitabine IC50 values. The 
concentrations of gemcitabine used for drug combination analyses were selected 
between  the range of 5nM and 100nM, which inhibited cell proliferation in BxPC-3 
and PANC-1 cells in a dose-dependent manner (Fig. 3.2).  
 
 
 
Table 3.1: Characteristics of human pancreatic cancer cell lines. 
Information for each cell line was obtained from the COSMIC database and the Broad Institute Cancer 
Cell Line Encyclopedia. IC50 values of gemcitabine were calculated with the GraphPad/Prism6 software. 
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Figure 3.2: Effects of gemcitabine on cell proliferation in BxPC-3 and PANC-1 cell lines. 
BxPC-3 and PANC-1 cells were treated for 96 hours with increasing concentrations of gemcitabine (5, 
25, 50 and 100nM). Inhibition of cell growth was measured using MTT assay. Absorbance values 
obtained from treated samples were normalized to untreated controls and presented as % 
proliferation.  Each experiment was performed in triplicates and results are presented as mean, error 
bars ± SD.  
 
3.3.2 Pimasertib inhibits cell proliferation and activation of ERK 
signalling in human pancreatic cancer cell lines 
Pimasertib acts by inhibiting MEK protein in phosphorylating and thus activating 
downstream ERK (Yoon et al. 2011). To determine the optimal concentration to use 
for our combination experiments, the pharmacodynamics effects of pimasertib on ERK 
pathway inhibition were investigated. Firstly, BxPC-3 and PANC-1 cell lines were 
treated with increasing concentrations of pimasertib (0.1, 0.5, 1µM) for 24 hours. 
Pimasertib effectively inhibited P-ERK signalling in both cell lines at all concentrations 
tested (Fig. 3.3). Next, the effect of pimasertib treatment on ERK signalling over time 
was analysed. PANC-1 and BxPC-3 cell lines were treated with 1µM pimasertib and 
total cell lysates were extracted at different times. Both cell lines exhibited total 
inhibition of P-ERK expression from 30 minutes of exposure with pimasertib, which 
was sustained over the time course (Fig. 3.4). 
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Figure 3.3: Dose-dependent inhibition of P-ERK signaling by pimasertib.  
PANC-1 and BxPC-3 cells were treated with increasing concentrations of pimasertib (0.1 µM, 0.5 µM 
and 1µM) for 24 hours. Total cell lysates were extracted and analysed by immunoblotting with the 
indicated antibodies. Calnexin was used as loading control. The experiment shown is representative of 
three independent experiments. 
 
 
 
 
 
 
 
 
Figure 3.4: Time-dependent inhibition of P-ERK signalling by pimasertib.  
PANC-1 and BxPC-3 cells were treated with 1µM pimasertib and harvested at different time points 
(30min to 48h). Total cell lysates were extracted and analysed by immunoblotting with the indicated 
antibodies. Calnexin was used as loading control. The experiment shown is representative of three 
independent experiments. 
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To determine the responsiveness of pimasertib on cell proliferation, PANC-1 and 
BxPC-3 cell lines were treated with pimasertib at concentrations ranging from 0.01μM 
to 10μM, continuously for 48 hours. Inhibition of cell proliferation induced by 
pimasertib was determined by MTT assay. At 48 hours treatment, BxPC-3 and PANC-1 
cells viability was higher than 70% (IC70) at all concentrations of pimasertib tested (Fig. 
3.5). A subtoxic concentration of pimasertib (0.5μM) was used for our combination 
treatments to explore whether pimasertib sensitized cells to gemcitabine-induced 
cytotoxicity since this concentration, as previously shown, also effectively inhibited 
ERK phosphorylation (Fig. 3.4).  
 
 
 
 
Figure 3.5: Effects of pimasertib on cell proliferation in BxPC-3 and PANC-1 cell lines.  
PANC-1 and BxPC3 cells were treated for 48 hours with increasing concentrations of pimasertib 
(0.01μM, 0.1μM, 0.5μM, 1µM, 10µM). Inhibition of cell growth was measured using MTT assay. 
Absorbance values obtained from treated samples were normalized to untreated controls and 
presented as % proliferation. Each experiment was performed in triplicate and results are presented as 
mean, error bars ± SD. 
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3.3.3 Cell cycle effects of pimasertib and gemcitabine  
Flow cytometry analysis was performed to determine the effects of pimasertib and 
gemcitabine on the cell cycle. BxPC-3 cell lines were treated for 48 hours with 100nM 
pimasertib or gemcitabine. Next, cells were harvested, stained with propidium iodide 
and analysed by flow cytometry. Pimasertib treatment resulted in accumulation in G1 
phase as shown by the DNA histograms (Fig. 3.6). On the other hand, gemcitabine 
increased the percentage of cells in S phase of the cell cycle (Fig. 3.6). 
A 
 
B 
 
Figure 3.6: Effect of pimasertib and gemcitabine on the cell cycle. 
A. BxPC-3 cells were treated for 48 hours with 100nM pimasertib or 100nM gemcitabine. Cells were 
harvested, stained with propidium iodide and analysed by flow cytometry. Cell cycle distribution is 
shown. B. Bar graphs showing the percentage of cells in each phase of the cell cycle. 
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3.3.4 Combination of pimasertib with gemcitabine according to a non-
constant ratio design 
The effect of pimasertib treatment in combination with gemcitabine on the 
proliferation of BxPC-3 and PANC-1 cell lines was investigated. A non-constant ratio 
design employing a fixed concentration of pimasertib (500nM), combined with 
increasing concentrations of gemcitabine (5nM, 25nM, 50nM, 100nM) was applied. A 
dose-effect curve of each drug alone was also performed.  
Three combination schedules were designed: 
 
1. Simultaneous and continuous exposure to pimasertib with gemcitabine for 48 
hours. 
2. Sequential combination consisting of 4 hour pre-treatment with pimasertib 
followed by 48-hour treatment with gemcitabine 
3. Sequential combination consisting of 4 hour pre-treatment with pimasertib 
followed by 24-hour treatment with gemcitabine.   
 
The choice of administering pimasertib 4 hours before gemcitabine was associated 
with the effect observed upon 4 hours treatment with pimasertib on RRM1 protein 
expression, which will be discussed in detail in this chapter. 
Combination indices (CI), which describe the interaction between drugs, were 
calculated using the methodology of Chou and Talalay, (Chou 2010) with the Calcusyn 
Software. This software performs a dose-effect analysis based on the mass-action law 
based theory (Chou 2006). The CI values generated for each drug combination 
describe the drug interactions. CI values > 1 indicate antagonism, values =1 indicate 
additivity and values < 1 indicate synergism. 
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3.3.4.1 Simultaneous administration of pimasertib with gemcitabine 
induces antagonistic or additive antiproliferative effects  
BxPC-3 and PANC-1 cells were exposed to increasing concentrations of gemcitabine 
(5nM, 25nM, 50nM and 250nM) together with a fixed concentration of pimasertib 
(500nM) for 48 hours continuously. Inhibition of cell proliferation was determined by 
MTT assay (Figure 3.7A, 3.8A). The effects of the drugs combination was analysed with 
the CI method. At all concentrations of gemcitabine tested the combination resulted 
in CI values > 1 in BxPC-3 cell lines indicating a negative interaction and in CI values ≥ 1 
in PANC-1 cell lines indicating an additive or negative interaction. A bar chart of CI 
values obtained from the simultaneous combination of gemcitabine with pimasertib is 
illustrated (Fig. 3.7B-3.8B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 102 
A                
 
B 
 
 
Figure 3.7: Effects of simultaneous treatment of pimasertib plus gemcitabine on BxPC-3 cells 
proliferation.  
A. The MTT assay was used to assess the effect of a 48h simultaneous treatment of 500nM pimasertib 
with increasing concentrations of gemcitabine (5-25-50-250nM) on the growth of BxPC-3 cells. B. 
Combination Indices (CI) values describing drug combinations were calculated with the Calcusyn 
program. Experiments were repeated three times and are represented as mean, Error Bars ± SD. 
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A                                                                                                                     
 
B 
 
 
Figure 3.8: Effects of simultaneous treatment of pimasertib plus gemcitabine on PANC-1 cells 
proliferation.  
A. The MTT assay was used to assess the effect of a 48h simultaneous treatment of 500nM pimasertib 
with increasing concentrations of gemcitabine (5-25-50nM) on the growth of PANC-1 cells. B. 
Combination Indices (CI) values describing drug combinations were calculated with the Calcusyn 
program. Experiments were repeated three times and are represented as mean, Error Bars ± SD. 
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3.3.4.2 Sequential administration of pimasertib with gemcitabine 
induces synergistic antiproliferative effects 
Since simultaneous administration of pimasertib with gemcitabine did not produce 
any synergistic antiproliferative effects (Fig. 3.7-3.8), a different time schedule was 
evaluated in which the MEK inhibitor was administered prior to chemotherapy. 
Because we found that pimasertib was able to downregulate an important biomarker 
of gemcitabine resistance after a 4-hour exposure (These results will be described 
later in the chapter), we decided to adopt the following sequential schedule of 
administration: BxPC-3 and PANC-1 cells were pre-treated for 4 hours with 500nM 
pimasertib after which gemcitabine (5nM, 25nM, 50nM, and 250nM) was 
administered for 48 hours continuously. Inhibition of cell proliferation was 
determined by MTT assay (Fig. 3.9A, 3.10A). Interestingly, this time schedule of drug 
administration induced synergistic antiproliferative effects in BxPC-3 and PANC-1 cell 
lines as indicated by CI values generated from all concentrations of gemcitabine 
examined being <1. Bar charts of CI values are illustrated in Fig. 3.9B and 3.10B. 
Additionally, a 4-hour pre-exposure to pimasertib followed by a short time exposure 
with increasing concentrations of gemcitabine (24 hours) showed synergistic growth 
inhibitory activity (Fig. 3.11A), as shown by the CI values generated from all 
concentrations of gemcitabine examined being < 1 (Fig. 3.11B). 
  
 105 
A     
 
B 
 
 
Figure 3.9: Effects of sequential treatment of pimasertib with gemcitabine on BxPC-3 cells 
proliferation. 
A. The MTT assay was used to assess the effect of a 4h pre-treatment of 500nM pimasertib followed by 
continuous exposure for 48h with increasing concentrations of gemcitabine (5-25-50-250nM) on the 
growth of BxPC-3 cells. B. Combination Indices (CI) values describing drug combinations were calculated 
with the Calcusyn program. Experiments were repeated three times and are represented as mean, 
Error Bars ± SD. 
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Figure 3.10: Effects of sequential treatment of pimasertib with gemcitabine on PANC-1 cells 
proliferation. 
A. The MTT assay was used to assess the effect of a 4h pre-treatment of 500nM pimasertib followed by 
continuous exposure for 48h with increasing concentrations of gemcitabine (5-25-50-250nM) on the 
growth of PANC-1 cells. B. Combination Indices (CI) values describing drug combinations were 
calculated with the Calcusyn program. Experiments were repeated three times and are represented as 
mean, Error Bars ± SD. 
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Figure 3.11: Effects of short sequential administration of pimasertib with gemcitabine on BxPC-3 cells 
proliferation. 
A. The MTT assay was used to assess the effect of a 4h pre-treatment of 500nM pimasertib followed by 
continuous exposure for 24h with increasing concentrations of gemcitabine (5-25-50-250nM) on the 
growth of BxPC-3 cells. B. Combination Indices (CI) values describing drug combinations were calculated 
with the Calcusyn program. Experiments were repeated three times and are represented as mean, 
Error Bars ± SD. 
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3.3.5 Pimasertib enhances gemcitabine-induced apoptosis in a 
sequence-dependent fashion  
One of the mechanisms of gemcitabine cytotoxicity is the induction of cell death 
which is mainly caused by dFdTCP (gemcitabine triphosphate form) incorporation into 
DNA (Huang and Plunkett 1995). We sought to investigate whether pimasertib was 
able to enhance gemcitabine-induced apoptosis. Simultaneous treatment of 500nM 
pimasertib with 50nM gemcitabine for 48 hours continously did not enhance 
gemcitabine-induced apoptosis as measured by caspase 3/7 enzyme activity in PANC-
1 cells (from 3.38 ± 0.87 fold with gemcitabine alone to 3.43 ± 0.31 with the 
combination) (Fig. 3.12A) and in BxPC-3 cells (from 2.95 ± 0.78 fold with gem alone to 
3.48 ± 0.31 with the combination) (Fig. 3.12B). 
A                                                                                                                     
 
Figure 3.12: Simultaneous treatment of pimasertib with gemcitabine does not enhance apoptosis.  
A. PANC-1 cells were treated with 500nM pimasertib and 50nM gemcitabine for 48h continuously. 
Apoptosis was assessed by measuring the caspase 3-7 enzymatic activity with the Caspase Glo Assay 
(Promega). Results are presented as fold increase to untreated samples. Each experiment was repeated 
in triplicate and results are presented as mean, Error Bars ± SD. P values > 0.05 were considered not 
statistically significant (ns). 
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Figure 3.12 continued: Simultaneous treatment of pimasertib with gemcitabine does not enhance 
apoptosis. 
B. BxPC-3 cells were treated with 500nM pimasertib, plus 50nM gemcitabine for 48h. Caspase 3-7 
enzymatic activity was measured as an indicator of apoptosis induction. Results are presented as fold 
increase to untreated samples. Each experiment was repeated in triplicate and results are presented as 
mean, Error Bars ± SD. P values > 0.05 were considered not statistically significant (ns). 
 
 
The effect of sequential administration was investigated. A 4-hour pre-treatment with 
500nM pimasertib followed by 48 hour treatment with 50nM gemcitabine significantly 
enhanced gemcitabine-induced apoptosis as measured by the caspase 3/7 enzyme 
activity in PANC-1 cells (from 1.39 ± 0.12 fold with gemcitabine alone to 2.15 ± 0.42 
with the combination) (Fig. 3.13A) and in BxPC-3 cells (from 3.78 ± 0.11 fold with 
gemcitabine alone to 5.65 ± 0.06 with the combination) (Fig. 3.13B). Treatment with 
pimasertib alone did not induce any significant increase of apoptosis in both PANC-1 
cells (Fig. 3.12A, 3.13A) and BxPC-3 cells (Fig. 3.12B, 3.13B), as has been previously 
observed in other preclinical studies of pimasertib (Martinelli et al. 2013). 
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Figure 3.13: Pre-treatment with pimasertib enhances gemcitabine-induced apoptosis. 
A. PANC-1 cells were pre-treated with 500nM pimasertib followed by 50nM gemcitabine for 48h. 
Apoptosis was assessed by measuring caspase 3-7 enzymatic activity. B. BxPC-3 cells were pre-treated 
with 500nM pimasertib followed by 50nM gemcitabine for 48h. Caspase 3-7 enzymatic activity was 
measured as an indicator of apoptosis induction. Results are presented as fold increase to untreated 
samples. Each experiment was repeated in triplicate and results are presented as mean, Error Bars ± 
SD. Stars indicate statistical significance of pimasertib combined with gemcitabine compared to 
gemcitabine alone (***P<0.001). 
*** 
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We next sought to investigate whether a higher concentration of gemcitabine would 
produce synergistic apoptotic activity when combined with pimasertib, independent 
of the time of administration. A 4-hour pre-treatment with 500nM pimasertib 
followed by 48 hour treatment with 100nM gemcitabine significantly enhanced 
gemcitabine-induced apoptosis as measured by the caspase 3/7 enzyme activity (from 
3.5 ± 0.40 fold with gemcitabine alone to 5.0 ± 0.46 with the combination.) in BxPC-3 
cells (Fig. 3.14A), similarly to what observed with 50nM gemcitabine (Fig. 3.13B). 
However, simultaneous combination of 500nM pimasertib with 100nM gemcitabine 
for 48 hours significantly reduced gemcitabine-induced apoptosis (from 4.27 ± 0.10 
fold with gemcitabine alone to 2.26 ± 0.95 with the combination) in BxPC-3 cells (Fig. 
3.14B), confirming the inefficacy of a simultaneous administration of gemcitabine with 
pimasertib.  
 
A 
 
Figure 3.14: Sequential but not simultaneous combination of pimasertib with 100nM gemcitabine 
enhances gemcitabine-induced apoptosis. 
A. BxPC-3 cells were pre-treated with 500nM pimasertib followed by 100nM gemcitabine for 48h. 
Caspase 3-7 enzymatic activity was measured as an indicator of apoptosis induction. Results are 
presented as fold increase to untreated samples. Each experiment was repeated in triplicate and results 
are presented as mean, Error Bars ± SD. Stars indicate statistical significance of pimasertib combined 
with gemcitabine when compared to gemcitabine alone (**P<0.01). 
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B                                                                                       
 
Figure 3.14 continued: Sequential but not simultaneous combination of pimasertib with 100nM 
gemcitabine enhances gemcitabine-induced apoptosis. 
B. BxPC-3 cells were treated with 500nM pimasertib, plus 100nM gemcitabine for 48h. Caspase 3-7 
enzymatic activity was measured as an indicator of apoptosis induction. Results are presented as fold 
increase to untreated samples. Each experiment was repeated in triplicate and results are presented as 
mean, Error Bars ± SD. Stars indicate statistical significance of pimasertib combined with gemcitabine 
when compared to gemcitabine alone (**P<0.01). 
   
 
To further confirm that pimasertib enhances gemcitabine-induced apoptosis 
immunoblotting analysis was performed on BxPC-3 and PANC-1 cell lysates after 
sequential treatment with pimasertib plus gemcitabine. The apoptosis marker 
cleaved-PARP was more strongly induced in cells pre-treated with pimasertib (500nM) 
followed by gemcitabine (100nM) compared to gemcitabine or pimasertib alone (Fig. 
3.15A). Bar graphs showing the quantification of C-PARP immunoblots are illustrated 
in Figure 3.15B.  
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Figure 3.15: Pimasertib plus gemcitabine combination enhances cleaved-Parp expression.  
A. PANC-1 and BxPC-3 cells were treated with 500nM pimasertib, 100nM gemcitabine or their 
combination for 24 hours. Protein levels of cleaved-PARP were analysed by immunoblotting. After drug 
treatment, proteins samples were extracted and analysed by immunoblotting with the indicated 
antibodies. β-Actin was used as loading control. B. Densitometric analysis of the immunoblots 
presented in Figure 3.15A. Image J software was used for the quantitation of the western blot bands. 
Fold increase of C-Parp was calculated by normalization to the loading control and comparison to the 
untreated sample. 
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3.3.6 Effects of pimasertib on the modulation of genes involved in 
gemcitabine resistance 
To explore the molecular mechanism behind the synergistic activity observed between 
pimasertib and gemcitabine we investigated alterations of expression of genes 
involved in gemcitabine metabolism, transport or activity following pimasertib or 
gemcitabine treatment.  
Cytidine Deaminase (CDA) is responsible for deactivating gemcitabine triphosphate 
(dFdCTP) by converting it into its inactive form difluorodeoxyuridine (dFdU) (Nakano 
et al. 2007). Preclinical work on pancreatic cancer mouse models has identified a 
mechanism by which nab-paclitaxel sensitizes to gemcitabine therapy, as a result of a 
ROS-mediated reduction in the protein levels of CDA (Frese et al. 2012). The effects of 
pimasertib and gemcitabine on CDA protein expression were explored. PANC-1 and 
BxPC-3 cells were treated for 24 hours with 1μM pimasertib, 50nM gemcitabine or 
their combination. Pimasertib alone caused a reduction of CDA protein expression in 
PANC-1 cells and to lesser extent in BxPC-3 cells; whereas gemcitabine increased CDA 
protein expression in BxPC-3 cells (Fig. 3.16). CDA protein levels were not altered upon 
the combination treatment (Fig. 3.16). 
 
 
 
Figure 3.16: Effects of pimasertib on CDA protein levels.  
BxPC-3 and PANC-1 cells were treated for 24 hours with 1µM pimasertib, 50nM gemcitabine alone or in 
combination with 1µM pimasertib. Total cell lysates were analysed by immunoblotting. Calnexin was 
used as loading control. 
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We then treated BxPC-3 cells for 24 hours with 1μM pimasertib, 50nM gemcitabine or 
their combination. The protein levels of RRM1, RRM2 and dCK were analysed by 
immunoblotting analysis. dCK protein expression was upregulated upon pimasertib 
and gemcitabine administration in BxPC-3 cells (Fig. 3.17A). RRM2 expression was 
reduced (Fig.3.17A), and this could be explained by the fact that its protein levels are 
low in the G1 phase of the cell cycle (Nordlund and Reichard 2006) as pimasertib 
induces a G1 arrest (Fig. 3.6). A slight decrease in RRM2 protein expression was 
observed with gemcitabine. Interestingly, treatment with pimasertib alone and in 
combination with gemcitabine reduced RRM1 protein levels (Fig. 3.17A). Bar graphs 
showing the quantification of RRM1 immunoblots are illustrated in Figure 3.17B. 
 
A                                                                                                        B                                                       
   
 
 
Figure 3.17: Pimasertib reduces RRM1 protein levels. 
A. BxPC-3 cells were treated for 24 hours with 1µM pimasertib, 50nM gemcitabine alone or in 
combination with 1µM pimasertib. Total cell lysates were analysed by immunoblotting. Calnexin was 
used as loading control. B. Densitometric analysis of the immunoblots presented in Figure 3.17A. 
Results are presented as mean ± SD of three independent experiments. Image J software was used for 
the quantitation of the western blot bands. Fold decrease of RRM1 was calculated by normalization to 
the loading control and comparison to the untreated sample. 
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Downregulation of RRM1 protein was also observed in PANC-1 cell lines after 24h 
treatment with pimasertib alone or in combination with gemcitabine (Fig. 3.18) but no 
change in dCK or RRM2 protein expression was found upon gemcitabine or pimasertib 
(Fig. 3.18A). Bar graphs showing the quantification of RRM1 immunoblots are 
illustrated in Figure 3.18B. 
 
A                                                                                            B                                                             
     
 
 
Figure 3.18: Pimasertib reduces RRM1 protein levels.  
A. PANC-1 cells were treated for 24 hours with 1µM pimasertib, 50nM gemcitabine alone or in 
combination with 1µM pimasertib. Total cell lysates were analysed by immunoblotting. Calnexin was 
used as loading control. B. Densitometric analysis of the immunoblots presented in Figure 3.19A. 
Results are presented as mean ± SD of three independent experiments. Image J software was used for 
the quantitation of the western blot bands. Fold decrease of RRM1 was calculated by normalization to 
the loading control and comparison to the untreated sample. 
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Next, we investigated whether pimasertib induces RRM1 downregulation in other 
human pancreatic cancer cell lines. SUIT-2 and MIAPaCa-2 cell lines, which had been 
previously tested for gemcitabine sensitivity, were treated with 1μM pimasertib, 
50nM gemcitabine or their combination for 24 hours and protein lysates were 
analysed by immunoblotting. Pimasertib alone and in combination with gemcitabine 
reduced RRM1 protein levels in both cell lines tested (Fig. 3.19). 
Previous studies have shown that RRM1 protein expression was upregulated in 
gemcitabine resistant cells (Nakahira et al. 2007). In this present study, gemcitabine 
increased RRM1 protein levels in PANC-1 (Fig. 3.18), which displayed the highest 
resistance to gemcitabine, but also in MIAPaCa-2 and SUIT-2 sensitive cell lines (Fig. 
3.19). No upregulation of RRM1 was observed in BxPC-3 cells after gemcitabine 
treatment. 
 
 
 
Figure 3.19: Pimasertib reduces RRM1 protein levels in other human pancreatic cancer cell lines. 
SUIT-2 and MIAPaCa-2 cells were treated for 24 hours with 1µM pimasertib, 50nM gemcitabine alone 
or in combination with 1µM pimasertib. Total cell lysates were analysed by immunoblotting. Calnexin 
was used as loading control.  
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To explore whether the effect induced by pimasertib on RRM1 expression occurred 
with other MEK inhibitors, BxPC-3 cells were treated with AS703988 a potent, 
allosteric MEK1/2 inhibitor. AS703988 inhibited ERK phosphorylation at 1µM and 
showed the identical effect on RRM1 expression after 24 hours treatment (Fig. 3.20A). 
Inhibition of ERK phosphorylation and RRM1 protein expression was also observed 
when AS703988 was combined with gemcitabine (50nM) (Fig. 3.20A). Bar graphs 
showing the quantification of RRM1 immunoblots are illustrated in Figure 3.20B. 
 
A                                                                                     B 
    
 
Figure 3.20: The MEK1/2 inhibitor AS703988 alters RRM1 protein expression.  
A. BxPC-3 cells were treated for 24 hours with 1µM AS703988, 50nM gemcitabine alone or in 
combination with 1µM pimasertib. Total cell lysates were analysed by immunoblotting. Calnexin was 
used as loading control. B. Densitometric analysis of the immunoblots presented in figure 3.20A. 
Results are presented as mean ± SD of three independent experiments. Image J software was used for 
quantitation of the western blot bands. Fold decrease of RRM1 was calculated by normalization to the 
loading control and comparison to the untreated sample. 
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3.3.7 Downregulation of RRM1 protein expression induced by MEK 
inhibition occurs through a posttranslational modification 
To determine whether the effect on modulation of RRM1 expression was specifically 
associated with inhibition of MEK protein an EGFR inhibitor (gefitinib), which blocks 
EGFR intracellular phosphorylation, was used to inhibit upstream MEK signalling.  
BxPC-3 cells were treated with 1µM gefitinib for 30 minutes, 4 hours and 24 hours. 
Gefitinib reduced P-EGFR protein expression within 30 minutes after treatment, but 
did not alter RRM1 protein levels as shown by immunoblotting analysis (Fig. 3.21). 
Next, we asked whether biological inhibition of MEK protein would have an effect on 
RRM1 expression. To test this hypothesis we performed siRNA to knockdown the 
expression of MEK1 and MEK2. Immunoblotting analysis showed reduction of RRM1 
protein expression following MEK1 and MEK2 knockdown in PANC-1 (Fig. 3.22A) and 
BxPC-3 cells (Fig. 3.22B), indicating that the effect on RRM1 protein expression is 
specifically due to on-target inhibition of MEK protein. 
                                                                                                     
 
 
Figure 3.21: EGFR inhibition does not affect RRM1 protein expression. 
BxPC-3 cells were treated with 1µM gefitinib and extracted at 30min, 4h and 24h. Total cell lysates 
were analysed by immunoblotting. Calnexin was used as loading control.  
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Figure 3.22: Knockdown of MEK1 and MEK2 by siRNA causes inhibition of RRM1 protein. 
(A) BxPC-3 and (B) PANC-1 cells were transfected with 50nM siRNA targeting MEK1 and MEK2 for 72 
hours. Total cell lysates were analysed by immunoblotting. Calnexin was used as loading control.  
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To assess if RRM1 down-regulation induced by pimasertib occurred at the 
transcriptional level, BxPC-3 and PANC-1 cells were treated with 1µM pimasertib for 
24 hours and mRNA levels of RRM1 and RRM2 were analysed by RT-PCR. While the 
mRNA levels of RRM2 decreased after 24-hour treatment with pimasertib in BxPC-3 
cells and remained constant in PANC-1 cells (Fig. 3.23), the mRNA levels of RRM1 were 
not significantly altered in BxPC-3 cells and were upregulated upon pimasertib 
treatment in PANC-1 cells (Fig. 3.24). The basal mRNA levels of RRM1 were higher in 
PANC-1 cells compared to BxPC3 cells (Fig. 3.24).  
In contrast, immunoblotting analysis revealed a substantial reduction of RRM1 protein 
levels following only 4 hours treatment with pimasertib in BxPC-3 and PANC-1 cells, an 
effect that was not observed on RRM2 protein expression (Fig. 3.25). These results 
suggest that pimasertib reduces RRM1 through a post-translational modification. 
 
 
              
 
Figure 3.23: Pimasertib effect on RRM2 mRNA levels in BxPC-3 and PANC-1 cells. 
Real-time PCR analysis of the mRNA expression of RRM2 in BxPC-3 and PANC-1 cells. Data represent the 
mean ± SD (n=3) from three independent experiments. Statistical analysis was performed with One 
Way Anova and Bonferroni post-test (**P<0.01, ns P>0.05). 
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Figure 3.24: RRM1 mRNA levels are not affected by pimasertib in BxPC-3 and PANC-1 cells lines. 
Real-time PCR analysis of the mRNA expression of RRM1 in BxPC-3 and PANC-1 cells. Data represent the 
mean ± SD (n=3) from three independent experiments. Statistical analysis was performed with One 
Way Anova and Bonferroni post-test (***P<0.001, ns P>0.05).  
 
 
 
 
 
 
Figure 3.25: Pimasertib reduces RRM1 protein levels after a 4–hour treatment in BxPC-3 and PANC-1 
cell lines. 
BxPC-3 and PANC-1 cells were treated for 1 hour and 4 hours with 1µM pimasertib. Total cell lysates 
were analysed by immunoblotting. Calnexin was used as loading control. The experiment shown is 
representative of two independent experiments. 
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3.3.8 RRM1 basal protein expression predicts gemcitabine efficacy  
To explore whether a correlation existed between gemcitabine cytotoxicity and RRM1 
basal expression in human pancreatic cancer cell lines, the IC50 values of each cell line 
were compared with their basal levels of RRM1 protein. Gemcitabine IC50 values of 
each cell line were calculated as previously described (Table 3.2). RRM1 protein 
expression was analysed by immunoblotting (Fig. 3.26A) and quantified by 
densitometry (Fig. 3.26B). PANC-1 cells exhibited the highest expression of RRM1 
protein and were the most resistant to gemcitabine treatment.  
 
 
 
Table 3.2: IC50 values of BxPC-3, MIAPaCa-2 and PANC-1 cell lines. 
BxPC-3, PANC-1 and MIAPaCa-2 cells were treated with increasing concentrations of gemcitabine for 96 
hours. MTT assay was assessed to determine cell viability and IC50 values were calculated. 
 
A                                                                                    B                                                                                  
                   
Figure 3.26: RRM1 expression correlates with pancreatic cancer cell sensitivity to gemcitabine.  
A. Basal RRM1 protein expression of BxPC-3, PANC-1 and MIAPaCa-2 cell lines was analysed by 
immunoblotting. β-Actin was used as loading control. B. Densitometric analysis of the immunoblots 
presented in figure 3.28A. Results are presented as mean ± SD of three independent experiments. 
Image J software was used for the quantitation of the western blot bands.  
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3.3.9 Inhibition of RRM1 expression by siRNA sensitizes BxPC-3 and 
PANC-1 cells to gemcitabine 
Previous studies have shown that inhibition of RRM1 by siRNA increases gemcitabine 
efficacy in NSCLC cell lines and sensitizes RRM1-overexpressing mice to gemcitabine 
cytotoxicity, suggesting that RRM1 is a potential target of chemosensitization 
(Wonganan et al. 2012). 
To confirm RRM1 expression effects on gemcitabine response, BxPC-3 and PANC-1 
cells were transfected with specific siRNA against RRM1 for 72h prior to gemcitabine 
treatment. Immunoblotting analysis was performed and demonstrated that RRM1 
specific-siRNA efficiently inhibited RRM1 protein expression in PANC-1 cells (Fig. 
3.27A) and BxPC-3 cells (Fig. 3.28A). RRM1 siRNA transfected cells were then treated 
for 48 hours with 100nM gemcitabine, after which apoptosis was assessed as 
previously described in section 3.3.5. PANC-1 cells transfected with RRM1 siRNA 
exhibited enhanced apoptosis upon gemcitabine treatment compared to cells treated 
with scrambled, as levels of caspase 3/7 activity increased from 2.1 ± 0.42 fold to 4.1 ± 
0.93 (Fig. 3.27B). Furthermore, knockdown of RRM1 with siRNA enhanced apoptosis 
also without drug treatment in PANC-1 cells, suggesting that depletion of RRM1 is 
cytotoxic in these cell lines (Fig. 3.27B). 
Gemcitabine treatment induced a significantly higher apoptotic effect in BxPC-3 cells 
transfected with RRM1 siRNA compared to cells transfected with scrambled as shown 
by levels of caspase 3/7 activity (from 6.30 ± 0.91 to 9.71 ± 4.1) (Fig. 3.28B). 
Additionally, RRM1 knock-down cells treated with gemcitabine exhibited higher levels 
of cleaved caspase-3 activation compared to RRM1 knock-down cells that did not 
receive any drug treatment (from 0.96 ± 0.14 to 9.60 ± 1.32) (Fig. 3.28B). 
These results confirm the role of RRM1 expression in modulating human pancreatic 
cancer cells sensitivity to gemcitabine treatment.  
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Figure 3.27: RRM1 downregulation sensitizes PANC-1 response to gemcitabine.  
A. PANC-1 cells were transfected with 50nM siRNA targeting RRM1 or scrambled for 72 hours and 
immunoblotted with the indicated antibodies. Calnexin was using as loading control. B. Scrambled and 
RRM1 transfected cells were treated with 100nM gemcitabine for 48 hours after which Caspase 3/7 
activity was measured to detect apoptosis. Results are presented as fold increase relative to untreated 
sample and are shown as mean  SD (n=3). Stars indicate a significant increase in apoptosis (**, P<0.01) 
after gemcitabine treatment in PANC-1 cells transfected with RRM1 siRNA compared to cells 
transfected with scrambled.  
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Figure 3.28: RRM1 downregulation sensitizes BxPC-3 response to gemcitabine.  
A. BxPC-3 cells were transfected with 50nM siRNA targeting RRM1 or scrambled for 72 hours and 
immunoblotted with the indicated antibodies. Calnexin was using as loading control. B. Scrambled and 
RRM1 transfected cells were treated with 100nM gemcitabine for 48 hours after which Caspase 3/7 
activity was measured to detect apoptosis. Results are presented as fold increase relative to untreated 
sample and are shown as mean  SD (n=3). Stars indicate a significant increase in apoptosis (***, 
P<0.001) after gemcitabine treatment in BxPC-3 cells transfected with RRM1 siRNA compared to cells 
transfected with scrambled and between RRM1-transfected cells non-treated and treated with 
gemcitabine. 
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3.4 DISCUSSION 
3.4.1 Improving gemcitabine efficacy with MEK inhibitors 
The combination of cytotoxic agents with molecular-targeted agents has been the 
focus of intense study for cancer therapy and has the aim to reduce the acquired 
resistance to conventional chemotherapy, to lower the doses of highly cytotoxic drugs 
or to sensitize the action of one drug with the use of another drug (Fitzgerald et al. 
2006). Importantly, the combination of two or more drugs aims to achieve a 
synergistic effect on cell growth inhibition or cell killing compared to single drugs 
alone. Combinations can include drugs that inhibit a single target, the same signalling 
pathway but at different levels or two distinguished pathways (Fitzgerald et al. 2006).  
In the locally advanced and metastatic setting, the chemotherapeutic agent 
gemcitabine represents an important standard of care for PDAC patients but the 
overall surival still remains very low (Seufferlein et al. 2012).  
Inhibition of downstream effectors of RAS, such as MEK protein has provided clinical 
benefit against human tumors (Flaherty et al. 2012). Mutant BRAF melanoma cells rely 
on ERK for survival (Balmanno and Cook 2009), thus BRAF inhibitors are commonly 
used for the treatment of metastatic melanoma patients carrying a BRAF mutation 
since they inhibit ERK signalling in cells with activating mutations of BRAF; however, in 
most patients, BRAF inhibitors have short efficacy as the tumour reccurs. This is the 
case of melanoma cells because they are able to overcome BRAF inhibition (Cheng et 
al. 2013). A Phase III trial involving the MEK inhibitor trametenib was performed on 
patients with metastatic melanoma harbouring BRAF V600E or V600K mutation that 
had not previously received BRAF or MEK inhibitors. Trametenib-treated patients 
showed longer PFS of 4.8 months vs 1.5 months (HR of 0.45, 95% confidence interval 
(CI), 0.33-0.63 P<0.01) and OS rate at 6 months was 81% vs 67% compared to patients 
receiving only chemotherapy (dacarbazine or paclitaxel) (HR for death = 0.54, 95% 
confidence interval (CI), 0.32-0.92 P<0.01) (Flaherty et al. 2012).  
A large Phase II trial was later conducted to investigate the efficacy of trametenib in 
combination with BRAF inhibitors. Although the adverse effects associated with MEK 
inhibition were more frequent upon combination treatment, a significant 
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improvement in PFS was achieved when trametinib was added to BRAF inhibitors. The 
results allowed the FDA approval of trametenib for clinical use for patients with 
metastatic melanoma harbouring BRAF V600E/K mutation both as monotherapy and 
in combination with the BRAF inhibitor dabrafenib (Flaherty et al. 2012). No other 
MEK inhibitors have so far gained approval by the FDA to be used in the clinic.  
In this present study the effects of combining an allosteric MEK1/2 inhibitor 
(pimasertib) with gemcitabine was evaluated in human pancreatic cancer cell lines. 
Gemcitabine showed antiproliferative activity with different sensitivities among the 
human pancreatic cancer cell lines tested (Fig. 3.1). Pimasertib inhibited cellular 
proliferation (Fig. 3.5) and induced specific target modulation by inhibiting P-ERK 
signalling in a dose and time dependent fashion (Fig. 3.3-3.4).  
Different schedules of drugs administration were evaluated to determine the effects 
of gemcitabine plus pimasertib in combination. Interestingly, the order in which 
pimasertib and gemcitabine were administered influenced the cellular response to 
these agents. In fact, only a short pre-treatment with pimasertib followed by 
gemcitabine induced synergistic antiproliferative (Fig. 3.9, 3.10, 3.11) and increased 
apoptosis (Fig. 3.13-3.14A). On the other hand, additive or antagonistic 
antiproliferative activity and no enhancement of apotosis was observed upon 
simultaneous administration of the two agents (Fig. 3.7, 3.8, 3.12, 314B) in all cell lines 
tested. To support these results, an increase in the expression of the apoptotic marker 
cleaved caspase-3 was also observed upon sequential combination of pimasertib with 
gemcitabine (Fig. 3.15).  
Previous reports have demonstrated how scheduling affects drug treatments. A 
preclinical study on biliary cancer models aimed to investigate the cytotoxic effects 
induced by the combination of the MEK inhibitor selumetinib (AZD6244) with 
gemcitabine. Pre-treatment with selumetinib followed by gemcitabine enhanced the 
cytotoxicity of the latter, as opposed to simultaneous treatment that did not show any 
synergistic cytotoxic effect (Xu et al. 2013). The MEK inhibitor led to an accumulation 
of cells in G1, thus blocking the progression into DNA synthesis where gemcitabine 
acts. (Xu et al. 2013). The results obtained in this study could draw interest in the 
antagonism observed in our study after simultaneous treatment of pimasertib with 
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gemcitabine, since pimasertib caused an accumulation of cells in G1-phase of the cell 
cycle (Fig. 3.6). 
 
3.4.2 RRM1 protein expression is modulated by MEK inhibition 
A limitation of gemcitabine-based therapy is the rapid development of resistance 
(Nakano et al. 2007). The identification of biomarkers associated with tumor 
sensitivity to gemcitabine is of high importance to predict patients’ response and 
allow patients’ stratification. Furthermore, biomarkers are important in the 
development of new therapeutic targets (Colburn 2003).  
Several studies have demonstrated that modulation of expression of genes that 
regulate gemcitabine metabolism, transport or mechanism of action can significantly 
enhance its efficacy (Ogawa et al. 2005, Giovannetti et al. 2006). The ribonucleotide 
reductase (RR) enzyme catalyses the production of dNTP pools required for new DNA 
synthesis and repair (Nordlund and Reichard 2006). Several studies have now 
established that overexpression of RR large subunit 1 (RRM1) is associated with poor 
response to gemcitabine treatment (Nakahira et al. 2007). Excessive production of 
dNTP pools produced by RR competes with gemcitabine for incorporation into DNA 
(Duxbury et al. 2004). Furthermore, RRM1 inhibits the activity of dCK, thus impairing 
gemcitabine activation (Heinemann et al. 1990). 
Previous investigators have demonstrated how modulation of RRM1 or RRM2 
expression affects cellular sensitivity to gemcitabine. For example, RRM1 knock down 
using specific siRNA enhanced sensitivity to gemcitabine both in vitro and in cancer 
mouse models (Nakahira et al. 2007) (Wonganan et al. 2012). Silencing RRM2 with 
specific siRNA has been reported to enhance gemcitabine-induced cytotoxicity in 
PDAC cell lines through decrease of NF-kB activity. Furthermore, systemic treatment 
of RRM2 siRNA in combination with gemcitabine induced a marked suppression of 
tumor growth accompanied by inhibition of liver metastasis in a mouse xenograft 
model of pancreatic cancer (Duxbury et al. 2004). 
Analysis of pimasertib effects on multiple genes associated with gemcitabine 
resistance was performed. Interestingly, pimasertib induced a striking reduction of 
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RRM1 protein levels in all cell lines tested (Fig. 3.17-19). The same effect on RRM1 
downregulation was observed with another allosteric MEK1/2 inhibitor (AS703988) 
(Fig. 3.20) but did not occur in response to an EGFR inhibitor (Fig. 3.21), Furthermore 
MEK1/2 knock down by siRNA caused a reduction of RRM1 protein expression (Fig. 
3.22) indicating that this effect is specifically dependent on MEK inhibition.  
Previous reports have observed modulation of RR activity by MEK signalling. 
Activation of MEK2 protein by serum stimulation increased RR activity by interacting 
with and regulating the P53R2 subunit, an effect that was impaired by specific 
inhibition of MEK2. Rapid activation of P53R2 upon MEK2 stimulation allowed efficient 
production of dNTP pools for prompt DNA repair, which would normally occur over a 
much longer period of time (Piao et al. 2012).  
Another study found a correlation between poor survival and high expression of RRM1 
in gastric cancer patients. Interestingly, downregulation of RRM1 using specific siRNA 
reduced P-MEK and P-ERK levels accompanied by inhibition of gastric cancer cells 
growth and invasion, indicating RRM1-induced proliferation through activation of MEK 
signalling (Wang et al. 2013). 
Our results showed that RRM1 mRNA expression levels were not reduced by addition 
of pimasertib (Fig. 3.23-3.24). On the other hand, a reduction of RRM1 protein was 
observed after a short exposure (4 hours) to pimasertib (Fig. 3.25). These results could 
also in part explain why the 4-hour pre-treatment with pimasertib is required to 
sensitize pancreatic cancer cells to gemcitabine cytotoxicity.  
Finally, we explored whether inhibition of RRM1 expression would alter human 
pancreatic cancer cells’ response to gemcitabine. As expected, we observed enhanced 
gemcitabine cytotoxicity in RRM1 depleted cells (Fig. 3.27-3.28), confirming that 
RRM1 expression affects gemcitabine response. These results are in agreement with 
previous studies showing that RRM1 inhibition potentiated chemosensitivity to 
gemcitabine both in vitro and in vivo (Wonganan et al. 2012) (Nakahira et al. 2007). 
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3.5 CONCLUSIONS 
The results presented in this chapter indicate different sensitivity of human pancreatic 
cancer cell lines to both gemcitabine and pimasertib and efficient inhibition of ERK 
activation upon MEK inhibition. The interaction between pimasertib and gemcitabine 
was investigated and the results indicate MEK as a potential target to enhance 
gemcitabine efficacy in human PDAC cell lines. Importantly, sequential but not 
simultaneous administration of pimasertib followed by gemcitabine produced 
synergistic anti-proliferative and pro-apoptotic effects, underlining the importance of 
dose and duration of drug treatments in achieving efficacious antitumor activity. The 
results shown suggest that the enhanced sensitivity to gemcitabine cytotoxicity 
obtained by a pre-exposure to pimasertib could be explained by its ability to modulate 
RRM1 protein expression. 
These preclinical investigations, which demonstrated that the schedule of 
administration significantly impacted the mechanism of the combination and, 
consequently, the efficacy of the combination in vitro were performed after the Phase 
I/II trial examining pimasertib in combination with gemcitabine (which were 
administered simultaneously) in PDAC patients was initiated (Van Cutsem E, et al. 
2015). While clinical data for combinations of MEK inhibitors, like pimasertib, with 
gemcitabine have been disappointing up to now, we suggest that a modified approach 
may be considered in future studies, such as using preclinical studies to optimize the 
right combination therapy schedule before proceeding to clinical trials. Moreover, the 
establishment of molecular therapies targeting RRM1 should be further explored in 
the future both in preclinical and clinical settings to enhance the activity of 
gemcitabine in PDAC patients. 
The ability of pimasertib to inhibit RRM1 expression, which has been described in this 
chapter, is of crucial importance since its expression is associated with gemcitabine 
resistance and the mechanism by which this occurs will be further investigated in the 
next chapter. 
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CHAPTER 4  
PIMASERTIB INDUCES 
POLYUBIQUITINATION AND 
PROTEASOMAL DEGRADATION OF 
RRM1 
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4.1 INTRODUCTION 
4.1.1 The Ubiquitin-Proteasome System (UBS): biology and mechanisms 
Proteins are subject to a great variety of post-translational modifications. One of them 
is the formation of a transient bond between a small protein called ubiquitin and a 
target protein, which is carried out by an enzymatic system: the ubiquitin proteasome 
system (UPS) (Hochstrasser 2009) (Fig. 4.1). 
The UPS machinery depends on metabolic energy for its function and is often used by 
eukaryotic cells for protein degradation. Other ways in which cells degrade proteins 
and organelles is through the lysosome, where they are engulfed and degraded by 
lysosome proteases, or through non-lysosomal proteolysis systems (Almond and 
Cohen 2002). 
The UPS is composed of two main elements: a protein complex referred as the 
proteasome and a 76 amino acid protein (ubiquitin). Before being degraded by the 
proteasome, the target protein has to be tagged by ubiquitin (Dahlmann 2007) (Fig. 
4.1). This process occurs through three consecutive biochemical steps: in the first 
step, the cysteine residue of an E1 enzyme (also called ubiquitin-activating enzyme) 
forms a thioester bond with the C-terminus of ubiquitin through an ATP-dependent 
reaction. The thioester-linked ubiquitin is then transferred to a cysteine residue of an 
E2 conjugating enzyme. In the last step, an E3 ligase enzyme catalyses the formation 
of a covalent bond between the cysteine residue of ubiquitin and the lysine residue of 
a target protein (Almond and Cohen 2002)(Fig. 4.1).  
E3 enzymes can interact with more than one protein substrates at the same time and 
they determine substrate specificity in the ubiquitination process since they recognize 
the target protein that will be ubiquitinated (Almond and Cohen 2002). There are two 
types of E3 ligases. The first type forms a thioester intermediate with ubiquitin and 
they are called HECT (homology to E6‐AP C‐terminus) domain ligases. The second type 
has a RING finger domain and associates directly with the target protein (Lilienbaum 
2013). Ubiquitin elongation occurs through the addition of one or more ubiquitin 
proteins to the first one. Ubiquitin chains are formed through several lysine residues 
(k11, k27, k29, k6, k33, k48, k63). The different ubiquitin linkages attached to the 
target protein determines the fate of that protein (Hochstrasser 2009). For example, 
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substrates that are polyubiquitinated via lys48 ubiquitin chains are recognized by the 
proteasome for degradation.  In the final step, the target protein is then transferred 
into the proteasome. This complex is composed of a core (20S) and a regulatory 
subunit (19S). The 20S subunit is made of 4 heptameric rings: two α rings on the 
outside and two β inner rings, which contain the catalytic sites for peptide bonds 
cleavage (Orlowski and Wilk 2000). The 19S subunit contains ubiquitin receptors, 
regulates substrates entry into the proteasome and removes ubiquitin from the target 
protein.  Proteins are unfolded and degraded into short peptides. In addition, 
ubiquitin proteins are released by deubiquitinating enzymes (DUBs) and can be reused 
(Hershko and Ciechanover 1998).UPS regulates several processes such as cell division, 
apoptosis, signal transduction and gene expression, thus its activity is essential for 
maintaining cell integrity (Hershko and Ciechanover 1998). 
 
 
Figure 4.1: The ubiquitin-proteasome pathway.  
Ubiquitin (Ub) is attached to an E1 activating enzyme through an ATP dependent process. This reaction 
leads to a subsequent binding of ubiquitin to an E2 conjugating enzyme. E3 ligase catalyses the 
formation of an isopeptide bond between Ub and the substrate protein, which is recognized by the 
proteasome, unfolded and degraded (Lilienbaum 2013). 
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4.1.2 AKT/PI3K signalling pathway 
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases whose main mediator 
is represented by the serine/threonine kinase AKT that exists in three different 
variations: AKT1, AKT2 and AKT3 (Hers et al. 2011). PI3 kinases are divided into three 
different classes. PI3K class IA, the most implicated in human cancers, is a 
heterodimer composed of a catalytic subunit (p110) and an adaptor/regulatory 
subunit (p85). The PI3/AKT signalling pathway (Fig. 4.2) is activated by receptor 
tyrosine kinases (RTKs) or G-protein coupled receptors (GPCR) and sends signal to 
downstream molecules that ultimately regulate several cellular processes such as 
proliferation, differentiation and survival (Hers et al. 2011) (Engelman 2009) 
(Montagut and Settleman 2009). Following RTK activation, PI3K is recruited directly or 
through docking proteins to the cell membrane where it catalyses the conversion of 
phosphatidylinositol-4,5-biphosphate (PIP2) into phosphatidylinositol-3,4,5-
triphosphate (PIP3). PIP3 mediates the recruitment of AKT and 3-phosphoinositide-
dependent kinase-1 (PDK1), which partially activates AKT through phosphorylation on 
threonine 308. Complete activation of AKT occurs upon phosphorylation of serine 473 
from the second mTOR complex (mTORC2). Once AKT is activated, it phosphorylates 
many proteins involved in different cellular processes such as mTORC1. The 
phosphatase and tensin homologue (PTEN) is responsible for the negative regulation 
of this pathway by dephosphorylating PIP3 thus impairing AKT activation (Mendoza et 
al. 2011).  
 
4.1.3 PI3K/AKT signalling pathway is deregulated in human cancers 
Deregulation of the PI3K/AKT signalling pathway frequently occurs in human cancers 
and can be caused by several factors:  
1)  Hyperactivation of the upstream receptor tyrosine kinase (RTK) (such as EGFR) 
2)  Activating mutations in the catalytic subunit of PI3K (PIK3CA or P110α) 
3) Loss of PTEN expression (Vivanco and Sawyers 2002)  
Although not a common event, PIK3CA mutation has been reported in pancreatic 
tumors and even in absence of detectable alterations within the PIK3CA gene, this 
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pathway is often constitutively activated in PDAC due to loss of PTEN gene (Asano et 
al. 2004). Furthermore, AKT2 kinase has been found to be overexpressed in 60% of 
pancreatic cancers (Altomare et al. 2002).  
Previous evidence has demonstrated the importance of this pathway in pancreatic 
cancer (Reichert et al. 2007, Ying et al. 2011). For example, a preclinical study on 
pancreatic cancer GEM models has indicated that the introduction of an activating 
mutation of PI3K is critical for tumor maintenance upon loss of oncogenic K-RAS 
function (Lim and Counter 2005).  
 
 
Figure 4.2:  PI3K/PDK1/AKT signalling pathway. 
Receptor tyrosine kinases (RTKs) activate downstream molecules such as K-RAS. PI3K is recruited and 
converts phosphatidylinositol-4,5-biphosphate (PIP2) into its triphosphate form (PIP3). PIP3 activates 
AKT, which in turns activates mTOR.  
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Compensatory cross talk occurs between different effector pathways activated by 
oncogenic K-RAS. The RAS/RAF/MAPK and PI3K/AKT signalling pathways interact with 
each other through various negative feedback loop mechanisms (Liu et al. 2009). For 
example, an in vitro study identified a mechanism of feedback activation of AKT 
signalling by MEK inhibition, which occurs through blockade of the ERK-inhibitory 
effect on PI3K recruitment to the EGF receptor (Zhang et al. 2002).  
Another report has observed that MEK depletion induced inhibition of a negative 
feedback loop on ERBB3 receptors, which led to the activation of AKT signalling (Turke 
et al. 2012). In particular, treatment with a MEK inhibitor was able to suppress the 
phosphorylation of the EGFR and HER2 juxtamembrane domain, thereby increasing 
phosphorylation of ERBB3.  
Finally, MEK1 protein has been shown to be required for regulating PTEN localization 
at the cell membrane; therefore inhibition of MEK protein enhances PIP3 
concentrations and AKT signalling (Zmajkovicova et al. 2013). 
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4.2 RESEARCH HYPOTHESIS AND AIMS 
Hypothesis: The results presented in Chapter 3 have demonstrated the ability of 
pimasertib to sensitize human pancreatic cancer cells to gemcitabine in a schedule-
dependent fashion. Additionally, we have shown that genetic and pharmacologic 
inhibition of MEK protein reduces RRM1 protein expression, a key determinant of 
gemcitabine response. We believe that the downregulation of RRM1 is one of the 
mechanisms by which pimasertib enhances gemcitabine cytotoxicity, since RRM1 
depletion increases gemcitabine-induced apoptosis.  
This chapter investigates the molecular mechanisms by which pimasertib reduces 
RRM1 with the following aims: 
 To understand whether RRM1 downregulation induced by pimasertib is caused 
by its proteasomal degradation. 
 To elucidate the mechanism by which inhibition of downstream molecules 
within the RAS signalling pathway can modulate the expression of an 
important biomarker of gemcitabine response. 
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4.3 RESULTS 
4.3.1 Pimasertib-induced downregulation of RRM1 protein expression 
occurs through a post-translational modification  
The data presented previously indicate that pimasertib reduces RRM1 protein levels, a 
mechanism that could in part explain the synergistic interaction observed in the 
combination of pimasertib with gemcitabine in human pancreatic cancer cell lines. In 
the previous chapter we showed that RRM1 mRNA levels were not significantly 
reduced by pimasertib treatment (Fig. 3.24); on the other hand the protein levels of 
RRM1 were decreased after only 1-hour treatment with pimasertib (Fig 3.25).  
To better elucidate the mechanisms responsible for the observed pimasertib-induced 
rapid downregulation of RRM1 protein, we investigated whether RRM1 protein 
stability was regulated by the ubiquitin-proteasome system. To do that, we first used 
the proteasome inhibitor MG132, a peptide-aldehyde, whose structure is similar to 
the substrates of the chymotrypsin-like active site (Goldberg 2012). MG132 inhibits 
the activity of the 26S proteasome, the core complex where ubiquitin proteins are 
degraded, by binding the catalytic active site located in the β-subunits (Goldberg 
2012).  
A 4-hour exposure with 1µM pimasertib reduced RRM1 protein expression in BxPC-3 
and PANC-1 cell lines (Fig. 4.3A). Nonetheless, pre-treatment with 1µM MG132 
followed by a 4-hour exposure to 1µM pimasertib impaired the effects of pimasertib 
on downregulating RRM1 protein expression in both cell lines (Fig. 4.3A), indicating 
that pimasertib induces RRM1 degradation through the ubiquitin-proteasome 
pathway. Bar graphs showing the quantification of RRM1 immunoblots are illustrated 
in Figure 4.3B. 
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B 
        
 
Figure 4.3: RRM1 protein levels are reduced by pimasertib through a post-translational modification.  
A. BxPC-3 and PANC-1 cells were pre-treated for 1 hour with 1µM MG132 followed by 1µM pimasertib 
for 4 hours. Total cell lysates were analysed by immunoblotting. Calnexin was used as loading control. 
B. Densitometric analysis of the immunoblots presented in figure 4.3A. Results are presented as mean ± 
SD of three independent experiments. Image J software was used for quantitation of the western blot 
bands. Fold average of RRM1 was calculated by normalization to the loading control and comparison to 
the untreated sample. 
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4.3.2 RRM1 is polyubiquitinated through lys48-mediated linkage 
Ubiquitin chains are formed through different lysine residues and this phenomenon is 
referred as polyubiquitination (Hochstrasser 2009). In particular, ubiquitin proteins 
attached to each other through lysine residues at position 48 target proteins for 
proteasomal degradation (Xu et al. 2009).  
To confirm that the decrease in RRM1 expression induced by MEK inhibition was due 
to its proteasomal degradation, we explored whether RRM1 undergoes lys48 
polyubiquitination. RRM1 was immunoprecipitated from PANC-1 and BxPC-3 cells pre-
treated for 1 hour with 1µM MG132 followed by 4 hours exposure to 1µM pimasertib, 
and immunoblotted with an antibody against Lys48. Proteasomal inhibition (by 
MG132) produced a ladder of bands at high molecular weights whose intensity 
increased after pimasertib treatment, indicating that pimasertib enhances RRM1 
polyubiquitination through lys48-mediated linkage (Fig. 4.4).  
 
 
 
 
Figure 4.4: Pimasertib enhances polyubiquitination of RRM1.  
PANC-1 and BxPC-3 cells were pre-treated for 1 hour with 1µM MG132 followed by 1µM pimasertib for 
4 hours. Immunoprecipitation was performed using anti-RRM1 antibody or anti-IgG antibody, and 
immunoblotted with anti-RRM1 and anti-K48 antibodies. Inputs lysates (25μg/μl) were blotted with 
RRM1 antibody. Calnexin was used as loading control.  
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4.3.3 MDM2 inhibition impairs RRM1 degradation induced by 
pimasertib 
To gain insights into how pimasertib promotes RRM1 degradation by the ubiquitin-
proteasome pathway, we explored what effects inhibition of RING1-B and MDM2 E3 
ubiquitin ligases would have on RRM1 protein stability. The RING1-B protein was 
selected based on previous findings that showed it to be involved in the ubiquitination 
and degradation of RRM1 (Zhang et al. 2014). MDM2 was selected because of the 
results from a recent preclinical study indicating that MDM2 induces proteasomal 
degradation of the P53R2 subunit of Ribonucleotide Reductase (Chang et al. 2008).  
BxPC-3 cells were transfected with RING1-B specific siRNA for 72 hours and total cell 
lysates were analysed by immunoblotting. Depletion of RING1-B slightly increased 
RRM1 protein levels compared to scrambled (lane 1 and 4 of Fig. 4.5A), confirming 
previous results that showed RING1-B mediating ubiquitination and degradation of 
RRM1. However, treatment with 1µM pimasertib for 4 hours caused downregulation 
of RRM1 protein expression in cells transfected with scrambled (lane 3) and cell 
transfected with RING1-B siRNA (lane 2) (Fig. 4.5A), indicating that RING1-B is not 
implicated in RRM1 degradation triggered by pimasertib, since its depletion does not 
affect the pimasertib effect on RRM1 protein expression. Bar graphs showing the 
quantification of RRM1 are illustrated in Figure 4.5B. 
 
Figure 4.5: RNF2 E3 ligase activity on RRM1 protein stability.  
A. BxPC-3 cells were transfected with 50nM siRNA targeting RING1B or scrambled siRNA for 72 hours 
and treated with pimasertib for the last 4 hours of transfection. Total cell lysates were immunoblotted 
with the indicated antibodies. Calnexin was using as loading control. B. Densitometric analysis of the 
immunoblots presented in Figure 4.5A. Image J software was used for quantitation of the western blot 
bands. Fold decrease of RRM1 was calculated by normalization to the loading control and comparison 
to the untreated sample.  
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MDM2 mediates proteasomal degradation of other protein targets apart from P53 
(Ambrosini et al. 2007). To investigate whether MDM2 was involved in RRM1 
degradation, BxPC-3 cells were transfected with MDM2-specific siRNA for 72 hours 
and RRM1 protein levels were analysed by immunoblotting. RRM1 protein levels 
accumulated in MDM2 knocked-down cells suggesting that MDM2 is involved in the 
proteasome-dependent degradation of RRM1 (Fig. 4.6A). When BxPC-3 cells, 
transfected with siRNA against MDM2, were treated with pimasertib for the last 4h of 
transfection, RRM1 downregulation was impaired (Fig. 4.6B), suggesting that 
pimasertib-induced RRM1 degradation occur through MDM2 activity. Bar graphs 
showing the quantification of RRM1 immunoblots are illustrated in Figure 4.6C. 
A 
 
B                                                                                                        C 
           
 
Figure 4.6: MDM2 modulates RRM1 degradation induced by pimasertib.  
A. BxPC-3 cells were transfected with 50nM siRNA targeting MDM2 or scrambled for 72 hours and 
immunoblotted with the indicated antibodies. B. BxPC-3 cells were transfected with 50nM siRNA 
targeting MDM2 or scrambled for 72 hours followed by a 4-hour treatment with pimasertib and 
immunoblotted with the indicated antibodies. β-Actin was using as loading control. C. Densitometric 
analysis of the immunoblots presented in Figure 4.6B. Fold decrease of RRM1 was calculated by 
normalization to the loading control and comparison to the untreated sample. Results are presented as 
mean ± SD of three independent experiments. 
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To further confirm that MDM2 mediates RRM1 degradation through its 
polyubiquitination and degradation by the proteasome system, myc-labeled wild-type 
or truncated MDM2 (p60), the latter lacking the E3 ligase domain, were transiently 
transfected into the MIAPaCa-2 cell line and treated with pimasertib for 4 hours. 
Protein lysates were analysed by immunoblotting. When MDM2p60 was expressed, 
accumulation of RRM1 protein expression was observed compared to MDM2wt (lane 
1,2 Fig. 4.7). Importantly, RRM1 downregulation caused by pimasertib administration 
was impaired in MDM2p60 transfected cells (Lane 3,4 Fig. 4.7). These findings further 
confirm the involvement of MDM2 in targeting RRM1 for proteasomal degradation. 
 
 
 
Figure 4.7: RRM1 protein levels are increased in truncated mutant MDM2 cells. 
MIAPaCa-2 cells were transiently transfected with MYC-labelled MDM2wt or MDM2p60. After 48 
hours, transfected cells were selected with neomycin and treated with pimasertib for an additional 4 
hours. Total cell lysates were analysed by immunoblotting with the indicated antibodies. β-Actin was 
using as loading control. 
 
Nutlin-3 belongs to the class of small molecule antagonists of MDM2 that binds the 
P53 binding pocket of MDM2, thus disrupting the interaction between p53 and 
MDM2, which results in the inhibition of P53 degradation (Vassilev 2007). Several 
studies have demonstrated a P53 independent role of nutlin-3 (Ambrosini et al. 2007). 
For example, small molecule antagonists of MDM2 can disrupt the binding between 
MDM2 and E2F1 in P53 mutant cells (Ambrosini et al. 2007). We sought to investigate 
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if nutlin-3 could alter the effect of pimasertib on RRM1 stability by inhibiting MDM2 
E3 ligase activity. BxPC-3 cells were treated with 1µM pimasertib and 1µM nutlin-3 for 
24 hours. Immunoblotting analysis showed that treatment with nutlin-3 impaired 
RRM1 downregulation induced by pimasertib (Fig. 4.8A). Bar graphs showing the 
quantification of RRM1 immunoblots are illustrated in Figure 4.8B. 
A 
 
 
B 
 
 
Figure 4.8: The MDM2 antagonist Nutlin-3 impairs RRM1 degradation.  
A. BxPC-3 cells were co-treated with 1µM nutlin-3 and 1µM pimasertib for 24 hours and total cell 
lysates were analysed by immunoblotting with the indicated antibodies. Calnexin was used as loading 
control. Results are representative of three independent experiments. B. Densitometric analysis of the 
immunoblots presented in Figure 4.8A. Image J software was used for quantitation of the western blot 
bands. Fold average of RRM1 was calculated by normalization to the loading control and comparison to 
the untreated sample. Results are presented as mean ± SD of three independent experiments. 
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4.3.4 RRM1 interacts with MDM2  
MDM2 acts as an E3 ubiquitin ligase by interacting with target proteins and regulating 
their proteasomal degradation(Iwakuma and Lozano 2003). To investigate whether 
RRM1 was an MDM2-binding protein, immunoprecipitation experiments were 
performed in BxPC-3 and PANC-1 cells. Endogenous RRM1 bound to total and 
phosphorylated forms of MDM2 (Serine 166). In particular, the binding between P-
MDM2 and RRM1 increased after treatment with pimasertib in BxPC-3 cells and to a 
greater extent in PANC-1 cells (Fig 4.9).  
 
 
 
 
Figure 4.9: Pimasertib enhances MDM2 interaction with RRM1. 
BxPC-3 and PANC-1 cells were treated with the same conditions described in Fig. 4.4. Total cell lysates 
were immunoprecipitated (IP) with control IgG or anti-RRM1 antibody. IP complexes were 
immunoblotted with the indicated antibodies. 
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Previous studies have shown that MDM2 is active in a P53 mutant setting (Bouska and 
Eischen 2009). Our results have shown that MDM2 mediates ubiquitination and 
degradation of RRM1 in mutant BxPC-3 cell lines. To confirm that the effect observed 
in our study on RRM1 stability is independent of the functional activity of P53, BxPC-3 
cells were transfected with specific siRNA targeting P53 for 72 hours and treated with 
pimasertib for the last 4 hours of transfection. Total cell lysates were immunoblotted 
against P53 and RRM1. Inhibition of P53 by siRNA did not affect the reduction of 
RRM1 protein induced by pimasertib treatment (Fig. 4.10). 
 
 
 
Figure 4.10: Pimasertib-induced downregulation of RRM1 is independent of P53 activity.  
BxPC-3 cells were transfected with 50nM siRNA targeting P53 or scrambled for 72 hours and 
immunoblotted with the indicated antibodies. Calnexin was using as loading control. 
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4.3.5 Pimasertib induces activation of P-AKT  
MEK inhibition has been shown to induce activation of the PI3K/AKT signalling 
pathway through various feedback loop mechanisms (Zmajkovicova et al. 2013) (Turke 
et al. 2012).  A previous preclinical study has shown activation of AKT signalling by 
pimasertib in multiple myeloma cell lines (Kim et al. 2010). To investigate whether 
pimasertib had an effect on AKT, BxPC-3 cells were treated with 1μM pimasertib and 
extracted at different time point (1h, 4h and 24h). Immunoblotting analysis showed an 
increase of P-AKT protein levels along with sustained P-ERK inhibition after 1-hour 
treatment with pimasertib (Fig. 4.11). 
 
 
 
Figure 4.11: Pimasertib induces rapid activation of P-AKT. 
BxPC-3 cells were treated for 1, 4 and 24 hours with 1µM pimasertib. Total cell lysates were 
immunoblotted using the indicated antibodies. Calnexin was used as loading control. Data is 
representative of two independent experiments. 
 
 
4.3.6 AKT activation is required for pimasertib-mediated degradation of 
RRM1 
The results presented in Figures 4.7-4.9 show that pimasertib triggers MDM2-
mediated polyubiquitination and degradation of RRM1. Previous studies have 
reported that phosphorylation of MDM2 on serine 166 and 186 can be triggered by P-
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AKT, an effect that stimulates MDM2 entry into the nucleus and increases its ability to 
target P53 (Mayo and Donner 2001) (Zhou et al. 2001). One potential route by which 
pimasertib enhances MDM2 E3 ligase activity may be the PI3K/AKT pathway, since we 
have previously shown it is activated by the MEK inhibitor (Fig. 4.11). To explore this 
hypothesis, BxPC-3 cells were treated with 1μM pimasertib for 4 hours. Total lysates 
were immunoprecipitated with MDM2 antibody and probed for AKT and P-AKT. 
Results showed an interaction between MDM2 and AKT (Fig. 4.12). In particular, a 
strong interaction between MDM2 and P-AKT was observed upon pimasertib 
treatment (Fig. 4.12), suggesting that P-AKT directly activates MDM2 E3 ligase activity 
in BxPC-3 cells. 
 
Figure 4.12: MDM2 interacts with P-AKT. 
BxPC-3 cells were pre-treated for 4 hours with with 1µM pimasertib. Total cell lysates were 
immunoprecipitated with anti-MDM2 antibody. Immunoprecipitates were analysed by immunoblotting 
by using the indicated antibodies. 
 
We then used a selective inhibitor of class-I PI3K (GDC-0941) to determine whether 
MEK inhibition-feedback activation of P-AKT was implicated in RRM1 degradation. 
Immunoblotting analysis showed that the combination of both drugs effectively 
inhibited AKT and ERK phosphorylation, but total levels of ERK and AKT remained 
unchanged (Fig. 4.13A). Quantitatively, the ratio of P-AKT/T-AKT increased upon 4 
hours treatment with 1μM pimasertib (Fig 4.13B). Importantly, 1μM pimasertib plus 
1μM GDC-0941 treatment for 4 hours antagonised the effect of pimasertib on 
downregulating RRM1 protein expression (Fig 4.13A). Based on these findings, we 
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suggest that AKT phosphorylation induced by MEK inhibition might trigger MDM2-
mediated degradation of RRM1.  
A 
 
B 
 
 
Figure 4.13: PI3K/AKT signalling inhibition impairs the downregulation of RRM1.  
A. BxPC-3 and PANC-1 cells were treated for 4 hours with 1µM of PI3K inhibitor GDC-0941 together 
with 1µM pimasertib and total cell lysates were immunoblotted using the indicated antibodies. β-actin 
was used as loading control. B. Densitometric analysis of the immunoblots presented in figure 4.13A. 
Results are presented as mean ± SD of three independent experiments. Image J software was used for 
the quantitation of the western blot bands. Increase of P-AKT/T-AKT was calculated by normalization to 
the loading control and comparison to the untreated sample.  
** 
* 
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4.4 DISCUSSION 
This chapter presented a series of experiments conducted to investigate the molecular 
mechanisms by which the MEK inhibitor pimasertib modulates RRM1 protein stability.  
 
4.4.1 Ribonucleotide Reductase stability is modulated by the ubiquitin-
proteasome system 
Ribonucleotide Reductase (RR) activity is tightly regulated through several 
mechanisms (Aye et al. 2015). For example, RR regulation occurs through the cell 
cycle, in which RRM2 protein and mRNA levels reach maximum peaks in S-phase. RR 
activity is also modulated by the binding of ATP or dATP molecules to the catalytic site 
of RR (Nordlund and Reichard 2006). Recent findings have shown that RR enzyme 
stability is regulated by the action of the proteasome pathway. An in vitro study has 
demonstrated that RRM2 protein stability is regulated by the ubiquitin-proteasome 
system through Cyclin F, an SCF E3 ubiquitin ligase F-box protein. Upon DNA damage 
Cyclin F is downregulated in an ATR (ataxia telangiectasia and Rad-3 dependent 
protein) dependent manner, thus increasing RRM2 stability (D'Angiolella et al. 2012). 
In the study just described, defective elimination of Cyclin F enhanced RRM2 
proteasomal degradation thus producing an imbalance in the levels of dNTPs. 
Inappropriate production of dNTP pools sensitized cells to DNA damage, which led to 
genomic instability. (D'Angiolella et al. 2012).  
Another example of RR activity being regulated post-translationally came from a pre-
clinical study investigating P53R2 activity. RR subunit p53R2 is induced upon DNA 
damage and associates with RRM1 to supply dNTP pools for DNA repair. However, its 
mRNA transcription is not induced rapidly enough to provide dNTP for immediate DNA 
repair (Nordlund and Reichard 2006). Recent findings revealed that ataxia 
telangiectasia mutated (ATM) phosphorylation on Ser72 maintains P53R2 stability, by 
blocking MDM2-mediated degradation of P53R2 in response to genotoxic stress 
(Chang et al. 2008). In agreement, mutation of Ser72 impaired P53R2 phosphorylation 
and resulted in hyperubiquitinated P53R2 upon DNA damage. Interestingly, co-
immunoprecipitation analysis demonstrated not only a physical interaction between 
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ATM and P53R2 but between ATM/P53R2 and RRM1 subunit after 30 minutes of UV 
irradiation, suggesting that RRM1 and P53R2 form a complex, which interacts with 
ATM in vivo (Chang et al. 2008).  
Finally, another study identified RNF2 and Bmi1 E3 ubiquitin ligases to interact with 
and induce RRM1 polyubiquitination. Silencing of both genes induced accumulation of 
RRM1 protein (Zhang et al. 2014). These results indicate that the ubiquitin 
proteasome system is involved in the regulation of RR stability. Enhancing the activity 
of specific E3 ligases within the proteasome pathway could be an effective way to 
downregulate RR activity and thus overcome gemcitabine resistance. 
 
4.4.2 Pimasertib induces MDM2-mediated proteasomal degradation of 
RRM1  
The P53 tumor suppressor gene is activated in response to stress signals or DNA 
damage to induce cell proliferation arrest, senescence or apoptosis. P53 is one of the 
most frequently mutated gene in human cancer (Vogelstein et al. 2000). One of the 
functions of the murine double minute 2 (MDM2) gene is to bind the N-terminal 
transactivation domain of P53 and thus inactivates P53 transcriptional activity 
(Michael and Oren 2003). Additionally, MDM2 acts as an E3 ubiquitin ligase by binding 
P53 through its RING finger domain and inducing its proteasomal degradation 
(Freedman et al. 1999). Loss of MDM2 causes embryonic lethality in mice during early 
development, a phenotype that is rescued by concomitant deletion of P53 (Jones et al. 
1995). MDM2 expression is also regulated by P53 and MDM2 inhibits P53 activity; 
both auto regulatory feedback loop mechanisms are important to maintain P53 levels 
under normal physiological conditions (Wu et al. 1993). MDM2 is classified as an 
oncogene because of its property on inhibiting P53 tumor suppressive functions. 
However, different alternative splicing of MDM2 transcripts exist which do not include 
sequences encoding for the P53 binding domain, suggesting that MDM2 has also p53-
independent functions (Steinman et al. 2004). 
Several studies have shown that MDM2 possesses E3 ubiquitin ligase activity against 
other target proteins, such as the activating transcription factor 3 (ATF3) (Mo et al. 
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2010), the tumor suppressor protein Rb (Loughran and La Thangue 2000), the 
androgen receptor (AR) (Zhau et al. 1995) and P53R2 subunit (Chang et al. 2008). 
In human pancreatic cancer cells, MDM2 was shown to regulate the expression of 
target genes involved in cellular proliferation such as C-jun, C-Myc and cyclin D1 (Sui et 
al. 2009). 
In this study, human pancreatic cancer cells were treated with the proteasome 
inhibitor MG132 to explore whether the decrease of RRM1 protein expression 
induced by pimasertib was due to its degradation through the proteasome system. 
MG132 prevented RRM1 downregulation caused by pimasertib suggesting that the 
degradation of RRM1 is proteasome dependent (Fig. 4.3). Additionally, pimasertib 
caused accumulation of polyubiquitinated RRM1 through Lys48-mediated linkage, 
which is associated with proteasomal degradation of the target protein (Fig. 4.4) 
(Tenno et al. 2004).  
The results from this chapter have also shown the depletion of MDM2 by siRNA 
impaired RRM1 degradation induced by pimasertib (Fig. 4.6). Furthermore, in 
transient transfection experiments we have shown that RRM1 accumulated more in 
cells overexpressing a truncated form of MDM2, which does not have functional E3 
ligase activity (Fig. 4.7).  
Small molecule antagonists of MDM2 (Nutlins) have been developed to disrupt the 
binding between MDM2 and P53 and thus increase p53 signalling only in cells with 
wild-type p53 (Vassilev 2004). However, nutlins have proved to be active in a mutant 
P53 setting (Ambrosini et al. 2007). For instance, a study has demonstrated that 
treatment with nutlin-3 disrupted the binding of E2F1 with MDM2, thus increasing the 
stability of E2F1. Enhanced activation of E2F1 led to an increase of pro-apoptotic 
proteins, which enhanced cytotoxicity of cisplatin therapy (Ambrosini et al. 2007). We 
used the MDM2 antagonist nutlin-3, which block MDM2 E3 ubiquitin ligase activity 
and observed that administration of nutlin-3 prevented pimasertib-induced 
downregulation of RRM1, further confirming MDM2 involvement in RRM1 
degradation (Fig. 4.8). Finally, to determine whether RRM1 and MDM2 interact we 
performed co-immunoprecipitation analysis and demonstrated a direct association 
between RRM1 and MDM2 or P-MDM2 (Fig. 4.9).  These results all together confirm 
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the role of MDM2 in mediating RRM1 proteasomal degradation induced by 
pimasertib. 
 
4.4.3 The PI3K/AKT pathway is involved in RRM1 degradation induced 
by pimasertib 
MEK inhibitors can induce activation of the PI3K/AKT signalling pathway due to 
presence of compensatory feedback systems (Zmajkovicova et al. 2013). For instance, 
recent findings have shown that MEK inhibitors increased AKT phosphorylation 
through activation of ERBB3 tyrosine receptor, which led to the upregulation of 
ERBB3/PI3K association. This effect, induced by MEK inhibition, is caused by the loss of 
ERK-inhibitory feedback action on phosphorylating EGFR T669 and HER2 T667, which 
inhibits ERRB3 activity. (Turke et al. 2012).  
Other reports have demonstrated the role of the PI3K/AKT signalling pathway in 
promoting MDM2 E3 ligase activity. AKT has been reported to phosphorylate MDM2 
at Ser166 and Ser186, necessary for its translocation into the nucleus. In fact, depletion 
of AKT signalling significantly enhanced P53 transcriptional activity and thereby P53-
dependent apoptosis (Mayo and Donner 2001).  
Additionally, the AKT pathway is involved in MDM2-mediated degradation of the 
androgen receptor (AR), a transcription factor that mediates the regulation of 
prostate cell growth and apoptosis (Grossmann et al. 2001). AKT phosphorylates both 
AR and MDM2 and this leads to ubiquitination and thus degradation of the receptor 
by the 26S proteasome (Lin et al. 2002). The overall results indicate important 
mechanisms of regulation of MDM2 activity through PI3K signalling pathway. 
In this present study we have shown an increase in P-AKT levels following pimasertib 
administration (Fig. 4.11) and we asked if this effect could be associated with RRM1 
downregulation observed upon pimasertib treatment. Our results first confirmed the 
existence of a physical interaction between P-AKT and MDM2, which increased after 
treatment with the MEK inhibitor (Fig. 4.12). Next, we observed that co-treatment of 
pimasertib with the PI3K inhibitor GDC0941 resulted in impaired downregulation of 
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RRM1 (Fig. 4.13). These results suggest that MEK inhibition mediates P-AKT activation 
of MDM2 to target RRM1.  
 
4.5 CONCLUSIONS 
The experiments conducted in this chapter reveal new mechanistic insights in the 
modulation of RRM1 protein stability induced by MEK inhibition in human pancreatic 
cancer cell lines. In this context we demonstrated that pimasertib triggers RRM1 
proteasomal degradation through MDM2 E3 ligase activity. We believe RRM1 
degradation contributes to pimasertib effects in enhancing gemcitabine efficacy in 
vitro. Additionally, we propose that pimasertib-induced phosphorylation of AKT might 
be responsible for the activation of MDM2 to promote polyubiquitination and 
degradation of RRM1 protein. Further experiments will have to be performed to 
validate this hypothesis and understand how P-AKT interacts and activates MDM2 
protein. RRM1 is a key determinant of gemcitabine response in PDAC. Therefore, 
understanding the mechanism by which MEK inhibition modulates RRM1 expression is 
of crucial importance to develop new combination treatments with the aim of 
improving the small survival benefit provided by gemcitabine therapy. In the next 
Chapter experiments conducted on a mouse model of pancreatic cancer will be 
presented to further evaluate and confirm our in vitro findings. 
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CHAPTER 5  
EFFECTS OF PIMASERTIB IN 
COMBINATION WITH GEMCITABINE IN 
AN ORTHOTOPIC MODEL OF 
PANCREATIC TUMOR 
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5.1 INTRODUCTION 
5.1.1 In vivo model systems to study human cancers 
In vivo model systems have been extensively used in cancer research and have proved 
to be an important tool to investigate the role that specific genetic alterations have in 
tumor initiation, progression and maintenance (Qiu and Su 2013) (Guerra and 
Barbacid 2013). Mouse models have accelerated the identification of novel 
therapeutic drugs for PDAC, whose mechanisms of action can be studied in these 
models before clinical testing (Hidalgo et al. 2014) (Hidalgo et al. 2015). 
 
5.1.1.1 Human tumour xenograft models 
Human tumour xenograft models are widely used in cancer research for the preclinical 
evaluation of therapeutic drugs and are generated by implantation of human tumour 
cells in immunodeficient mouse hosts (Rubio-Viqueira et al. 2006) (Qiu and Su 2013). 
Human tumour xenograft models are used to examine the potential effects of 
anticancer therapies on tumour regression and long-term survival (Kelland 2004).  
Xenograft models can be divided into two categories: 
1. Heterotopic mice: when the tumour cells are injected subcutaneously 
2. Orthotopic mice: when the tumour cell is injected or implanted directly into 
the corresponding host organ.  
Orthotopic models are more appropriate to investigate the metastatic process since 
their tumour microenvironment resembles that of the original tumour and they 
develop distant metastasis in a similar way to what is observed in human cancers 
(Killion et al. 1998). However, orthotopic models are time consuming and more 
challenging to generate compared to the corresponding heterotopic models. 
Human tumour xenograft models have some limitations: tumours develop very rapidly 
therefore they do not acquire the full characteristics of a human tumour. Additionally, 
as these models are immunocompromised, they do not simulate an immune 
response, which is integral to tumour initiation and progression. For these reasons, 
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the response to therapy obtained from these preclinical models is not always fully 
reproducible in the clinical setting (Gopinathan and Tuveson 2008).  
 
5.1.1.2 Genetically engineered mouse models of PDAC 
Genetically engineered mouse models (GEMMs) are models in which one or several 
genes expression has been manipulated to recapitulate the main features of a 
particular human cancer (Dow and Lowe 2012). The KC mouse model 
(KrasLSL.G12D/+; PdxCretg/+) is one of the most commonly used GEM models of 
PDAC (Fig. 5.1). This model was generated by crossing mice carrying KRASG12D 
knocked-in allele containing a cassette with transcriptional termination stop codon 
flanked by LoxP sites (LSL cassette) that prevents expression of the allele, with 
transgenic mice expressing a bacterial CRE recombinase under the control of a 
pancreas specific promoter (PDX1). Expression of CRE recombinase removes the stop 
cassette and activates the KRASG12D allele specifically in the pancreatic tissue 
(Hingorani et al. 2003) (Fig. 5.1). After induction of oncogenic KRASG12D, KC mice start 
developing all three stages of PanIN lesions, acquire ductal morphology and slowly 
progress to PDAC (Hingorani and Tuveson 2003).  
Simultaneous induction of oncogenic KRASG12D and a loss of function allele of the 
tumor suppressor p53 led to the development of KPC mice (KrasLSL.G12D/+; 
p53R172H/+; PdxCretg/+) that develop pancreatic cancers more rapidly and generate 
liver metastasis that closely resemble that of the corresponding human tumour 
(Hingorani et al. 2005). 
Although these models allow the manipulation of expression of genes frequently 
mutated in PDAC, the concurrent introduction of these genetic alterations does not 
reflect the real scenario in which mutations occur in specific stages of tumour 
development and not at the same time (di Magliano and Logsdon 2013). For this 
reason, a second model of pancreatic cancer has been developed characterised by 
spatial and temporal control of K-RASG12D expression (Guerra et al. 2007). This model 
is ideal to investigate how the temporal order of genetic alterations occurring in PDAC 
determines cancer progression. 
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Figure 5.1: Schematic representation of the KC mouse model. 
The KC mouse model is generated by crossing a mouse strain containing oncogenic K-RAS
G12D
 preceded 
by a STOP cassette flanked by two LoxP sites, with a strain containing the Pdx1 promoter-regulated 
CRE. Endogenous allele of KrasG12D is conditionally activated in the mouse pancreatic tissue by Pdx-1 
CRE recombinase, which recognizes the LoxP sites and deletes the DNA sequence (containing the STOP 
cassette) between the two LoxP sites. Adapted from (Hingorani et al. 2005). 
 
The establishment of GEMMs have helped to study the biology of pancreatic cancer 
and to validate genes mutation, such as K-RAS as main drivers of pancreatic tumor 
initiation and development (Frese and Tuveson 2007) (Westphalen and Olive 2012). 
Additionally, GEM models have proved to be critical tool for the identification of new 
therapeutic strategies at various stages during tumor development (Olive et al. 2009) 
(Dow and Lowe 2012). However there are some disadvantages which make their use 
limited: they are time consuming, requiring almost a year to develop and they are 
highly expensive to generate (Dow and Lowe 2012). Additionally, it is not possible to 
define the function that specific genes have in tumor maintenance (Saborowski et al. 
2014). Faster and more scalable approaches than knock-out mice have been recently 
developed; for example, shRNA technology enables the silencing of a gene in a 
reversible manner, allowing the investigation of gene function in a determined period 
of time (Dow and Lowe 2012).  
Another faster approach compared to GEMMs is the mulltiallelic transgenic mouse 
model known as GEMM-ESC. This model is generated by injecting mouse embryonic 
stem cells (ESC) (derived from a GEM model) in a mouse host, whose genome had 
been modified in vitro to carry the essential genetic modifications needed to develop 
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a particular type of cancer. This system does not require breeding and the mice 
generated develop tumour within 3 months, therefore they represent an efficient 
platform for preclinical treatment studies (Dow and Lowe 2012). 
 
5.1.1.3 Syngeneic orthotopic mouse models 
Syngeneic orthotopic pancreatic cancer mouse models represent a lower cost and less 
time consuming alternative to GEMMs (Tseng et al. 2010). To generate these models, 
tumor cells derived from GEMMs are implanted into the pancreas of 
immunocompetent mice. Syngeneic orthotopic mouse models develop genetic 
mutations and an immune response typical of human pancreatic cancer and thus they 
are a powerful system for exploring novel therapeutic strategies (Tseng et al. 2010). 
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5.2 RESEARCH HYPOTHESIS AND AIMS  
Hypothesis: The MEK1/2 inhibitor pimasertib has demonstrated potent antitumor 
activity in mouse models of different malignancies (Kim et al. 2010) (Park et al. 2013) 
(Yoon et al. 2011). However, no in vivo studies on pancreatic cancer models involving 
pimasertib have been published to date. Our results on human pancreatic cancer cell 
lines demonstrated synergistic activity when pimasertib was combined with 
gemcitabine and we suggest that this effect is in part due to a significant 
downregulation of RRM1 protein levels.  
We believed that investigating the effects of pimasertib in orthotopic mouse models 
of pancreatic would be of significance to confirm our in vitro findings.  
This chapter validates the research hypothesis with the following aims:  
 To investigate the in vivo antitumor activity of pimasertib in combination with 
gemcitabine in an orthotopic model of pancreatic cancer. 
 To confirm the effects of pimasertib on the MAPK pathway and RRM1 
expression in the same mouse model. 
  
 162 
5.3 RESULTS 
5.3.1 Effects of pimasertib on TB32048 tumor cells  
To explore the antitumor activity of pimasertib in combination with gemcitabine in 
vivo, a syngeneic orthotopic mouse model of pancreatic cancer was generated by our 
collaborators at the Barts Cancer Institute (London, UK). TB32048 murine cells, 
derived from the KPC mouse model (previously described) were implanted in the 
pancreas of immunocompetent mice.  
Initially, the cellular effects of pimasertib in combination with gemcitabine were 
evaluated in the TB32048 cell line. As observed in the human pancreatic cancer cell 
lines (Fig. 3.9-3.10), a 4-hour pre-treatment with 500nM pimasertib followed by a 48-
hour treatment with increasing concentrations of gemcitabine (5nM, 25nM, 50nM 
and 250nM) induced synergistic antiproliferative effects (Fig. 5.2A) as indicated by CI 
values generated from all concentrations of gemcitabine examined being <1  (Fig. 
5.2B). A bar chart of CI values obtained from the sequential combination of 
gemcitabine with pimasertib is illustrated in Fig. 5.2B). 
A                                                                                                             
 
 
Figure 5.2: Sequential combination of pimasertib followed by gemcitabine induces synergistic 
antiproliferative activity in KPC cells. 
A. MTT assay was used to evaluate the effect of a 4-hour pre-treatment of 500nM pimasertib followed 
by increasing concentrations of gemcitabine (5-25-50-250nM) for 48 hours on the growth of TB32048 
cells.  
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Figure 5.2 continued: Sequential combination of pimasertib followed by gemcitabine induces 
synergistic antiproliferative activity in KPC cells. 
B. Combination Indices (CI) values describing drug combinations were calculated with the Calcusyn 
program. Experiments were repeated three times and are represented as mean, Error Bars ± SD. 
 
Next, we investigated the effects of pimasertib on MAPK signaling and RRM1 
expression on cultured TB32048 cells in vitro. Immunoblotting analysis showed 
inhibition of ERK phosphorylation and reduced RRM1 protein expression after 4 hours 
treatment with pimasertib and this effect was sustained for 24 hours (Fig. 5.3). 
Additionally, pimasertib led to an increase in P-AKT protein levels at 4 and 24 hours 
(Fig. 5.3). We have previously shown that treatment with the PI3K inhibitor GDC-0941 
impaired the effects of pimasertib on RRM1 protein expression (Fig. 4.13), suggesting 
that the PI3K/AKT pathway is involved in RRM1 degradation induced by MEK 
inhibition. To confirm these results, TB32048 cells were treated with 1μM GDC-0941 
and 1μM pimasertib for 4 hours. GDC-0941 treatment inhibited the pimasertib-
mediated decrease of RRM1 (Fig. 5.4A). P-AKT/T-AKT quantification was performed by 
densitometric analysis (Fig. 5.4B).  
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Figure 5.3: Pimasertib reduces RRM1 protein levels in TB32048 cells. 
TB32048 cells were treated for 4 and 24 hours with 1 µM pimasertib. Total cell lysates were 
immunoblotted using the indicated antibodies. Calnexin was used as loading control.  
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Figure 5.4: AKT inhibition impairs RRM1 downregulation induced by pimasertib in TB32048 cells. 
A. TB32048 cells were treated for 4 hours with 1µM of PI3K inhibitor GDC-0941 together with 1µM 
pimasertib. Total cell lysates were immunoblotted using the indicated antibodies and β-actin was used 
as loading control. B. Densitometric analysis of the immunoblots presented in figure 5.4A. Results are 
presented as mean ± SD of three independent experiments. Image J software was used for quantitation 
of the western blot bands. Fold increase of P-AKT/T-AKT was calculated by normalization to the loading 
control and comparison to the untreated sample. 
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5.3.2 Combination of pimasertib with gemcitabine induces tumor 
growth delay in TB32048 mice 
To investigate the antitumor activity of pimasertib with gemcitabine in vivo, an 
orthotopic mouse model was generated by injecting a total of 105 TB32048 cells in 
30 μl of matrigel into the pancreata of 6-week old immunocompetent C57/BL6 black 
female mice. Two weeks after orthotopic implantation, tumors were established and 
mice were randomly divided into 4 groups (n=6 for each group) to receive the 
following treatments: 1) 0.5% carboxyl methylcellulose and 0.25% Tween 20 by oral 
gavage (vehicle), 2) gemcitabine intraperitoneally 80mg/kg (twice/week), 3) 
pimasertib via oral gavage at 5mg/kg (daily), 4) with pimasertib 5mg/kg (daily) 
followed 4 hours later by gemcitabine 80mg/kg (twice/week) (Table 5.1).  
The choice of pimasertib dose was based on previous in vivo experiments conducted 
on xenograft models at EMD Serono, which showed that pimasertib was well 
tolerated at doses of 5 and 10mg/kg.  The dose of gemcitabine chosen for this study 
was the same adopted by our collaborators at Barts for other studies in pancreatic 
mouse models, which gave no evidence of acute toxicity. Additionally, 80mg/kg 
corresponds to ≈ 450mg/m2, which is below the standard clinically human dose of 
gemcitabine given once weekly (1000mg/m2). 
The schedule used in our in vivo experiments was designed according to the time of 
drug administration that produced the best synergistic effect in vitro. After two 
treatment cycles of 5 days each, all mice were sacrificed 4 hours after the last 
administration of pimasertib, tumor excised, weighed and sectioned for 
histopathologic analysis.  
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Table 5.1: Schematic schedule of treatments. 
The diagram shows an outline of the treatment schedule used in this study. After tumors were 
established, TB32048 mice were treated with gemcitabine intraperitoneally 80mg/kg (twice/week), 
pimasertib via oral gavage at 5mg/kg (daily) or with pimasertib 5mg/kg (daily) followed 4 hours later by 
gemcitabine 80mg/kg (twice/week). Mice were treated for 2 cycles of 5 days each. 
 
 
 
Mice treated with pimasertib or gemcitabine alone had no statistically significant 
difference in tumor weight compared to mice treated with vehicle (Fig. 5.5A). In 
contrast, the combination cohort resulted in significantly smaller tumors as compared 
to vehicle (**P< 0.01), gemcitabine (*P< 0.05) or pimasertib (**P< 0.01) (Fig. 5.5A).  
A decrease of tumor vasculature density was observed in pimasertib alone and 
pimasertib plus gemcitabine treated mice compared to the other cohorts (Fig. 5.5B), 
suggesting an anti-angiogenic effect induced by the MEK inhibitor. Representative 
gross images of dissected tumors from each group are shown in Figure 5.5B. 
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Figure 5.5: The sequential combination of pimasertib with gemcitabine delays tumor growth in vivo. 
A. TB32048 tumor-bearing mice were treated with vehicle, 5mg/kg pimasertib (daily) by oral gavage, 
gemcitabine 80mg/kg (twice/week) intraperitoneally or a sequential combination of pimasertib 5mg/kg 
followed 4 hours later by gemcitabine 80mg/kg. After 12 days, mice were sacrificed and tumor weight 
was measured. Student’s t test was used to determine the statistical significance of differences in 
tumor weight (**P<0.01 and *P<0.05). B. Gross images from representative excised tumors are shown.   
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Primary tumor volumes were measured using ultrasound imaging before drug 
treatment and before sacrifice. From these data changes in tumor volume were 
calculated. Tumor volumes from mice treated with gemcitabine (149mm3 vs 1112mm3 
P < 0.001) or pimasertib alone (90mm3 vs 673mm3 P < 0.001) significantly increased at 
the end of the treatment (Fig. 5.6). On the other hand, the average tumor volumes of 
the combination group were not significantly different before and after treatment 
(108mm3 vs 404mm3 P > 0.05) (Fig. 5.6). These results showed that only the 
combination of pimasertib with gemcitabine was effective at slowing down tumor 
growth in TB32048 mice. All drug treatments regimens were well tolerated in mice. 
No signs of acute toxicity were observed with any of the drug treatments. 
 
 
 
Figure 5.6: Tumor volumes of TB32048 mice before and after drug treatment. 
Pancreatic tumor volumes were measured before the start and at the end of each drug treatment by 
ultrasound analysis. Results are expressed in tumor volume (mm^3). Each data point represents the 
mean ± SD of 6 mice per treatment group. Statistical analysis was performed using One-way Anova with 
Bonferroni Post-test (***P<0.001, ns P>0.05).  
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5.3.3 Pimasertib/gemcitabine combination inhibits proliferation and 
induces apoptosis in TB32048 mice 
Hematoxylin and Eosin (H&E) staining of tumor sections was performed. H&E staining 
revealed spindle or oval-shaped tumor cells arranged in a weave pattern, indicative of 
poorly differentiated adenocarcinoma, with mild desmoplastic reaction and variable 
degree of lymphocytic infiltrate. No difference in tumor morphology was observed 
among the four groups (Fig. 5.7).  
Next, we investigated the effects of pimasertib, gemcitabine or their combination on 
proliferation and apoptosis in TB32048 mice. Immunohistochemical staining was 
performed by using antibodies against Ki67, a marker of cell proliferation, and cleaved 
caspase-3 (CC3), a marker of apoptosis.  Reduced nuclear expression of ki67 was 
observed in mice treated with pimasertib compared to the other treatments (Fig. 
5.8A). An increase in the number of CC3 positive cells was observed in mice treated 
with the pimasertib/gemcitabine regimen compared to the other treatment groups 
(Fig. 5.8B) suggesting that the antitumor effect of the combination is mediated by 
induction of apoptosis. On the other hand, treatment with gemcitabine alone did not 
seem to affect apoptosis of TB32048 mice as it did in human pancreatic cancer cell 
lines BxPC-3 and PANC-1 (Fig. 3.12-3.14). 
 
 
 
Figure 5.7:  TB32048 mice develop pancreatic tumor morphology. 
Representative H&E staining from mouse pancreas were performed to determine tissue morphology.  
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Figure 5.8:  Effects of pimasertib and gemcitabine on proliferation and apoptosis of TB32048 mice. 
A. Representative Images of Ki67 staining of paraformaldehyde-fixed sections derived from tumors 
treated with the indicated drugs or vehicle. B. Representative Images of CC3 staining of 
paraformaldehyde-fixed sections derived from tumors treated with the indicated drugs or vehicle.  
C. Ki67 and CC3 staining were quantified as previously described and scored. 
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5.3.4 Pimasertib inhibits P-ERK activation in vivo 
The molecular mechanism of action of pimasertib and gemcitabine was investigated in 
the TB32048 orthotopic mouse model of pancreatic cancer. First, to test the specificity 
of the MEK inhibitor, P-ERK staining was performed. Immunohistochemical analysis 
revealed that ERK phosphorylation was significantly reduced in TB32048 tumors 
harvested from the pimasertib and gemcitabine/pimasertib cohorts. On the other 
hand, gemcitabine activated phosphorylation of ERK (Fig. 5.9A). Gemcitabine induced 
activation of MAPK signaling in PDAC tumors have already been observed in other 
preclinical studies (Miyabayashi et al. 2013). Quantification of P-ERK staining was 
performed as described in the methods section and showed in Figure 5.9B 
A 
 
 
B 
 
Figure 5.9: Pimasertib inhibits P-ERK protein expression in TB32048 mice. 
A. Representative images of P-ERK staining of paraformaldehyde-fixed sections derived from tumors 
treated with the indicated drugs or vehicle (brown staining indicates detection of P-ERK in paraffin 
tissue sections). B. P-ERK staining was quantified and scored. Results are represented in the column 
graph. (n= 6/ group). One-way Anova was performed for statistical analysis (***P<0.001). 
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5.3.5 Pimasertib reduces RRM1 protein levels in vivo 
We have previously demonstrated that pharmacological or biological inhibition of 
MEK protein reduces RRM1 protein levels in human pancreatic cancer cell lines 
(Fig.3.23, 3.25) and mouse KPC cell line (TB32048) (Fig. 5.3). Immunohistochemical 
analysis showed a significant reduction in the expression of RRM1 in mouse tumors 
from pimasertib- and pimasertib/gemcitabine cohorts (Fig. 5.10A), a result 
comparable to what was observed in vitro. Quantification of RRM1 staining was 
performed and showed in Figure 5.10B. 
 
A 
 
 
 
B 
 
Figure.5.10: Pimasertib destabilizes RRM1 protein inTB32048 mice. 
A. Representative Images of RRM1 staining of paraformaldehyde-fixed sections derived from tumors 
treated with the indicated drugs or vehicle. B. RRM1 staining was quantified and scored. Results are 
represented in the column graph. (n= 6/ group). One-way Anova was performed for statistical analysis 
(**P<0.01). 
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5.3.6 Pimasertib increases P-AKT expression in vivo 
Previous reports have shown that MEK inhibitors activate the PI3K/AKT signalling 
pathway through mechanisms of feedback regulation. (Duncan et al. 2012). Our in 
vitro results showed an increase of AKT phosphorylation upon treatment with 
pimasertib (Fig. 4.12-4.13 and 5.3). To determine whether pimasertib activates P-AKT 
in vivo, we analysed its expression by immunohistochemistry. A significant increase in 
AKT phosphorylation was observed after pimasertib treatment in TB32048 xenograft 
tumors (Fig. 5.11A). Quantification of P-AKT staining was performed and showed in 
Figure 5.11B. 
A 
 
 
 
B 
 
Figure 5.11: Pimasertib increases P-AKT expression in xenograft mice.  
A. Representative Images of P-AKT staining of paraformaldehyde-fixed sections derived from tumors 
treated with the indicated drugs or vehicle. B. P-AKT staining was quantified and scored. Results are 
represented in the column graph (n= 6/ group). One-way Anova was performed for statistical analysis 
(**P<0.01). 
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5.3.7 High dose of pimasertib induces tumor growth delay in TB32048 
mice when combined with gemcitabine  
A second in vivo experiment was carried out using the same schedule described in 
5.3.2 but with a different dosing regimen of pimasertib (15mg/kg). The 
pimasertib/gemcitabine regimen produced significantly smaller tumors compared to 
vehicle (*P< 0.05) gemcitabine alone (**P< 0.01) and pimasertib alone (*P<0.05) (Fig. 
5.12A). Representative gross images of tumor from each group are shown (Fig. 5.12B). 
The higher dose of pimasertib was still well tolerated with no apparent signs of acute 
toxicity. 
A 
 
 
Figure 5.12: Pimasertib (15mg/kg) in combination with gemcitabine delays tumor growth in vivo. 
A. TB32048 tumor-bearing mice were treated with vehicle, 15mg/kg pimasertib (daily) by oral gavage, 
gemcitabine 80mg/kg (twice/week) intraperitoneally or a sequential combination of pimasertib 
15mg/kg followed by gemcitabine 80mg/kg. After 12 days mice were sacrificed and tumor weight was 
measured. Student’s t test was used to determine the statistical significance of differences in tumor 
weight (**P<0.01 and *P<0.05).  
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Figure 5.12 continued: Pimasertib (15mg/kg) in combination with gemcitabine delays tumor growth 
in vivo. 
B. Gross images from representative excised tumors of TB32048 mice treated with the indicated drugs. 
 
 
 
Immunohistochemical analysis on TB32048 mouse tumors showed a significant 
reduction in the expression of P-ERK and RRM1 in tumors from pimasertib (15mg/kg)- 
and pimasertib (15mg/kg) plus gemcitabine (80mg/kg) cohorts (Figure 5.13). 
 
 
       
 
 
Fig. 5.13: 15mg/kg pimasertib reduces P-ERK and RRM1 expression in TB32048 mice. 
 P-ERK and RRM1 staining was quantified and scored. Results are represented in the column graph. (n= 
5/ group). One-way Anova was performed for statistical analysis (***P<0.001 **P<0.01). 
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5.3.8 Metastatic spread is reduced in the combination cohort 
At the end of drugs treatment, mice were sacrificed and visible metastases were 
counted. No significant difference in the incidence of metastasis was observed 
between the groups when mice were treated with 5mg/kg pimasertib and 80mg/kg 
gemcitabine (Fig. 5.15). The combination cohort had significantly reduced metastases 
incidence compared with vehicle cohorts when pimasertib was administered at 
15mg/kg (Fig. 5.16A). In particular, visible liver and spleen metastasis were observed 
in mice treated with vehicle. Mice treated with pimasertib plus gemcitabine showed 
metastasis only in the spleen. Representative images are illustrated in figure 5.16B. 
One limitation of this result was due to the fact that visible metastases were counted 
by naked eye and no methods were used for this analysis. 
 
 
 
Figure 5.15 Pimasertib 5mg/kg plus gemcitabine-treated mice do not reduce the incidence of 
metastases compared to other cohorts. 
Visible metastases in mice treated with pimasertib, gemcitabine or their combinations were counted 
and the number of metastases in each individual mouse was quantified and showed in the graphs. The 
graph shows the number of metastases in each individual mouse.  
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Figure 5.16: pimasertib 15mg/kg plus gemcitabine-treated mice develop less metastases compared to 
vehicle-treated mice. 
A. Visible metastases in mice treated with 15mg/kg pimasertib, 80mg/kg gemcitabine or their 
combinations were counted and the number of metastases in each individual mouse was quantified 
and showed in the graphs (*P<0.05). B. Gross Images of TB32048 mouse tumors from vehicle or 
gemcitabine/pimasertib cohorts. Arrows indicate liver and spleen metastases. 
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5.4 DISCUSSION 
5.4.1 In vivo model systems to study cancer therapeutics 
An important challenge in cancer research is to generate predictive experimental 
models to study the function of genes in a particular tumor with the aim of improving 
patient’s personalized treatment (Dow and Lowe 2012). Several in vivo models of 
pancreatic tumors have been established and have helped to better understand the 
biology of this aggressive disease (Herreros-Villanueva et al. 2012). For example, 
patient-derived xenograft (PDX) models, developed from patients’ tumor tissues, are 
now an important system to study PDAC. To generate these models, tumors, obtained 
fresh after surgical resection or from tumor biopsies, are implanted into 
immunodeficient mice (Siolas and Hannon 2013). PDX models of pancreatic cancer 
have shown to recapitulate the genetic features found in the human disease but one 
limitation is the absence of an intact immunity. A recent study adopted PDX models as 
an investigational platform for drug response with the aim of personalizing treatment 
course for PDAC patients (Hidalgo et al. 2014). In particular, the patient’s treatment 
choice was based on the drug response against the xenograft models developed from 
the patient’s tumor. The results demonstrated that drugs activity in PDX models was 
in many cases correlated with the patient’s outcome, suggesting that the use of PDX 
models as a tool to predict patients’ drug response should be further investigated 
(Hidalgo et al. 2014). 
Organoids represent a recently established model system to grow pancreatic tissue in 
a three-dimensional culture system (Boj et al. 2015). Organoids can be generated from 
human patient tissues, by performing small patient biopsies, or from mice tissues (Fig. 
5.17). Because they can be genetically manipulated, they represent a powerful tool for 
the discovery of novel mediators of PDAC progression (Boj et al. 2015). Recently, 
organoids have been generated from adult KRASG12D GEM mouse ductal cells. Once 
isolated from murine tissues, ductal cells were embedded in matrigel and started 
folding and to develop into budding structures within 2-3 days (Huch et al. 2013). 
These organoids could then be orthotopically transplanted in mice, where they fully 
developed all the common features of human PDAC (Boj et al. 2015). 
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Figure 5.17: Establishment of pancreatic ductal organoids.  
Ductal cells from adult mice or patients biopsies are isolated and embedded in matrigel. Duct cells 
formed cystic structures after 24 hours and passaged in cultures. After 2-3 days cells started to fold and 
acquired cuboidal structures (Boj et al. 2015). 
 
The development of genetically engineered mouse models (GEMMs), such as the KPC 
mouse model, where mutant K-RAS and mutant TP53 is expressed specifically in the 
mouse pancreatic tissue, has been crucial to explore the role of these genetic 
alterations in pancreatic tumor initiation, development and progression (Ardito et al. 
2012) (Collins et al. 2012). However, these models require long times to develop and 
are extremely expensive, thus xenograft (orthotopic or heterotopic) mouse models 
are widely used instead as a model system to explore the effects of novel anticancer 
therapies. In the orthotopic model cells are implanted directly into the mouse organ 
of the corresponding tumor of origin. These models are less time consuming than 
GEM models and they rapidly develop palpable tumors. Orthotopic syngeneic mouse 
models established in immunocompetent mice have been demonstrated to be more 
effective than orthotopic isogenic models (generated from human tumor cell lines) at 
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predicting patient response to therapy. In fact, transplanted cells and mouse hosts 
share the same genetic background and this allow maintenance of an intact immune 
system development of a tumor microenvironment similar to what is observed in 
human tumors (Tseng et al. 2010). One disadvantage of these models is represented 
by the fact that transplanted mouse tissue might not fully recapitulate the complexity 
of human cancers in the clinical setting (Loukopoulos et al. 2004). 
 
5.4.2 MEK inhibition plus gemcitabine combination induces antitumor 
activity in an orthotopic mouse model of pancreatic cancer 
New therapies are urgently needed for PDAC patients since the current available 
treatments provide small survival benefit (Garrido-Laguna and Hidalgo 2015). MEK 
inhibitors in combination with gemcitabine, one of the standard chemotherapeutic 
agents used in PDAC, induced tumor stasis but not regression in a mutant K-RAS GEM 
model of pancreatic cancer (Junttila et al. 2015). However, the improvement in 
survival was not dramatic compared to the effects obtained by the combination of 
gemcitabine with the EGFR inhibitor erlotinib in the same model (Singh et al. 2010). 
This modest survival benefit was associated with the dose of the MEK inhibitor used, 
which produced only partial and not sustained MAPK pathway suppression (Junttila et 
al. 2015). 
For this project, we developed an orthotopic mouse model of pancreatic cancer by 
implanting tumor cells derived from the established KPC mouse model into the 
pancreas of immunocompetent mice. The biological matrix matrigel was used to inject 
the cells into the pancreas. This biological matrix remains in a liquid state at low 
temperatures but forms a gel once is injected into the mice where the local tissue 
temperature is increased. The use of this three-dimensional matrix prevents any 
injection site leakage (Jiang et al. 2014). These mice developed tumors within two 
weeks, after which they were treated with gemcitabine and pimasertib. Our study 
provided in vivo evidence that gemcitabine alone did not result in relevant slowing of 
tumor growth. The weak antitumor activity of gemcitabine in vivo has already been 
shown and it is often attributed to its short half-life (Frese et al. 2012). The addition of 
the MEK inhibitor pimasertib to gemcitabine induced significant tumor growth 
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attenuation (Fig. 5.5-5.12). No tumor regression was observed, as expected, since the 
treatment period in these experiments was brief (12 days). The purpose of the study 
was to examine dynamic effects on gene expression as in in vitro studies. Pimasertib 
induced strong pathway inhibition as shown by the reduction of phospho-ERK 
expression (Fig. 5.9, 5.15) and upregulation of phospho-AKT in pancreatic xenograft 
models (Fig. 5.11), further highlighting the existence of a feedback loop between MEK 
and PI3K signalling.  
The results of our experiments indicate that low doses of pimasertib are sufficient at 
inducing specific target inhibition and are effective at sensitizing mouse models of 
pancreatic cancer to gemcitabine treatment, supporting evaluation of such dosing 
schedules for future clinical trials to reduce the common side effects experienced with 
MEK inhibitors. 
 
5.4.3 Pimasertib modulates RRM1 expression in vivo 
Gemcitabine diphosphate covalently binds and inhibits Ribonucleotide Reductase (RR) 
large subunit-1 (RRM1) as one of its mechanisms of cytotoxicity (Gesto et al. 2012). 
Our in vitro results obtained from human pancreatic cancer cell lines identified RR 
large subunit-1 (RRM1) to be modulated by pimasertib treatment. This is an important 
finding since RRM1 overexpression has been frequently associated with increased 
resistance to gemcitabine (Zhang et al. 2014) (Bepler et al. 2006). Consistent with our 
in vitro observation, pimasertib induced downregulation of RRM1 protein in the KPC 
mouse cell line (Fig. 5.3). In addition, a significant decrease of RRM1 protein levels was 
observed in our pancreatic xenograft models treated with pimasertib alone and in 
combination with gemcitabine (Fig. 5.10, 5.13).  
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5.5 CONCLUSIONS 
The use of a syngeneic orthotopic mouse model of pancreatic cancer was valuable in 
the preclinical evaluation of the antitumor activity between pimasertib and 
gemcitabine. The orthotopic mouse model generated for this study was not 
significantly impacted by MEK inhibition or gemcitabine administration. However, 
sequential combination treatment of the two agents resulted in significantly delayed 
tumor growth. Moreover, pimasertib efficiently suppressed MAPK pathway activation 
and decreased RRM1 protein levels in mouse tumors, a mechanism that might explain 
why these models benefit from pimasertib plus gemcitabine combination.  
Our in vivo results further provide a biological rationale for further investigation of 
gemcitabine in combination with MEK inhibitors in the clinical setting for improving 
PDAC patient’s outcome.  
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Figure 5.18: Graphical abstract of the mechanism of action of pimasertib with gemcitabine. 
In normal conditions GTP-bound RAS activates RAF, which in turn phosphorylates and activates MEK, 
which ultimately phosphorylates ERK and induces its translocation into the nucleus where it induces 
expression of genes associated with cell proliferation, differentiation and survival. The active form of 
gemcitabine gets incorporated into the DNA double strand and leads to termination of DNA 
duplication. The MEK inhibitor pimasertib blocks MEK into a catalytically inactive conformation that 
blocks MEK from binding ERK. When MEK signalling is inhibited, there is an increase in AKT activation, 
which triggers MDM2 to ubiquitinate and degrade RRM1. As a result gemcitabine activity is 
potentiated.  
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CHAPTER 6 
 CONCLUSIONS AND FUTURE WORK 
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Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy characterised by a 1-
year survival rate of 18% (Hidalgo 2015). Less than 20% of PDAC patients are 
candidates for surgery at time of diagnosis, which is the only curative option available. 
However, almost 90% of these patients still die of local recurrence or metastatic 
disease (Hidalgo et al. 2015). In the adjuvant setting, gemcitabine, a deoxycytidine 
analogue, whose active form interferes with DNA synthesis leading to its termination, 
was approved in 1997 as a standard care for PDAC on the basis of improved quality of 
life indicators (Burris et al. 1997). Unfortunately, the survival benefit of gemcitabine is 
rather modest (median survival less than 6 months) and its limited efficacy is mainly 
caused by intrinsic and acquired resistance (Werner et al. 2013). Therapeutic 
strategies against PDAC have been the focus of intense studies for the last decade and 
have led to the approval of two novel chemotherapeutic regimens that produced a 
small but significant effect on survival: FOLFIRINOX and nab-paclitaxel plus 
gemcitabine combination (Conroy et al. 2011) (Von Hoff et al. 2013). 
The majority of PDAC patients harbour a mutation within the K-RAS gene, which is 
required for tumor initiation and development (di Magliano and Logsdon 2013). There 
has been extensive interest in the development of inhibitors of downstream effectors 
of K-RAS effectors as a strategy for PDAC therapy; in particular, MEK protein, a dual-
specific kinase, represents a potential target of therapeutic intervention since it is 
downstream RAS and activates ERK to stimulate proliferation, differentiation, 
migration and survival (Neuzillet et al. 2014) (Neuzillet et al. 2013). 
Ribonucleotide Reductase enzyme catalyses the conversion of ribonucleosides to 
deoxyribonucleosides triphosphates needed for new DNA synthesis and repair. 
Gemcitabine diphosphate is a direct inhibitor of Ribonucleotide Reductase subunit-1 
(RRM1) (Heinemann et al. 1990), whose expression has been frequently associated 
with gemcitabine resistance (Wang et al. 2013) (Wonganan et al. 2012) (Zhang et al. 
2014). Therefore, molecular agents that alter RRM1 stability could be a promising 
strategy for the management of gemcitabine resistance. 
In this study we sought to investigate the effects of combining gemcitabine with 
pimasertib, an allosteric MEK1/2 inhibitor and to explore their mechanisms of 
interaction in pancreatic cancer models.   
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Chapter three determined the biological effects of pimasertib and analysed the 
effects of pimasertib in combination with gemcitabine on proliferation, apoptosis and 
cell signalling pathway genes in human pancreatic cancer cell lines. Strong inhibition 
of ERK phosphorylation was observed upon pimasertib treatment. Simultaneous 
administration of pimasertib with gemcitabine was not effective at inhibiting 
proliferation or at enhancing apoptosis. On the other hand, synergistic 
antiproliferative effects and enhanced apoptosis were observed upon sequential 
treatment with pimasertib followed by gemcitabine. Our results showed that 
pimasertib arrested the cells at G1-phase and gemcitabine induced an S-phase arrest. 
Therefore we suggest that concomitant treatment would suppress the effects of 
gemcitabine to act as an S-phase specific agent.  
We then investigated whether the expression of genes associated with gemcitabine 
response could be modulated by MEK inhibition. To our surprise we found RRM1 to be 
significantly downregulated by pimasertib treatment. This effect was specifically 
dependent on MEK protein inhibition and was not induced by blocking upstream 
activators of the MEK pathway such as EGFR.  
Finally, the data provided confirmed the role of RRM1 in affecting gemcitabine 
response, since its depletion increased gemcitabine-induced apoptosis in human 
pancreatic cancer cell lines. 
Chapter four explored the molecular mechanisms by which pimasertib reduces RRM1 
protein expression. Subsequent mechanistic studies focusing on modulation of RRM1 
stability indicated that pimasertib reduced RRM1 protein by enhancing its ubiquitin-
dependent proteasomal degradation. Additionally, the results found MDM2 to be 
involved in mediating RRM1 polyubiquitination, since biological or pharmacologic 
inhibition of MDM2 impaired RRM1 downregulation occurring after pimasertib 
treatment.  
The involvement of PI3K/AKT signalling in the degradation of RRM1 induced by 
pimasertib was also studied. We observed increased phosphorylation of AKT after 
pimasertib treatment. Furthermore, co-treatment with pimasertib and a PI3K inhibitor 
impaired RRM1 downregulation triggered by the MEK inhibitor, thus we believe that 
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AKT activation induced by MEK inhibition is in part associated with MDM2-mediated 
degradation of RRM1 protein.  
Chapter five aimed to confirm the synergistic antitumour activity of pimasertib with 
gemcitabine combination observed in vitro, in an orthotopic pancreatic tumour 
model. Sequential combination of pimasertib followed by gemcitabine inhibited 
tumour growth. Additionally, the MEK inhibitor abrogated P-ERK signalling and 
markedly decreased RRM1 protein levels in vivo, an effect we believe is associated 
with the synergistic antitumour activity observed between pimasertib and 
gemcitabine. 
 
6.1 FUTURE DIRECTIONS:  
6.1.1 What are the effects of simultaneous administrations of 
gemcitabine with pimasertib in vivo? 
The results presented in this thesis indicate that sequential but not concomitant 
combination of MEK inhibitors with gemcitabine produces synergistic anti-
proliferative and pro-apoptotic effects in vitro. The schedule that induced the best 
synergism was used for assessing the antitumour activity of pimasertib plus 
gemcitabine combination in an orthotopic model of pancreatic cancer. It would be of 
great interest to investigate the effects of simultaneous administration of pimasertib 
with gemcitabine in the same model to confirm the antagonism observed in vitro. 
 
6.1.2 Does knockdown of MDM2 sensitize pancreatic tumour mouse 
models to gemcitabine treatment? 
Our study shows that pimasertib treatment reduces RRM1 protein levels and this 
occurs through its polyubiquitination and proteasomal degradation mediated by the 
E3 ligase MDM2. Transient inhibition of MDM2 would cause accumulation of 
intracellular RRM1, thus antagonising gemcitabine activity. This hypothesis could be 
explored further by examining gemcitabine cytotoxicity in MDM2 siRNA transfected 
mice. Potentially, shRNA against MDM2 in mouse models of pancreatic cancer treated 
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with gemcitabine could reveal some insights into the mechanism of gemcitabine 
efficacy.  
6.1.3 Can pre-treatment with pimasertib sensitize pancreatic cancer 
models to PI3K inhibitors plus gemcitabine combination? 
Several preclinical studies have focused on the evaluation of concurrent blockade of K-
RAS downstream pathways (MEK and PI3K) to overcome the effects of compensatory 
feedback loop mechanisms between the two pathways (Wee et al. 2009). Results 
obtained from human pancreatic cancer cell lines and GEM models of PDAC have 
shown modest but significant survival improvement upon combination of PI3K/AKT 
inhibitors with MEK inhibitors (Junttila et al. 2015) (Chang et al. 2010). Evaluation of 
novel therapeutic strategies that combine PI3K inhibitor, MEK inhibitors and 
gemcitabine should be explored. However, since we believe that pimasertib 
sensitizing effects on gemcitabine response is due to RRM1 degradation and we think 
AKT activation is involved in this mechanism, it would be rational to explore the 
effects of pre-treating pancreatic cancer mouse models with pimasertib for a window 
of time necessary to downregulate RRM1 protein, followed by gemcitabine treatment 
and finally administer a PI3K inhibitor to allow sustained inhibition of the MAPK 
pathway. 
 
6.1.4 Effect of RRM1 inhibition in a mouse model of pancreatic cancer  
Small interfering RNA (siRNA) represents a powerful method to achieve efficient knock 
down of a target gene (Burnett et al. 2011). This study showed that inhibition of RRM1 
expression by siRNA enhanced gemcitabine cytotoxicity in human pancreatic cancer 
cells. It would be interesting to explore whether systemic administration of RRM1 
specific siRNA in the orthotopic mouse model would be efficiently delivered into the 
tumour, downregulate RRM1 and would potentiate the antitumour activity of 
gemcitabine. In addition to this, RRM1 knock out pancreatic cancer cell lines, by using 
the CRISPR-Cas9 system could be developed and used as a platform to study the 
cytotoxic effects of gemcitabine. 
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6.1.5 Analysis of RRM1 expression on human samples of pancreatic 
cancer  
Our studies thus far have focused on in vitro models and animal models. It is also 
critical to evaluate clinical samples. Circulating tumour cells, detected in the blood 
stream of patients with solid cancers, represent an important tool for diagnosis and 
for monitoring response to chemotherapy (Rhim et al. 2012). The isolation of 
circulating tumour cells would allow analysis of RRM1 expression on pancreatic 
tumour specimens from patients treated with pimasertib and gemcitabine. This 
method would be important to confirm whether downregulation of RRM1 occurs in 
these patients. This could be done in a neoadjuvant ‘window study’. 
  
6.2 CONCLUSIONS 
The lack of efficacious therapies available for patients diagnosed with advanced PDAC 
increases the need to explore novel therapeutic strategies to target this disease. 
Combination treatments that include targeted agents represent a potential approach 
to potentiate the antitumour activity of chemotherapy. In particular, MEK proteins, 
downstream components of the RAS signalling pathway, are ideal therapeutic targets 
since this pathway is frequently deregulated in human cancers. The most recently 
developed MEK inhibitors do not affect other serine/threonine or tyrosine protein 
kinases targeting the ATP-binding site; therefore they overcome any adverse effects 
associated with this (Ohren et al. 2004). In the clinic, MEK inhibitors have proved to be 
well tolerated and have provided significant survival benefit in melanoma, a result 
that led to the FDA approval of these agents (Flaherty et al. 2012). 
The results obtained in this study support the clinical use of MEK inhibitors to enhance 
gemcitabine efficacy for pancreatic cancer treatment. The importance of drug 
scheduling as a factor by which MEK inhibition increases gemcitabine efficacy will 
inform future clinical investigations for combinations and schedules of gemcitabine 
with MEK inhibitors. Our hypothesis based on the results obtained suggests that the 
administration of pimasertib increases gemcitabine cytotoxicity in pancreatic cancer 
models in part by interfering with an important mechanism that contributes to 
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gemcitabine resistance. This study has provided mechanism insights to the synergistic 
interaction observed between gemcitabine and pimasertib that should be further 
investigated. The frequent use of gemcitabine in pancreatic cancer therapy and the 
awareness of RRM1 being an important factor in determining gemcitabine sensitivity 
urge a deeper understanding of the detailed mechanism of modulation of RRM1 
expression by MEK inhibition, to allow a better design of future clinical trials involving 
gemcitabine with MEK inhibitors and possibly other targeted therapies downstream 
RAS and to predict PDAC patient’s outcome.  
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